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Helminth infections induce protective type 2 (Th2) immune responses in the host
leading to arrested larval development and/or intestinal worm expulsion. Moreover,
Th2 immune responses are initiated against harmless environmental allergens and
mediate a development of allergic disease.
Among multiple mechanisms implicated in host responses to parasites and aller-
gens, mast cells (MCs) play a pivotal role. Until recently MCs were mainly conside-
red as late-stage effector cells, whereas the contribution of MCs in the early events
during Th2 immune response is relatively neglected. The present study shows that
MC-deficient mouse strains following infection with two gastrointestinal helminths
(Heligmosomoides polygyrus and Trichuris muris) had dramatically reduced early
production of the tissue-derived cytokines IL-25, IL-33, and thymic stromal lympho-
poietin (TSLP), which resulted in impaired induction of Th2 immune responses as
well as increased parasite burden. Increased production of IL-25, IL-33, and TSLP,
restored Th2 priming and reduced parasite burden was observed after ‘repair’ of the
MC-compartment. These data reveal an important role for MCs in orchestrating
type 2 immune responses.
Parasites have developed various strategies to modulate the immune system and
ultimately suppress host protective Th2-type immune responses via the induction of
a range of regulatory mechanisms. Additionally, treatment of inappropriate immune
responses by the suppression of overwhelming inflammation by helminths has shown
promise in initial clinical trials. For that reason, this work further explores the im-
munomodulatory role of the filarial cysteine inhibitor AvCystatin and its structural
and functional characteristics in the murine model of airway hyperreactivity and
inflammation induced by a clinically relevant allergen of timothy grass pollen. In
this study AvCystatin was found to inhibit airway inflammation, airway hyperreac-
tivity and to reduce grass pollen allergen-specific immune responses. At the same
time AvCystatin increased levels of the regulatory cytokine IL-10 and numbers of
CD4+CD25+Foxp3+ T cells. Furthermore, the immunomodulatory effect in vivo




The present study further aimed to evaluate the capacity of AvCystatin as a po-
tential alternative adjuvant in an allergen-specific immunotherapy (SIT) using a
novel murine model. It was found that AvCystatin did not exert additive or synergi-
stic effects when applied during immunotherapy with the target antigen. Therefore,
these data demonstrate that AvCystatin applied alone downregulates allergic in-
flammation and that its effect is not related to main cystatin’s characteristics.
Finally, the aim was to translate the efficacious effects of AvCystatin seen in
murine models to in vitro assays using human peripheral blood mononuclear cells
(PBMCs) from grass pollen allergic patients. In the approach before the grass pollen
season, AvCystatin suppressed allergen-specific production of IL-13 and created a
shift towards Th1 immunity by increased levels IFN-γ. These findings suggest that
AvCystatin may also have efficacy in the suppression of unwanted immune responses
in disease patients.
Taken together the findings of the present study contribute to a better under-
standing of the early events that dictate the priming of type 2 immune responses,
such as those raised during helminth infection or during allergies and, furthermore,
show that helminths have co-evolved with the host to produce potent immunomo-
dulatory products that act to suppress and modulate the Th2 response to ensure
their survival. Heminth product-induced suppression may also have effects on by-
stander responses to unrelated antigens, thus, suggesting a promising preventive and
therapeutic concept in the treatment of aberrant inflammations.
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Zusammenfassung
Helmintheninfektionen induzieren in ihren Wirten schützende Typ 2 (Th2) Immun-
antworten, welche die Entwicklung von parasitären Larvenstadien hemmen und/oder
zur Abstoßung intestinaler Würmer führen. Th2-Antworten können auch gegenüber
harmlosen Umweltallergenen ausgebildet werden und vermitteln in diesem Zusam-
menhang die Entwicklung allergischer Erkrankungen.
Unter vielen Mechanismen, die für die Wirtsantwort gegen Parasiten und Aller-
genen von Bedeutung sind, spielen Mastzellen (MZ) eine herausragende Rolle. Bis
vor kurzem wurden MZ hauptsächlich als Effektorzellen für die späte Phase der Im-
munantwort betrachtet. Einer möglichen Rolle von MZ für die frühe Phase von Th2
Immunantworten wurde bisher wenig Beachtung geschenkt. Die Ergebnisse der vor-
liegende Arbeit zeigen, dass eine Infektion von MZ-defizienten Mausstämmen mit
gastrointestinalen Helminthen (Heligmosomoides polygyrus und Trichuris muris)
zu einer dramatisch reduzierten Produktion von IL-25, IL-33 und Thymus-Stromal-
Lymphopoietin (TSLP) sowie zu einer Beeinträchtigung der Etablierung von Th2
Immunantworten und einer erhöhten Wurmlast führt. Eine gesteigerte Produktion
von IL-25, IL-33 und TSLP, wiederhergestellte Th2-priming Konditionen sowie eine
verminderte Wurmlast konnte nach erfolgreichem Transfer von Knochenmark aus
Wildtypmäusen beobachtet werden. Die vorliegenden Arbeit beschreibt damit eine
wichtige Funktion von Mastzellen für die Initialisierung von Th2 Immunantworten.
Parasiten haben zahlreiche Strategien entwickelt um das Immunsystem ihrer Wir-
te zu modulieren und Th2 Immunantworten durch die Induktion regulatorischer Me-
chanismen zu supprimieren. Eine Behandlung von überschießenden Entzündungsre-
aktionen durch Helminthen wurde bereits durch erste klinische Studien demonstriert.
Ein weiteres Ziel der vorliegenden Arbeit war es deshalb, die strukturellen und im-
munmodulatorischen Eigenschaften des Cystein-Protease-Inhibitors AvCystatin in
einem murinen Modell für Atemwegsentzündung, induziert durch ein klinisch rele-
vantes Allergen aus Graspollen, zu untersuchen. In diesem Zusammenhang konnte
gezeigt werden, dass AvCystatin sowohl Parameter von Atemwegsentzündung und
-hyperreaktivität als auch Graspollen-spezifische Immunantworten inhibiert. Gleich-
zeitig führte die Behandlung mit AvCystatin zu einem Anstieg von IL-10 und zu
7
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erhöhten Frequenzen von CD4+CD25+Foxp3+ T Zellen. Die in vivo Effekte von Av-
Cystatin wurden dabei unabhängig von der Protease-inhibitorischen Aktivität des
Immunmodulators oder einer Oligomerisation desselben vermittelt.
Des Weiteren sollte das Potential von AvCystatin als alternatives Adjuvans im
Rahmen einer Allergen-spezifischen Immuntherapie (SIT) für ein neues Mausmodell
untersucht werden. Dabei zeigte sich, dass eine Applikation von AvCystatin zusam-
men mit dem Zielantigen keine ergänzenden oder synergistischen Effekte vermittelt
konnte. Diese Ergebnisse verdeutlichen, dass durch die Applikation von AvCystatin
allergische Entzündungsreaktionen herunterreguliert werden und dass dieser Effekt
unabhängig von der Protease-inhibitorischen Aktivität von AvCystatin vermittelt
werden kann.
Ein weiteres Ziel der vorliegenden Arbeit war es, die Effekte von AvCystatin durch
die Etablierung eines in vitro Systems mit mononukleären Zellen des peripheren Blu-
tes (PBMCs) von Graspollen allergischen Patienten im humanen System zu untersu-
chen. In einem Versuchsansatz, der die Situation der Patienten vor der Graspollen-
Saison widerspiegelt, unterdrückte AvCystatin die Allergen-spezifische Produktion
von IL-13 und induzierte stattdessen eine Th1 Immunantwort durch die Induktion
erhöhter Mengen von IFN-γ. Diese Ergebnisse zeigen, dass AvCystatin auch in hu-
manen Graspollen-Allergikern unerwünschte Immunantworten unterdrücken kann.
Zusammenfassend tragen die Ergebnisse der vorliegenden Arbeit dazu bei, ein bes-
seres Verständnis für die frühen Ereignisse von Th2 Immunantworten zu entwickeln,
welche durch Helminthen oder Allergene induziert werden. Darüber hinaus bekräfti-
gen die Daten die Hypothese, dass Helminthen im Rahmen einer langen Koevolution
mit ihren Wirten effektive immunmodulatorische Strategien entwickelt haben, um
die gegen sie gerichtete Th2-Antwort zu unterdrücken. Die Immunsuppression durch
Helminthenmoleküle kann zugleich Bystandereffekte auf Immunantworten gegen an-




Helminths have developed a unique evolutionary dialogue with their hosts’ immune
system due to multicellular nature, complex life cycles and their longevity within
the host. These pathogens induce different immune responses than bacteria, fungi,
viruses or protozoa do. Especially host mucosal epithelia are in close contact with
helminths, common antigens and are important for initiation of type 2 (Th2) immu-
nity that characterizes helminth infections as well as allergic reactions. Moreover,
Th2 immune responses are also initiated against harmless environmental allergens
and may lead to the development of allergic diseases.
Among multiple mechanisms implicated in host responses to parasites, mast cells
(MCs) play a pivotal role. As tissue-based inflammatory cells they respond to si-
gnals of innate and adaptive immunity. Although classically considered as late-stage
effector cells actively involved i.e., during host responses against parasitic helminths
(reviewed in Pennock and Grencis, 2006), their innate role in orchestration of early
stages of the Th2 immune responses is relatively overlooked. Sharing of critical roles
in Th2-cell priming has been ascribed to tissue-derived cytokine signals, in parti-
cular IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) (reviewed in Saenz
et al., 2008). Thus, the question on the role of MCs in the regulation of the tissue-
derived cytokines and subsequently the development of type 2 immunity remains
unanswered.
Interestingly, parasites have developed various strategies to modulate the immune
system and ultimately suppress host protective Th2-type immune responses e.g., by
induction of innate and adaptive regulatory cells, anti-inflammatory cytokines and
specific inhibitory antibody isotypes (Fig. 1.1; reviewed in Anthony et al., 2007;
Daniłowicz-Luebert et al., 2011).
Helminth parasites are master regulators of immune responses in order to ensure
life-long persistence in the host (Maizels and Yazdanbakhsh, 2003). Many studies of
animal and human helminth infections have shown their potential for downregula-
ting the immune system. Moreover, relevant epidemiological studies have observed
that helminth-infected populations exhibit lower levels of immunopathological dis-
orders such as Th1-related autoimmune diseases or aberrant Th2-related conditions
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e.g., asthma or allergic rhinitis. These observations indicate an inverse global distri-
bution of allergy and helminth infections. The first being an expanding problem of
industrialized high-income countries, while the latter being a feature of developing
countries (Fallon and Mangan, 2007; Yazdanbakhsh and Luty, 2011). The most pro-
mising strategy for treatment of allergic diseases is the suppression of overwhelming
Th2 immunity and the induction of regulatory mechanisms (reviewed in Bosnjak
et al., 2011; Jutel and Akdis, 2011).
This work is composed of two interconnected projects. It explores a role of ele-
ments of Th2 immunity in the development of early responses to helminths and
investigates the potential of a single worm-derived molecule to downregulate Th2-
type immunopathologies in allergic airway hyperreactivity and inflammation. The
latter constitutes the core of this thesis.
1.2 Helminths and allergens induce type 2 immune
responses
Helminth infections as well as allergic disorders represent complex innate and adap-
tive immune responses to foreign antigens leading, in most of the cases, to inflamma-
tory reactions. In response to antigens and the context they are presented in, naive
CD4+ T cells can differentiate into four T helper (Th) cells subsets: Th1, Th2, Th17
and inducible regulatory T cells (iTregs) (Mosmann and Sad, 1996; Zhu et al., 2010;
Wisniewski and Borish, 2011). Th2 cells play an important role in host immunity
to extracellular parasites (e.g. helminths), which can impair larval development and
adult worm feeding or leading to intestinal worm expulsion (Anthony et al., 2007;
Herbert et al., 2009; Liu et al., 2010). They are also responsible for the development
of bronchocontriction and airway remodeling leading to allergic disorders (Fujita
et al., 2012).
During Th2 immune response, professional antigen presenting cells (APCs) pro-
cess helminth antigens or allergens and display them to CD4+ T cells that diffe-
rentiate into polarised Th2 cells. Th2 cells function through production of various
Th2-associated cytokines, such as interleukin (IL)-4, IL-5, IL-9, IL-10 and IL-13 and
via homing to specific tissue compartments (Saenz et al., 2008; Lloyd and Hessel,
2010). Theses cytokines activate macrophages, eosinophils, and other immune cells
including MCs . IL-4 and IL-13 induce differentiation of antigen-specific B cells and
production of large amounts of antibodies (characteristically IgE) (Swain et al., 1990;
Paul and Zhu, 2010). IgE immune complexes activate innate immune cells (like ba-




ment of memory cells takes place, and the late phase when the effector cells lead to
inflammation and tissue injury upon repeated exposure to the allergen (Akdis, 2006;
Valenta, 2002). The early and late phases of Th2-type response in allergy are well
studied. For that reason, the present work addresses early Th2 immune response
induced by helminth infections where a role of MCs remains unclear.
1.2.1 Cytokines of early type 2 immune responses
Although later phases of Th2 immunity are well understood, the early events in
Th2-type responses are relatively neglected.
Recent studies using Th2-associated disease animal models, reported on several
novel innate immune cells and tissue-derived cytokines to be involved in shaping Th2
immune responses. Nuocytes (Neill et al., 2010), natural helper cells (NHCs) (Moro
et al., 2010) and MPPtype2 cells (Saenz et al., 2010) are necessary in the initiation
of Th2 cascade. As Th2 priming happens at the tissue sites where allergens and
parasites get in touch with e.g., skin, lung and gut tissue, ‘early’ tissue-derived
cytokines such as IL-25, IL-33 and TSLP play a pivotal role.
Interleukin-25 is highly relevant in induction of Th2 immune responses. It has been
described to be produced by Th2-polarized CD4+ T cells, murine and human epithe-
lial cells upon exposure to allergens (Fort et al., 2001; Angkasekwinai et al., 2007).
Exogenous administration of IL-25 amplifies allergic type inflammatory responses
with high expression of IL-4, IL-5 and IL-13, induces eosinophilia and increases IgE
levels (Fort et al., 2001). In asthmatic mice IL-25 acts directly on CD4+ T cells and
promotes Th2-cell differentiation in an IL-4- and STAT6-dependent manner (Angka-
sekwinai et al., 2007). IL-25 also plays an important role in Th2-cell-mediated immu-
nity to parasitic infections. Fallon et al. (2006) showed that mice lacking IL-25 have
impaired Nippostrongylus brasiliensis worm expulsion and delayed Th2-associated
cytokine production. IL-25, via regulation of non-B/non-T (NBNT), c-kit+, FcϵRI-
cells producing IL-4, IL-5 and IL-13, initiates worm expulsion (Fallon et al., 2006).
Furthermore, Owyang et al. (2006) reported that Trichuris muris-infected genetical-
ly susceptible mice treated with exogenous IL-25 exhibited protective Th2 response
to the infection.
Interleukin-33 induces differentiation of murine eosinophils (Stolarski et al., 2010),
as well as activates human basophils and eosinophils of atopic patients (Pecaric-
Petkovic et al., 2009; Suzukawa et al., 2008b,a). IL-33 acts, both alone or together
with TSLP, on human primary MCs (Allakhverdi et al., 2007b). Upregulation of
IL-33 is found in early phases of T. muris infection. Additionally, application of
exogenous IL-33 leads to worm expulsion and increases TSLP expression within
infected ceacum (Humphreys et al., 2008).
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TSLP is overexpressed in lungs of allergic mice and by human epithelial cells from
atopic patients (Zhou et al., 2005). It acts directly on CD4+ T cells (Isaksen et al.,
1999; Al-Shami et al., 2005), dendritic cells (DCs) (Soumelis et al., 2002) and MCs
to increase Th2-cell responses (Allakhverdi et al., 2007a). Moreover, TSLP-activated
DCs prime naive CD4+ T cells to produce Th2 signature cytokines, such as IL-4,
IL-5 and IL-13, and at the same time to downregulate IL-10 and IFN-γ (Soumelis
et al., 2002). TSLP was reported to promote development of Th2 immune responses
in infections with T. muris but not Heligmosomoides polygyrus or N. brasiliensis
(Taylor et al., 2009; Humphreys et al., 2008).
In this context, IL-4 plays an essential role in communicating and differentiation
of Th2 cells (Swain et al., 1990). Additionally, IL-4 upregulates the expression of
GATA-binding protein 3 (GATA-3), the master regulator for Th2 differentiation and
activator of genes encoding Th2-associated cytokines (Zheng and Flavell, 1997; Lee
et al., 2000).
Although IL-25, IL-33 and TSLP are described to be mainly epithelial and endo-
thelial cell-derived cytokines, recent studies identified alternative cell sources and
various innate immune cells these cytokines act on (reviewed in Bartemes and Ki-
ta, 2012). Therefore it is important to further explore the role of mast cells in the
regulation of these early type 2 immune responses.
1.2.2 Mast cells in parasite infections and allergy
Mast cells (MCs) are located at strategically important body barriers (such as skin,
gut and lung tissue) and are recognized as important cells involved in Th2-associated
immune responses. Their ‘allergic activation’ is initiated by allergens cross-linking
of effector-cell-bound IgE via FcϵRI expressed on cell surface and leads to release
of various pre-formed biologically active mediators (e.g., histamine, leukotrienes)
(Rivera and Gilfillan, 2006). Late-phase reactions due to leukocytic and inflamma-
tory (eosinophil, neutrophil and basophil) cell recruitment, lead to further cytokine
production, tissue remodeling and in consequence to the development of type I hy-
persensitivity reactions (such as allergy, allergic asthma, rhinitis or urticaria) and
later to the disease progression (reviewed in Moiseeva and Bradding, 2011).
The most commonly used animal model to study the role of MCs in immune re-
sponses is the WBB6F1-KitW/KitW−v or C57BL/6-KitW−sh/KitW−sh mouse. Both
strains are profoundly deficient in MCs and melanocytes due to an improper trans-
crition of the kit gene as a result of a mutation in the W locus. Due to the fact that
KitW/KitW−v mice apart from their MC-deficiency have other abnormalities (such
as anemia, sterility and almost complete lack of Cajal cells), it is often practiced
to perform additional experiments in KitW−sh/KitW−sh mice that do not exhibit
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those phenotypic abnormalities. The lack of MCs can be selectively repaired by the
adoptive transfer of wild type, either whole bone marrow (BM) containing mast
cell-progenitors or in vivo- or in vitro-derived MCs. BM or MCs can be adminis-
tered in various ways, depending on a studied organ, induced infection or type of
inflammation (reviewed in Metz et al., 2007).
In host defense against helminths, MCs contribute to elimination of established
infection by affecting worm reproduction and survival. It has been known for ma-
ny years that infections with nematodes such as Trichinella spiralis (Alizadeh and
Murrell, 1984), Strongyloides ratti (Abe et al., 1993), H. polygyrus (Ben-Smith et al.,
2003), T. muris (Betts and Else, 1999) and N. brasiliensis (Issekutz et al., 2001)
correlate with a large mastocytosis, which affects later stages of the infection and
accelerates adult worm (T. spiralis, S. ratti and H. polygyrus) expulsion from the
intestine. Particularly mechanisms such as secretion of mucosal specific mast cell
proteases (i.e., mMCP-1), increase of intestinal epithelial permeability or collabo-
ration with Th2-cell-dependent mechanisms lead to MC-mediated worm expulsion
(Knight et al., 2000; McDermott et al., 2003; Pennock and Grencis, 2006). MCs are
also regarded as capable to serve as a source of various Th2-associated cytokines
(such as IL-3, IL-5, IL-10, IL-13, IL-33 and TSLP), mediators (TNF-α, histamine,
platelet-activating factor - PAF, leukotriene C4 - LCT4) that induce the expres-
sion of endothelial adhesion molecules (E-selectin, ICAM, VCAM-1) essential for
lymphocyte homing (Mekori and Metcalfe, 1999; Henz et al., 2001; Saenz et al.,
2008).
Only recent studies have begun to identify critical roles for MCs in the promotion
of various immune responses to pathogens such as bacteria (Dietrich et al., 2010) or
viruses (Wang et al., 2012) as well as in contact allergy (Dudeck et al., 2011). As MCs
are located in a close proximity to DCs and epithelial cells, they can communicate
via released mediators and cytokines, however the exact mechanism is still unknown.
And although MCs are nowadays less considered only late-stage effector cells, their
innate role during the initial events of the Th2 immune response during helminth
infections remains relatively neglected.
1.3 Impact of helminths on prevalence of allergic
reactions
Helminths induce regulatory mechanisms via modulation of immune cells. These
mechanisms include alternatively activated macrophages (AAMs), regulatory T cells
(Treg), B cells and production of blocking antibodies (IgG4 in humans, IgG1 in
mice). AAMs in mice express various factors such as arginase-1 (Arg-1), resistin-like
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molecule-α (RELM-α), IL-10, transforming growth factor-β (TGF-β) and contribute
to wound healing. Treg produce IL-10 and TGF-β, whereas B cells can also elicit
regulatory mechanisms via IL-10. Blocking antibodies compete with IgE for binding
sites to worm antigens and minimize damage due to IgE-mediated response. These
cellular changes lead to a ‘modified Th2’ immune response and larvae survival and
can abolish unrelated inflammation such as allergic immune responses (Fig. 1.1)
(reviewed in Maizels and Yazdanbakhsh, 2003; Holgate and Polosa, 2008).
1.3.1 Evidence from field studies
Eradication of helminth infections in industrialised countries in last decades is
thought to have a great impact on the prevalence of diseases associated with inap-
propriate immune responses (reviewed in Fallon and Mangan, 2007). The observed
increase in the appearance of allergy-related diseases might be a result of this and
altered hygienic measures in everyday life. One possible explanation is the hygie-
ne hypothesis (Strachan, 1989; Yazdanbakhsh et al., 2002), which names a number
of factors like improved public health, use of antibiotics and vaccines that in con-
sequence reduced the occurrence of viral, bacterial or helminth infections early in
life, contributing to higher numbers of individuals with allergic and/or autoimmune
disorders.
There are numerous cohort studies determining immune responses to environmen-
tal allergens of helminth-infected individuals in parasite-endemic areas (reviewed in
Smits et al., 2010; Daniłowicz-Luebert et al., 2011). Particularly infections with tre-
matodes, whipworms and hookworms were described to be negatively correlated with
the allergen skin prick test against cockroach, house dust mites (HDMs) and com-
mon environmental aeroallergens (Araújo et al., 2000; Cooper et al., 2003; Medeiros
et al., 2003; Flohr et al., 2009). Results from a study of Gabonese school children
tested for skin reaction to HDMs and other allergens, showed lower prevalence of
a positive skin test to HDMs in individuals with urinary schistosomiasis. Moreo-
ver, schistosome antigen-specific concentrations of IL-10 were significantly higher
in infected children and concentrations of IL-10 were negatively associated with a
positive skin test result (van den Biggelaar et al., 2000).
A direct contribution of active helminth infections to the inverse correlation with
allergy-related diseases was demonstrated in anthelminthic treatment studies (Lynch
et al., 1993; Endara et al., 2010; Flohr et al., 2010). Repeated treatment with an-
thelminthics in a population of Gabonese school children significantly increased the
rate of developing skin sensitization to HDMs. Thus, the presence of live worms
that suppress allergic responses during infection and prevent allergy later in life
is important (van den Biggelaar et al., 2004). Also early exposures and infections
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with helminths may have a protective effect and suppress allergic inflammation later
during life (Huang et al., 2002; Rodrigues et al., 2008).
Additionally, host genetic factors may play a role in prevalence of helminth in-
fections and allergies (Barnes et al., 2007; Scirica and Celedon, 2007; Smits et al.,
2010).
In contrast to population studies reporting a negative correlation between allergy
and helminth infections as discussed above, various studies from South America,
Europe and Asia on Ascaris lumbricoides infections and allergy reported increased
rather than decreased prevalence of asthma (Joubert et al., 1980; Dold et al., 1998;
Palmer et al., 2002). It was proposed that heavy parasitic infections might generate
immune suppressive mechanisms, whereas mild worm exposure and low-level contact
with helminths may enhance reactivity to environmental allergens or even potentiate
the Th2 immune response that in some cases may promote allergic inflammation
(Dold et al., 1998). Additionally due to the specific pulmonary phase in the Ascaris
life cycle that causes inflammation and eosinophilia (Enobe et al., 2006) and/or
cross-reactivity of Ascaris-specific molecules (e.g., tropomyosin) with environmental
allergens (HDMs, Blomia tropicalis that induce allergen-specific IgEs (Fernandes
et al., 2003; Acevedo et al., 2011; Santiago et al., 2011), Ascaris infection has been
well documented as a risk factor for asthma (Leonardi-Bee et al., 2006; Hagel et al.,
2007; Alcantara-Neves et al., 2010).
Interestingly, the promotion of atopy can also be observed in parasitic infections
where the human is not the definitive host e.g., Toxocara spp. (Gonzalez-Quintela
et al., 2006; Flohr et al., 2009) or Anisakis simplex (Daschner et al., 2008). In
this case the immune system may be exposed to Th2-inducing events rather than
to immunomodulatory mechanisms that occur in chronic infections. In addition to
field studies, experimental approaches in animal models are well reported.
1.3.2 Evidence from animal models of allergy
Due to the complexity of the population-association studies, animal models of allergy
can complement the understanding on the effect and mechanism of individual hel-
minth infections or more specifically, helminth-derived products on downregulating
allergy-related diseases (Table 1.1).
Infection with male Schistosoma mansoni worms mediated resistance to oval-
bumine (OVA)-induced AHR. The schistosome worm-infection prevented allergen-
induced inflammation via IL-10-dependent suppression of pulmonary eosinophilia
(Mangan et al., 2006). Moreover, infection with H. polygyrus was reported to sup-
press murine allergic asthma to both OVA and the HDM major allergen - Der
p 1 (Wilson et al., 2005). Additionally, in a model of food allergy induced by
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Table 1.1: Effects of helminth infections and helminth-derived products/molecules
on improvement of symptoms in allergy-related experimental animal models.
Allergy model Suppressive mechanism Reference
Helminth infections and undefined products
S. mansoni infection;
males and females; males
Pen V-induced sys-
temic anaphylaxis
IL-10-producing B cells Mangan et al. 2004
S. mansoni infection;
males





Pacifico et al. 2009
S. japonicum egg
antigen (SEA)
OVA-induced AI CD4+CD25+ Treg, IL-10 Yang et al. 2007
A. suum adult worm
extract (ASC)
OVA-induced AHR NAc Lima et al. 2002
H. polygyrus infection OVA-induced AHR IL-10 Kitagaki et al. 2006
OVA-induced AHR IL-10-independent,
CD4+CD25+ T cells
Wilson et al. 2005
HDM-induced AI IL-10-independent, Breg cells Wilson et al. 2010




OVA-induced AI HES-induced Treg cells Grainger et al. 2010









OVA-induced AI NA Wang et al. 2001
Strongyloides venezue-
lensis infection
OVA-induced AI NA Negrão-Corrêa et al.
2003
T. spiralis infection OVA-induced AI IL-10, TGF-β, CD4+CD25+ T
cells
Park et al. 2011
L. sigmodontis infection OVA-induced AHR TGF-β, CD4+CD25+ Treg Dittrich et al. 2008
Defined helminth-derived molecules
smCKBP (S. mansoni) Hapten-induced con-
tact hypersensitivity
NA Smith et al. 2005
Sm22.6, PIII, Sm29
(S. mansoni)
OVA-induced AI CD4+Foxp3+ Treg Cardoso et al. 2010
As-MIF (A. simplex) OVA-induced AI IL-10, TGF-β and Treg Park et al. 2009
PAS-1 (A. suum) APAS-3-induced AI Possibly IL-10 Itami et al. 2005
OVA-induced AHR CD4+CD25+ T cell-, CD8+ T
cell-dependent and IL-10/TGF-
β, IFN-γ-mediated
Araújo et al. 2008;
de Araújo et al. 2010
Nippocystatin (NbCys)
(N. brasiliensis)
OVA-inudced AI Cathepsin B and cathepsin L-
dependent
Dainichi et al. 2001b
AvCystatin (Av17)
(A. viteae)
OVA-induced AHR IL-10, macrophages, partially
CD4+CD25+ T cell
Schnoeller et al. 2008






Melendez et al. 2007
aAHR - airway hyperreactivity
bAI - airway inflammation
cNA - data not known
dPN - peanut extract
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peanut (PN), H. polygyrus infection decreased PN-specific IgEs, anaphylactic sym-
ptoms and secretion of IL-13 by PN-specific T cells (Bashir et al., 2002). Other
helminths like N. brasiliensis or Litosomoides sigmodontis suppressed the develop-
ment of OVA-induced airway eosinophilia and reduced the production of eotaxin in
the airways of asthmatic mice either in IL-10- or in TGF-β- and Treg-dependent
manner (Wohlleben et al., 2004; Dittrich et al., 2008).
Strikingly, a pre-existing helminth infection with Strongyloides stercoralis increa-
sed systemic OVA-induced Th2-type responses while at the same time reduced levels
of allergen-specific IgE and eotaxin levels in bronchoalveolar lavage (BAL) fluid after
exposure to the allergen (Wang et al., 2001). Also infection with H. polygyrus in a
murine model of OVA-induced atopic dermatitis, led to the aggravation of allergen-
induced inflammation and recruitment of MCs into eczematic regions. Production
of allergen-specific IgEs, infiltration of CD8+ and CD4+ T cells into the skin was
reduced with unaltered numbers of Treg cells (Hartmann et al., 2009).
It is evident that the protective role of helminth infections on allergic reactions
depends on the type of parasitic infection and on investigated experimental model
of allergic disease. Published reports help understanding the mechanism of helminth
immunomodulation of non-related inflammation and shed some light on the potential
of specific helminth-derived products that should be further evaluated.
1.4 Impact of helminth-derived products and
defined molecules on allergy models
Studies from helminth infections in experimental animal models where infection-
induced suppression of allergen specific Th2 responses is observed, suggest that
products that are actively or passively released by the parasites may mediate the
immuneregulation. Table 1.1 reviews described helminth-derived products and de-
fined molecules and their mechanism of action in interference with allergy-related
symptoms.
For example the helminthic excretory/secretory (E/S) of H. polygyrus (HES) was
shown to bear TGF-β-like activity and to directly drive forkhead box trasnscription
factor p3 (Foxp3) expression in CD4+ T cells. Adoptively transferred HES-induced
Treg cells suppressed OVA-induced allergic airway inflammation in vivo, as well as
effector cell proliferation in vitro (Grainger et al., 2010). The E/S product of N.
brasiliensis (NES) inhibited the development of eosinophilia, goblet cell metaplasia
in the lungs and the development of AHR. NES decreased levels of OVA-specific
IgG1 and IgE in serum, as well production of IL-4 and IL-5 in the airways in IL-
10-independent manner. Interestingly, some non-protein components of NES were
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found to be responsible for its suppressive effects (Trujillo-Vargas et al., 2007).
Another, apart from AvCystatin, well-defined molecule from Acanthocheilonema
viteae, ES-62, was described to promote differentiation of DCs and macrophages to
anti-inflammatory phenotype (Goodridge et al., 2004). The molecule interfered with
a mouse model of immediate-type hypersensitivity to oxazolone and diminished ear
swelling, as well as reduced degranulation of MCs. In the same report authors provi-
ded evidence that ES-62 molecule ameliorated OVA-induced airway inflammation,
airway hyperresponsiveness, lung pathology and eosinophilia, as well as decreased
production of IL-4 via suppression of MC-function (Melendez et al., 2007).
Although several helminth-derived molecules are described to interfere with
antigen-dependent immune reactions, cysteine protease inhibitors (cystatins) are
well-characterized protease inhibitors that are not only involved in biological pro-
cesses but have also immunomodulatory potential.
1.5 Cystatins
Cystatins are inhibitors of cysteine proteases of the papain-like family and represent
an important tool for regulation of potentially harmful activities of proteases present
in the body (reviewed in Turk et al., 2008).
1.5.1 Cystatins - classification and structural characteristics
Cystatin superfamily encompasses proteins that contain multiple cystatin-like se-
quences and based on the primary sequence homology, it is composed from three
families: stefins (family 1), cystatins (family 2) and kininogens (family 3) (Abra-
hamson et al., 2003).
Cystatins typically possess an N-terminal signal peptide and two conserved inter-
nal disulfide bonds. However, filarial cystatins lack the second disulphide bridge as
the second C-terminal cysteine residue pair around PW is missing. A further struc-
tural characteristic is the existence of a conserved glycine residue (GG) within the
N-terminal region of the protein that may function as a hinge between the flexible
N-amino-terminal segment and the rest of the molecule (Hall et al., 1998).
The N-terminal region with the conserved glycine residue forms - together with a
central Q-X-V-X-G motif and a C-terminal PW hairpin loop - the cysteine protease
interaction site, which directs the cystatin molecule into the active site cleft of the
cysteine protease (Bode et al., 1988). All three regions form a hydrophobic wedge-like
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a reduced number of epitopes presented to T cells in vitro (Manoury et al., 2001). L.
sigmodontis at various stages of the life cycle secretes a cystatin, which after injection
via micro-osmotic pumps into the peritoneal cavity of L. sigmodontis-infected mice
greatly decreased nitric oxide production and proliferation of antigen-specific spleen
cells (Pfaff et al., 2002). The recombinant cystatin from the E/S product of N.
brasiliensis (nippocystatin, NbCys) inhibits cathepsins L and B, and suppresses
antigen processing by APCs (Dainichi et al., 2001a). In vitro studies on cystatin
from human filarie O. volvulus (Ov17) revealed that the molecule interfered with
mitogen- and antigen-induced stimulation of human peripheral blood mononuclear
cells (PBMCs) and led to secretion of high amounts of IL-10 and inhibition of T
cell proliferation (Schönemeyer et al., 2001; Hartmann et al., 2002). An arthropod-
derived sialostatin L from a parasite Ixodes scapularis with anti-cathepsin L activity,
exhibits anti-inflammatory role and inhibits proliferation of cytotoxic T lymphocytes
contributing to tick-feeding success (Kotsyfakis et al., 2006). Two protease inhibitors
suppressing non-related immune reactions are included in the Table 1.1.
1.5.3 Filarial cystatin - AvCystatin
One of the best-described cystatins of parasites is a filarial cysteine protease inhi-
bitor from A. viteae with molecular weight of 17kDa, AvCystatin (cystatin, Av17).
Previous studies showed AvCystatin to be a potent modulator of macrophages and
to induce anti-inflammatory and anti-proliferative immune responses in vitro (Hart-
mann et al., 1997, 2002; Schierack et al., 2003). AvCystatin is recognized by ma-
crophages (Hartmann et al., 1997; Klotz et al., 2011b). Furthermore, AvCystatin
administered intraperitoneally (i.p.) in an OVA-induced asthma model, suppressed
recruitment of eosinophils into the lungs, total and OVA-specific IgE levels and re-
duced OVA-specific IL-4 production by induction of IL-10-producing macrophages
(Schnoeller et al., 2008).
This thesis investigates properties and further clinical potential of AvCystatin in
an experimental model of allergy.
1.6 Experimental models to study allergies
In order to explore treatment strategies of allergy and asthma and to propose new
therapeutic interventions, the development of improved animal models using clini-
cally relevant allergens is necessary.
Up-to-date the most commonly used mouse model of allergic airway hypereactivi-
ty is an OVA-induced model, where OVA is a classical, inexpensive, widely available
allergen. However, OVA while being a model allergen that does not cause allergic
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reactions in every-day life, it bears certain limitations in animal models such as the
quite possible induction of tolerance and therefore alleviation of airway inflamma-
tion (Wiedermann et al., 1999; Fuchs and Braun, 2008). Moreover, repeated airway
administrations with OVA were reported to induce a progressive reduction of asth-
matic symptoms in sensitized mice (Schramm et al., 2004; van Hove et al., 2007).
For this reason it is essential to work with improved animal models of allergic airway
hyperreactivity and inflammation that use clinically relevant inhalant allergens such
as HDMs or pollens that humans are allergic to (Herz et al., 2004).
Several groups report on mouse models using human relevant allergens either as
major recombinant allergens or natural extracts, such as house dust mite allergen
(rDer f l) and cockroach allergen (rBla g 2) (Sarpong et al., 2003), recombinant or
natural olive pollen allergen (rOle e 1, nOle e 1) (Batanero et al., 2002), birch pollen
allergen (rBet v 1) (Wiedermann et al., 2001), timothy grass pollen allergen (rPhl p
5) (Linhart et al., 2007), rye grass pollen extract (Cadot et al., 2010) or Aspergillus
fumigatus extract (Murdock et al., 2012). Depending on many factors (e.g., usage of
adjuvants, mice strain, ways of administration) efficiency of clinically relevant aller-
gens to activate the immune response and induce allergic symptoms vary (reviewed
in Torres et al., 2005). Thus, considering above, timothy grass pollen was used in
the present study to establish a mouse model of allergic airway hyperreactivity and
inflammation.
Grass pollen allergens are the most prevalent in causing allergic disorders. It is
known that around 40% of allergic patients are sensitized to grass pollens with
timothy grass (Phleum pratense) pollen being the most common allergen in Europe
with harmful effects in the season from April to October (Andersson and Lidholm,
2003). Its major allergen group V isoform b (Phl p 5b) is responsible for more than
90% of allergic activity in grass pollen-sensitized patients (Petersen et al., 1993;
Flicker et al., 2000).
This study evaluates whether a mouse model of asthma can be established using
recombinant Phl p 5b and if the resulting airway hyperreactivity and inflammation
can be ameliorated using the helminth immunomodulator AvCystatin.
1.7 Allergen-specific immunotherapy
Recently more popular to study in animal models and one of the most promising
treatment strategies of allergy in humans is an immunemodifying therapy - ‘allergen-
specific immunotherapy (SIT)’ giving reasonably promising results, exists since 101
years. In SIT repeated exposure to allergen(s) leads to immunological tolerance,
production of blocking antibodies IgG4 in humans, allergen-specific IgAs, potentially
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regulatory cytokine IFN-γ and induction of CD4+CD25+Foxp3+ regulatory T cells
that are a source of regulatory IL-10 and/or TGF-β. These mechanisms attenuate
allergen-specific Th2-cell responses, including MCs, basophils, eosinophils, allergen-
specific IgEs and Th2-associated cytokines (reviewed in Jutel and Akdis, 2011), and
were initially described by Platts-Mills et al. (2001) as ‘modified Th2’ responses in
cat-allergic children.
Currently practiced subcutaneous administration of allergen extracts or recombi-
nant allergens as subcutaneous immunotherapy (SCIT) gives good results and long-
term efficacy (Durham et al., 1999). Moreover, clinical trials with children showed
that SCIT not only decreased symptoms of allergy, but also reduced development
of asthma and might prevent new sensitizations in rhinitis (Möller et al., 2002; Ja-
cobsen et al., 2007). An alternative to SCIT is a sublingual immunotherapy (SLIT),
which implies administration of higher doses of allergens to the oral mucosa with
very mild side-effects. In 2009, based on a review of more than 60 controlled trials,
a World Health Organization (WHO) confirmed the safety and clinical efficacy of
SLIT (Canonica et al., 2009).
Despite the advances in SIT over a century, decreased immunogenicity, improved
efficacy and safety are the main aims of research on SIT nowadays. This includes ad-
dition of omalizumab; usage of T-cell-reactive peptides, hypoallergenic recombinant
allergens, chemically modified allergens; embedding allergens into nanoparticles; sup-
plementing with immunostimulatory DNA sequences (CpG) or novel adjuvants with
decreased side-effects (reviewed in Casale and Stokes, 2011).
In frame of this work, the potential of AvCystatin as an alternative adjuvant was
evaluated.
1.8 Treatment strategies of allergy and asthma
Incidence of allergic diseases is increasing and have already reached epidemic pro-
portions worldwide. Thus, it is critical to identify new small-molecules and biological
interventions, as well as improve existing treatment strategies that efficiently tackle
the ‘allergic cascade’.
One of the existing strategies proposed to combat allergies is ‘allergen avoidance’.
Although used as primary prophylaxis, it gives disappointing results because e.g. the
complete elimination of contact with allergens is not possible in all cases. Available
established treatments are mainly based on symptom relieving (e.g., corticostero-
ids, β-adenoreceptor agonists, mediator antagonists such as cetirizine or loratadine
and leukotriene modifiers) (reviewed in Holgate and Polosa, 2008). Additionally, few
therapeutics influencing IgEs are being tested, with the most successful so far - oma-
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lizumab, a humanized IgE-specific, non-anaphylactic IgG1 that has been developed
for severe IgE-mediated allergic asthma (Holgate et al., 2005). New therapeutic ap-
proaches to inhibit MC-activation via the modulation of Fc-receptor signaling, as
well as drug candidates targeting stem-cell factor (SCF) with its tyrosine-kinase re-
ceptor (KIT), which is necessary for MCs development, are currently being evaluated
(reviewed in Malbec and Daëron, 2007).
Further on, application of biological agents such as blocking monoclonal antibo-
dies, different fusion proteins or inhibitors of Th2-cell transcription factors aims to
modulate Th2 cells and their responses that orchestrate development of allergic in-
flammation. Some of the targets has successfully completed one or more phases of
clinical trials in asthma (Bosnjak et al., 2011).
In order to assess whether AvCystatin is able to exert its immunomodulatory
effect not only in the pre-clinical murine model but also in the human system,
the effect of AvCystatin on peripheral blood mononuclear cells (PBMCs) isolated
from clinically characterized, timothy grass (P. pratense) pollen allergic patients
was tested in frame of this thesis.
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Led by the above discussed findings, the aim of this study was to test the following
hypotheses:
1. One component of the early events in Th2 immunity are innate immune cells.
It is predicted that in helminth infections mast cells (MCs) are particularly
involved in early responses, priming and establishment of type 2 immunity.
2. The helminth immunomodulator AvCystatin was shown to reduce OVA-
induced allergic asthma in mice. Therefore, depending on its structure (mo-
nomers/oligomers) and biological function as cysteine protease inhibitor, Av-
Cystatin should suppress timothy grass pollen-specific allergic responses by
controlling excessive Th2 immune reaction.
3. AvCystatin was shown to downmodulate allergy through reduction of inflam-
mation and induction of regulatory mechanisms. The hypothesis that AvCysta-
tin can serve as an alternative adjuvant, which enhances the effect of treatment
with allergen-specific immunotherapy was evaluated.
Results of this dissertation are presented in five sections.
Section 3.1 explores a role of MCs in early events of parasitic infection using two
helminths (H. polygyrus and T. muris).
Section 3.2 evaluates the effect of a single helminth molecule AvCystatin in a
mouse model of allergy induced by timothy grass pollen.
Section 3.3 analyzes the relevance of structural and functional aspects of AvCy-
statin in the immunomodulatory effect.
Section 3.4 examines AvCystatin as an adjuvant in allergen-specific immunothe-
rapy.
Section 3.5 assesses the capacity of AvCystatin on modulation of timothy grass




3.1 The role of mast cells during Th2 immunity in
helminth infection
3.1.1 Impaired Th2 responses and reduced host protection
following intestinal helminth infections during mast cell
deficiency
Mast cells (MCs) are well described as effector immune cells and their central role
in Th2-type immune responses (e.g. allergy) is well recognized. Moreover, MCs are
now considered major immune cells involved in host defense, and no longer solely as
‘allergy cells’. Although vast knowledge on the role of MCs in allergy, it is unknown
whether MCs contribute to the early events of non-allergic conditions, as helminth
infections that induce Th2-type immune reactions.
In order to address this question, an influence of MCs during infection with two
model gastointestinal parasites was studied. H. polygyrus is a small intestinal dwel-
ling helminth that can establish Th2-type chronic infection and T. muris - a caecal















Figure 3.1: Scheme of infection with (A) Heligmosomoides polygyrus and (B) Tri-
churis muris. Animals were infected at day 1 with L3 H. polygyrus larvae or em-
bryonated T muris eggs. Immunological parameters were analyzed at day 0 (naive
animals), days 2, 4, 6 and 21 postinfection (p.i.) for H. polygyrus-infected animals









Moreover, all three cytokines were detected at protein level in gut homogenates
of WT, but not MC-deficient animals at day 6 p.i. (Fig. 3.6B). Similarly, results
were confirmed in a second MC-deficient mouse strain (KitW−sh/KitW−sh), where
production of IL-25, IL-33 and TSLP in gut homogenates was also found to be
reduced at day 6 p.i. with either H. polygyrus (Fig. 3.6C) or T. muris (data not
shown). This suggests that MCs play a role in regulation of tissue-derived cytokines
and in return, in induction of Th2 immune responses.
As IL-25 was found to be expressed as the earliest cytokine and in the strongest
level at day 2 p.i. with H. polygyrus (Fig. 3.6A), it was interesting to determine whe-
ther exogenous application of IL-25 was sufficient to restore proper Th2 responses
in KitW/KitW−v MC-deficient mice.
To verify this, recombinant IL-25 was applied i.p. to MC-deficient mice during
the first 4 days of infection. Indeed, administration of rIL-25 dramatically increased
expression not only of IL-25 but also of IL-33 and TSLP in the intestine at day 6 p.i.
(larval stage of H. polygyrus) in comparison with untreated KitW/KitW−v control
infected mice (Fig. 3.7A). Treatment with rIL-25 significantly restored priming of
CD4+IL-13+ T cells in the MLNs to levels comparable with WT animals (Fig. 3.7B).
Additionally, assessment of adult worm burdens at day 21 p.i. (adult worms stage)
showed that application of rIL-25 did not change worm counts in MC-deficient mice.
However, it led to almost complete expulsion of adult worms in WT mice, which
suggests that very high amounts of IL-25 may induce worm expulsion during a
normally chronic infection (Fig. 3.7C). Surprisingly, although worm expulsion was
not affected in H. polygyrus-infected MC-deficient and rIL-25-treated mice, shedding
of parasite eggs into the faeces was significantly reduced in comparison to untreated
KitW/KitW−v controls (Fig. 3.7D). This points into the crucial role of early IL-25
in the development of anti-helminth immunity, which is characterized by impaired
H. polygyrus-egg production in MC-deficient mice.
3.1.3 Transfer of wild type bone marrow restores Th2
immunity and anti-parasitic responses in mast
cell-deficient mice
To further define the role of MCs in the orchestration of Th2 responses during H. po-
lygyrus infection, it was crucial to restore the MC-compartment of mucosal tissues in
KitW/KitW−v mice. The MC-compartment was restored via transfer of whole bone
marrow (BM) from WT animals as described in the literature (Sakata-Yanagimoto
et al., 2011). Although BM transfer results also in the transfer of other cells’ pro-
genitors, however due to the inability of MCs-transfer to properly reconstitute the




H. polygyrus-infected KitW/KitW−v animals that had been ‘repaired’ for MC-
deficiency via adoptive transfer of WT BM showed a significant reduction of worm
burdens and eggs shedding to faeces as assessed at day 21 p.i., comparable to WT
infected controls (Fig. 3.8A, B).
BM transfer also led to restoration of IL-25, IL-33 and TSLP levels in the duode-
num following H. polygyrus infection in comparison to infected, non-reconstituted
control MC-deficient mice at day 6 p.i. (Fig. 3.8D). Furthermore, an increase in the
total cell numbers in MLNs of CD4+IL-13+ T cells was observed in BM reconstitu-
ted H. polygyrus-infected KitW/KitW−v mice and levels were comparable with WT
mice (Fig. 3.8C). BM reconstituted mice had markedly enhanced Hp-Ag-specific
production of IL-5, IL-10 and IL-13 detected in the MLNs culture supernatants
(Fig. 3.8E).
These data indicate, that MCs play a crucial role in Th2 priming and in the
innate regulation of the tissue-derived cytokines IL-25, IL-33 and TSLP during the
early stages of immune responses in the intestine during helminth infection. Hence,
mice deficient in MCs developed a reduced early Th2-type response that could be
restored by reconstitution with exogenous IL-25 and bone marrow transfer. These
data provide novel information regarding the innate role of MCs in the development
of Th2 immune response. It is tempting to speculate that possibly MCs communicate
via the production of adjuvant signals during the early stages of gastrointestinal
helminth infections.
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3.2 Grass pollen-induced mouse model of allergic asthma
3.2 Establishment of a murine model of allergic
asthma with a clinically relevant allergen and
treatment with AvCystatin
3.2.1 Grass pollen- versus OVA-induced model
In order to establish a mouse model of allergic airway hyperreactivity and inflamma-
tion induced by a clinically relevant allergen, the recombinant timothy grass (Phleum
pratense) pollen allergen group V isoform b (rPhl p 5b) was used to sensitize mice
and timothy grass pollen extract (GPE) was used for intranasal challenges.
After a literature review on published mouse models of allergy, in frame of the
present work three intraperitoneal (i.p.) sensitizations with with rPhl p 5b/Alum and
two intranasal (i.n.) challenges with GPE were applied to BALB/c mice (Fig. 3.9A).
In parallel, a classical widely-used OVA-induced allergy model was performed where
animals were sensitized i.p. two times with OVA/Alum and challenged twice i.n.
with OVA (Fig. 3.9B).
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Figure 3.9: Scheme for allergen-induced mouse model of allergic airway hyperreac-
tivity. (A) rPhl p 5b-induced model: animals were injected three times i.p. with
rPhl p 5b/Alum and challenged two times i.n. with whole grass pollen extract
(GPE). (B) Ovalbumine (OVA)-induced model: mice were sensitized twice i.p. with
OVA/Alum and challenged twice i.n. with OVA. Naive control animals were treated
with PBS/Alum and challenged with PBS. Measurement of airway reactivity (AR)
was performed on day 31 and the dissection was done one day later.
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3.2 Grass pollen-induced mouse model of allergic asthma
Cytokine production in the BAL fluid was increased in both models when com-
pared with naive control group. Significantly higher levels of IL-4 were detected in
the BAL fluid of animals sensitized and challenged with the grass allergen (42 ±8.9
pg/ml) than mice treated with OVA (6.5 ±4.3 pg/ml). Production of IL-5 was simi-
lar in both asthma models, additionally significantly higher levels of IL-10 and IL-13
were measured in the BAL fluid of animals sensitized with rPhl p 5b (Fig. 3.10B).
Splenocytes of asthmatic animals from both groups equally proliferated to mitogen
restimulation with concavalin A (data not shown) and when restimulated with the
respective allergen produced high levels of Th2-associated cytokines (Fig. 3.10C).
Antibody titers indicated no pronounced, increasing production of allergen-
specific IgE antibodies after sensitization phase but a dramatic increase of specific
IgE production after challenges (Fig. 3.10D). Moreover, the kinetics of the Th2-
associated antibody: rPhl p 5b-specific IgG1 showed significantly higher levels in
sera of animals from the rPhl p 5b-model than OVA-specific IgG1 in sera of animals
from OVA-model (Figure 3.10E, G, H). This may be due to the clinical relevance of
grass pollen allergen (discussed in Section 4.2) and/or due to an additional sensiti-
zation performed in the rPhl p 5b-model. Assessment of total IgE levels in animals
from both asthma models showed significantly higher levels of antibodies in animals
from rPhl p 5b-model than in mice from OVA-model (Fig. 3.10F). Allergen-specific
IgG2a antibody subclass production was very low in all allergic experimental groups
(Fig. 3.10G, H).
In order to assess lung function, AHR to increasing doses of methacholine (MCh)
was measured at day 31 on in vivo restrained animals by whole body plethysmogra-
phy. At the dose of 50 mg/ml of MCh animals from both asthma models developed
‘longer’ breaks in breathing, which was indicated by high Penh (enhanced pause)
values. The mean ±SEM of Penh values in the rPhl p 5b-group was 5.3 ±2.9 and in
OVA-group 6.4 ±1.2. Naive control mice showed low mean Penh values of 2.6 ±0.6
(Fig. 3.10I). This indicates OVA had a stronger effect in the development of AHR
than the grass pollen allergen.
Taken together, these results clearly show that sensitization with a recombinant
clinically relevant aeroallergen (rPhl p 5b) and challenges with natural grass pollen
extract (GPE) significantly induced all hallmarks of asthma characterized by strong
Th2 responses and increased lung function. Moreover, eosinophils and lymphocytes
infiltration into the lungs, production of selected Th2-associated cytokines, levels of
total IgE, allergen-specific IgE and IgG1 antibodies were induced stronger in the
rPhl p 5b-model than the classical OVA-induced asthma model, which has been
broadly-used in the allergy research.
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3 Results
3.2.2 Treatment with AvCystatin interferes with the mouse
model of allergic asthma induced by the clinically
relevant allergen
To study the effect of the recombinant filarial cystatin (rAvCystatin) on allergen-
induced sensitization and AHR, the rPhl p 5b-induced murine model was employ-
ed, which was established during this work and descried above. For the preventive
treatment BALB/c mice were injected i.p. with rPhl p 5b/Alum allergen and were
treated i.p. four times in weekly intervals with rAvCystatin and then challenged
twice i.n. with GPE (Fig. 3.11). This approach provides rAvCystatin the possibi-
lity for interfere with the sensitization phase starting from the first immunization
with the allergen. As a control to rAvCystatin, a recombinantly expressed dihydro-
folate reductase (rDHFR) protein was applied in the same mode as rAvCystatin.
Experimental groups are provided in Table 3.1.
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Figure 3.11: Scheme of treatment with rAvCystatin intraperitoneal (i.p.) (Subsec-
tion 3.2.2)/ subcutaneous (s.c.) (Subsection 3.2.3) in the rPhl p 5b-induced model
of allergic asthma. Animals were treated with rAvCystatin/ control protein rDHFR
four times in weekly intervals during the sensitization phase with rPhl p 5b/Alum
and challenged two times i.n. with GPE. Naive controls were injected with Alum in
PBS and challenged PBS, accordingly. Measurement of airway reactivity (AR) was
performed on day 31 and dissection was done one day later.
Table 3.1: Experimental groups described in Subsections 3.2.2, 3.2.3 and 3.3.4.
Group name Treatment Sensitization Challenge
naive PBS i.p. PBS i.p. PBS i.n.
asthmatic controls, rPhl p 5b/GPE PBS i.p./s.c. rPhl p 5b i.p. GPE i.n.
rAvCystatin-treated (also with derivates), rAvCystatin
i.p./s.c., rAvCystatin/rPhl p 5b/GPE
rAvCystatin i.p./s.c. rPhl p 5b i.p. GPE i.n.




In order to evaluate the local effect after treatment with rAvCystatin, staining
with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS) and toluidine blue
of the histological lung sections was performed. Analysis of H&E-stained sections
showed downregulated local inflammation, reduced eosinophilia around bronchioles
and small vessels after treatment with rAvCystatin when compared to control groups
(Fig. 3.22C). Moreover, reduced goblet cell hyperplasia was observed in PAS-stained
lung sections when compared with asthmatic mice (Fig. 3.22H). As MCs play an im-
portant role in the development of allergic asthma, in an immediate reaction as well
as in a late phase contributing to lung remodeling and inflammation (see Subsection
1.2.2), the lung tissue was stained with toluidine blue to detect connective tissue MCs
residing in lungs. As expected, asthmatic animals showed local infiltration of MCs
into the tissue when compared with naive animals (8.5 ±4.6 vs. 5.7 ±2.2 MCs/10
high power fields (hpf)) (Fig. 3.16B). In contrast, rAvCystatin-treated animals exhi-
bited no mastocytosis in the lung tissue (4.5 ±2.1 MCs/10 hpf) (Fig. 3.16C). Lungs
of rDHFR-treated animals did not show significant changes when compared with
asthmatic controls.
Together, these results indicate that rAvCystatin interferes with allergen-induced
inflammatory processes in the lungs.
Altered cytokine production at the site of inflammation after treatment
with AvCystatin
Levels of local cytokines were measured ex vivo in the BAL fluid. Treatment
with rAvCystatin significantly suppressed production of IL-5 (p=0.005) and IL-
13 (p=0.02) when compared with asthmatic animals (Fig. 3.13A). However, levels
of IL-4 were not significantly changed after rAvCystatin treatment when compared
with asthmatic animals (p=0.54). Similarly, IL-10 levels in the BAL fluid showed
no statistically significant difference but an increased trend in rAvCystatin-treated
animals when compared with allergic controls (p=0.25) (Fig. 3.13A).
Moreover, treatment with rAvCystatin led to a significant suppression of local
allergen-specific Th2-type cytokines (IL-4, IL-5 and IL-13; p=0.04, p=0.009, p=0.03,
respectively) detected in the supernatants of lung-draining peribronchial lymph no-
de (PBLN) cells restimulated in vitro with the allergen rPhl p 5b. Any changes
in cytokine levels were not observed after treatment with rDHFR control protein
(Fig. 3.13B).





Downregulated systemic cytokine responses due to AvCystatin
treatment
To understand whether AvCystatin also interfered with allergen-specific responses on
systemic level the production of Th2-associated cytokines by splenocytes and serum
antibody levels were determined. In addition to alleviation of rPhl p 5b-induced
allergic asthma in local tissues, AvCystatin significantly downregulated systemic
production of grass pollen-specific Th2-type cytokines such as IL-4, IL-5 and IL-
13 (p=0.004, p<0.001 and p=0.02, respectively) detected in spleen cells culture
supernatants restimulated with rPhl p 5b (Fig. 3.13D). High levels of rPhl p 5b-
specific IL-10 were detected in asthmatic animals (p<0.001) when compared with
naive animals, however the levels were significantly decreased after treatment with
rAvCystatin (p<0.001) in contrast to treatment of mice with the control protein
rDHFR (Fig. 3.13D).
As IL-4 and IL-13 are involved in isotype class switching and/or IgE production,
serum antibody levels were analyzed in all groups. Treatment with rAvCystatin
significantly decreased production of total IgEs and rPhl p 5b-specific IgEs and IgG1s
(p=0.004, p=0.01 and p=0.03, respectively) (Fig. 3.13E-H). No significant changes
in rPhl p 5b-specific IgG2a levels were observed when compared with asthmatic
controls (p=0.66) (Fig. 3.13H). Thus, filarial cystatin shows the systemic effect on
downregulation of allergen-specific cytokines and antibodies.
Increased levels of IL-10 and numbers of CD4+CD25+Foxp3+ T cells
Although systemic grass pollen-specific IL-10 was reduced by rAvCystatin treat-
ment (Fig. 3.13D), restimulation of splenocytes with rAvCystatin resulted in signi-
ficant production of IL-10 in animals treated with rAvCystatin during sensitisation
(p=0.01) (Fig. 3.13C), in line with increased levels of IL-10 in the BAL fluid in the
rAvCystatin-treated group (Fig. 3.13A).
Ex vivo responses to rAvCystatin by splenocytes isolated from rAvCystatin-
treated animals did not lead to a significant increase in any other cytokines examined
(IL-12p40, IFN-γ, IL-4, IL-5, IL-13 or IL-6, data not shown). Thus, our data are in
line with previous findings that filarial cystatin specifically induces the expression
of IL-10 in the murine system.
Regulatory cells also play an important role in downmodulation of allergy and
asthma. Isolated splenocytes were analyzed for the ex vivo expression of regulatory T
cell markers including CD25 and Foxp3. Elevated total numbers of CD4+CD25+Foxp3+
T cells were detected in spleens from rAvCystatin-treated animals when compared




3.2 Grass pollen-induced mouse model of allergic asthma
Analysis of cytokines in the BAL fluid of animals treated with rAvCystatin s.c.
showed unaltered production of IL-4 (p=0.74) (Fig. 3.15C), IL-5 and IL-13 (data
now shown) when compared with asthmatic animals. No difference was observed in
cytokine levels in supernatants from spleen cells cultured with the allergen rPhl p 5b
(Fig. 3.15D). Finally, elevated levels of allergen-specific IgE and IgG1 were observed
in s.c.-treated animals (p=0.62 and p=0.63, respectively) (Fig. 3.15E, F).
A Naive rPhl p 5b/GPEB
rAvCystatin i.p.C rAvCystatin s.c.D
Figure 3.16: Application of rAvCystatin i.p. and s.c. reduced numbers of mast cells
(MCs) in the lungs. Representative lung sections stained with toluidine blue for re-
sident connective tissue MCs (black arrows). Quantification of the data in the text.
Naive: naive control, rPhl p 5b/GPE: asthmatic; rAvCystatin i.p.: rAvCystatin-
treated i.p.; rAvCystatin s.c.: rAvCystatin-treated s.c. animals. Original magnifica-
tion: x400, right side scale bars = 20 µm.
In order to explore on the level of activation and degranulation of MCs, the se-
rum was analyzed for mMCP-1. Treatment with rAvCystatin resulted in decreased
mMCP-1 levels, which were significantly reduced after i.p.-treatment (p=0.018 and
p=0.13, respectively) (Fig. 3.15G). Moreover, rAvCystatin i.p. (4 ±2.8 MCs/10 hpf)
and to lesser extend rAvCystatin applied s.c. (7 ±2.1 MCs/10 hpf), decreased infil-
tration of MCs in the lungs as indicated by toluidine blue staining of lung sections
when compared with asthmatic animals (10.7 ±1.1 MCs/10 hpf) (Fig. 3.16A-D).
The immunomodulatory effect was observed only when of rAvCystatin was applied
intraperitoneally but not subcutaneously. This indicates that rAvCystatin downre-
gulates allergic disease depending on the specific way of its administration.
47
3 Results
3.3 Structural and functional aspects of AvCystatin
in the immunomodulatory effect
In order to explore, whether main features of cystatins play a role in the immu-
nomodulatory effect of rAvCystatin, production and analysis of three forms of the
molecule was performed: (1) a mutated form, not active as protease inhibitor; (2)
truncated, mainly monomeric version; (3) demethylated molecule, designed to lack
a posttranslational modification (PTM) (Fig. 3.17B-D).
rAvCystatin





















Figure 3.17: Scheme of the four derivates of AvCystatin molecule. (A) recombinant
unmodified rAvCystatin; (B) mutated: rAvCystatinmut; (C) truncated: rAvCystatintr
and (D) demethlyted: rAvCystatindm. ‘VLVRC’ (grey): as part of the N-terminal ex-
tension five amino acids including one of the three cysteines ‘C’; ‘LLGG’, ‘QVVAG’
and ‘SW’: three conserved motifs involved in active centers constituting cysteine
protease inhibitor activity (red). ‘C’: conserved cysteine residues forming disulphi-
de bonds (between the second and third conserved domain); ‘K’: lysine, site of the
posttranslational modification (methylation). Information on specific changes of Av-
Cystatin molecules are described in the text.
3.3.1 Protease inhibitor activity: mutated AvCystatin
In order to study an influence of rAvCystatin’s protease inhibitor activity mediated
by three highly conserved motifs involved in active centers, a mutated derivate of
rAvCystatin (rAvCystatinmut) was produced.
The work was done in our group (J. Russ and T. Buhrke, unpublished) and is
described in detail in Section 6.1. Recombinant AvCystatinmut was obtained by site-
directed mutagenesis of each from three conserved domains to, first of all disrupt
the protease inhibition function and at the same time to preserve the overall con-
formational structure of the molecule. Thus, two leucines and two glycines (LLGG)




3.3 Structural and functional aspects of AvCystatin
mers, dimers and oligomers. The truncated derivate lacking the first five N-terminal
amino acids (rAvCystatintr) was detected as a majority of monomers and to lesser
extend dimers, as shown in Western blot under non-reducing conditions (Fig. 3.19A).
Results from this immunological method were confirmed by analytical gel filtrati-
on analysis and by RALS. The RALS-analyzed samples had a protein concentration
of 3-5 mg/ml. Thus, monomers were separated from dimers and oligomers. Next,
molecular weights (MW) of appearing peak populations in the solution were esti-
mated and the profile of examined proteins was graphed. After RALS rAvCystatin
was found to be predominantly oligomeric with a recognized molecular weight of 186
kDa and greater. Unless in Western blot analysis, smaller proportions of dimers and
monomers of a predicted mass of 36 kDa and 18 kDa, respectively, were identified
(Fig. 3.19B). Absorbance trace from a column loaded with rAvCystatintr showed
dimer and monomer peaks only with a predicted monomer mass of 18 kDa, which
confirms results from Western blot analysis (Fig. 3.19C).
These data provide an evidence of heavy oligomerization of unmodified rAvCy-
statin. On the other hand rAvCystatintr lacking an extra N-terminal cysteine is
monomeric in the solution and has the capability to assemble into dimers at high
protein concentrations.
3.3.3 Posttranslational modification: demethylated
AvCystatin
Many proteins undergo various posttranslational modifications, which can play im-
portant functional roles. In order to analyze a newly identified methylation moiety
of rAvCystatin (identified in a cooperation with AG Schmieder; T. Helmbrecht, per-
sonal communication), removal of a methylation at lysine (K) via site-directed DNA
mutagenesis (p.K137L) was done in frame of this work.
 
 
 301     330            360  
 
rAvCys           GTTGCTCAATCAGAATGCAAAAAAAGTTCAGGCGAGGAAGTTAATCTGAAAACATGTAAA  
rAvCysdm         GTTGCTCAATCAGAATGCAAAAAAAGTTCAGGCGAGGAAGTTAATCTGAAAACATGTAAA                       ************************************************************ 
   
 361      390          409        420 
 
rAvCys           AGATTGGAAGGACATCCGGATCAGATTATCACGTTGGAGGCATGGGAGAAATCATGGGAA  rAvCysdm         AGATTGGAAGGACATCCGGATCAGATTATCACGTTGGAGGCATGGGAGCTGTCATGGGAA  
                 ************************************************   ********* 
 
 421      450    471 
 
rAvCys           AATTTTTTGCAAGTCAAAATTCTGGAAAAAAAAGAAGTACTCTCATCAGTG rAvCysdm         AATTTTTTGCAAGTCAAAATTCTGGAAAAAAAAGAAGTACTCTCATCAGTG                  *************************************************** 
Figure 3.20: Alignment of rAvCystatin and rAvCystatindm cDNA sequences
(part). In red marked mutation site c.409_411AAA>CTG, which results in
p.K137L. Consensus: identical residues are indicated by ( * ).
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3 Results
A successful nucleotide mutation in DNA sequence of rAvCystatin in pET28b vec-
tor was confirmed by DNA sequencing (Fig. 3.20). Indeed, the introduced mutation
at c.409_411AAA>CTG was identified, which in consequence replaced lysine (K)
by leucine (L), p.K137L (Fig. 3.17D).
In frame of this work, the E. coli -recombinantly expressed demethylated rAvCy-
statin (rAvCystatindm) was purified and checked in a functional in vitro assay. The
suppressive function of rAvCystatindm was confirmed by the 3H-thymidine incorpo-
ration assay of in vitro proliferating splenocytes stimulated with OVA and rAvCy-
statin’s derivates (Fig. 3.18B). Demethylated rAvCystatindm, equally as unmodified
rAvCystatin, suppressed OVA-induced proliferation of splenocytes from DO10.11
mice as measured by the incorporated 3H-thymidine and displayed as counts per
minute (cpm) (Fig. 3.18B).
These data suggest the identified PTM is not responsible for rAvCystatin’s im-
munosuppressive capacity in vitro. Yet, its in vivo capacity could be addressed in
future studies.
3.3.4 Functional analysis of AvCystatin’s derivates in a
murine model with a clinically relevant allergen
To study the functional effect in vivo of recombinant AvCystatin’s derivates,
rAvCystatintr, rAvCystatinmut and rAvCystatin (as a positive control) were app-
lied in the model of allergic airway hyperreactivity and inflammation induced by
grass pollen allergen as shown in Fig. 3.11. Experimental groups are in Table 3.1.
The suppressive capacity of cystatin is independent of oligomerization
and protease inhibitor activity
Analysis of the BAL fluid and histology of lungs revealed that rAvCystatin deriva-
tes applied during sensitiation with rPhl p 5b suppressed local inflammation. All
forms of cystatin (unmodified rAvCystatin, rAvCystatintr, rAvCystatinmut) signifi-
cantly reduced numbers of total cells (p=0.01, p=0.02, p=0.01, respectively) and
eosinophils (p=0.0008, p=0.0002, p=0.0009, respectively) in the BAL fluid when
compared with asthmatic animals (Fig. 3.21A).
Staining of lung tissues with H&E and PAS confirmed that treatment with any of
the rAvCystatin derivate interfered with allergen sensitization and challenge resul-
ting in inhibition of eosinophils recruitment into the lung tissue, reduction of small









































Figure 3.22: Application of rAvCystatin and derivates suppressed inflammatory
changes in the lungs. Representative lung sections stained with H&E (A-E) for
detection of eosinophils. In blue: nuclei of cells, in red eosinophilic structures. (F-J)
Staining with PAS for analysis of goblet cells. Black arrows indicate goblet cells
producing mucus. Naive: naive control, rPhl p 5b/GPE: asthmatic; rAvCystatin:
rAvCystatin- or derivate-treated animals; aw: airways; bv: blood vessel. Original
magnification: H&E x100 (inset x400); PAS x400; left side scale bars = 100 µm,
right side scale bars = 20 µm.
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3.4 Allergen-specific immunotherapy and AvCystatin
3.4 Allergen-specific immunotherapy and adjuvant
capacity of AvCystatin
Currently the only successful and effective treatment available for allergy is an
allergen-specific immunotherapy (SIT). However, there is a need for improving the
efficacy of this treatment as well as reducing the incidence and severity of adverse
reactions. Thus, efforts to tackle this matter include the use of modified allergens,
alternative routes of administration and novel adjuvants.
In order to explore the capacity of filarial cystatin as an adjuvant in SIT, a mouse
model of OVA-specific immunotherapy was established in frame of this dissertati-
on (in a cooperation with AG Hamelmann) and rAvCystatin, as an adjuvant, was
applied together with the model allergen OVA.
3.4.1 Establishment of a model: OVA-specific
immunotherapy suppresses airway manifestations in
asthmatic mice
Two i.p. sensitizations with OVA/Alum and three aerosol challenges with OVA in
PBS were applied to BALB/c mice. The allergen-specific immunotherapy (SIT)
treatment was performed s.c. with high dose (SIT high) or lower dose (SIT low) of
OVA between the sensitization and the challenge phase. One day before analysis,
airway reactivity (AR) was measured in vivo (Fig. 3.23). Experimental groups are








Figure 3.23: Scheme of the OVA-induced immunotherapy model of allergic asth-
ma. Sensitization 2x i.p. with OVA/Alum in two-week intervals, SIT s.c.: 3x OVA
allergen-specific s.c. treatment with either SIT high or SIT low, followed by 3x ae-
rosol challenge with OVA.
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3.4 Allergen-specific immunotherapy and AvCystatin
To evaluate the effect of repeated s.c. administration of the allergen, local and
systemic level of inflammatory responses was assessed. Significantly reduced num-
bers of total cells, eosinophils and lymphocytes were observed in the BAL fluid after
SIT high (p=0.0004, p=0.003 and p=0.0001, respectively) and SIT low (p=0.0059,
p=0.04 and p=0.0003, respectively) treatment. Numbers of macrophages in the
BAL fluid were not significantly changed after SIT high (p=0.19) or after SIT low
(p=0.67) application when compared with asthmatic animals (Fig. 3.24A).
Analysis of cytokines in the BAL fluid indicated that SIT high and SIT low treat-
ment decreased, however not significantly, IL-5 and IL-13 levels (p=0.11, p=0.9, re-
spectively). On the other hand, SIT high significantly increased production of IL-10,
an important regulatory cytokine in asthma treatment, but not SIT low (p=0.007,
p=0.11, respectively) (Fig. 3.24B).
Allergen-specific immunotherapy had also a systemic effect in this allergy model.
Levels of total IgEs were decreased after SIT high treatment and surprisingly in-
creased after SIT low, however changes were not statistically significant (p=0.06,
p=0.1, respectively) (Fig. 3.24C). High and low doses of SIT significantly decreased
allergen-specific IgE and IgG2a antibody production (SIT high: p=0.005, p=0.03
and SIT low: p=0.02, p=0.03, respectively) (Fig. 3.24D, F). Only SIT high showed
trend towards increased production of allergen-specific IgG1 antibodies (p=0.34),
levels of those stayed unaltered after SIT low application (p=0.71) (Fig. 3.24E).
The OVA-induced immunotherapy murine model of allergic asthma and applica-
tion of the allergen as therapy were successfully established. SIT high treatment had
more beneficial effects than application of SIT low.
3.4.2 Adjuvant capacity and routes of AvCystatin
administration in the immunotherapy model
As the SIT high showed already very strong suppressive effect on allergic asthma,
treatment with SIT low seemed possible to be further improved. Therefore, SIT low
therapy was chosen to be applied together with a potential adjuvant, rAvCystatin.
Subsequently to test an adjuvant capacity of rAvCystatin, the molecule was mixed
with OVA and applied all together s.c. (rAvCystatin + OVA s.c.) as a therapy in
the first approach. In the second and third approach, it was administered in two
separate, either s.c. or i.p., injections at the same time with SIT low (rAvCystatin
s.c. & OVA s.c. or rAvCystatin i.p. & OVA s.c.) (Table 3.2 and Fig. 3.25).
Administration of rAvCystatin as an adjuvant in SIT low did not improve AHR.
The function of asthmatic lungs was even exacerbated after rAvCystatin-adjuvant
to SIT therapy (Fig. 3.26A).
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3 Results
Additional suppressive capacity of rAvCystatin as an adjuvant was not observed
locally after examination of the BAL fluid for total cell, eosinophils or lymphocy-
tes influx when compared with SIT low group. Surprisingly, a marked increase in
numbers of total cells and eosinophils into the site of inflammation was observed
after administration of rAvCystatin i.p. & OVA s.c. (p=0.03, p=0.009, respective-
ly) (Fig. 3.26B). This suggests i.p. application of rAvCystatin as an adjuvant in
allergen-specific immunotherapy aggravates local inflammation although SIT low
was applied.
1 28 49 5030
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Figure 3.25: Scheme of allergen-specific immunotherapy treatment with AvCysta-
tin as an adjuvant in the OVA-induced immunotherapy model of allergic asthma.
Sensitization 2x i.p. with OVA/Alum in two-week intervals, therapy (four separa-
te groups): SIT low s.c.; rAvCys + OVA s.c.; rAvCys s.c. & OVA s.c.; rAvCys i.p.
& OVA s.c., followed by 3x aerosol challenge with OVA. Airway reactivity (AR)
analysis was performed on day 49 and dissection was done one day later.
Analysis of systemic responses did not indicate further improvement. In addition,
rAvCystatin when applied s.c. as an adjuvant to SIT low (mixed or as a separate
injection) significantly magnified production of IL-4 (p=0.003, p=0.0003, respective-
ly) and IL-5 (p=0.02, p=0.04, respectively) by spleen cells restimulated with OVA
in vitro. Levels of IL-10 (p=0.26, p=0.43) and IL-13 (p=0.11, p=0.59) were unchan-
ged in those two groups. On the other hand a significant decrease of OVA-specific
IL-4 and IL-10 production was observed after administration of rAvCystatin i.p. &
OVA s.c. (Fig. 3.26C, D). Allergen-specific IgE production was unaltered after adju-
vant rAvCystatin application. However, a significantly increased OVA-specific IgG1
was determined in sera from rAvCystatin s.c. + OVA s.c.- and rAvCystatin i.p. &
OVA s.c.-treated animals when compared with SIT low-treated animals (p=0.0001,
p=0.0004, respectively). No significant increase in OVA-specific IgG2a levels was
observed (Fig. 3.26E-G). Thus, data do not show conclusive results.
Application of rAvCystatin did not show beneficial adjuvant capacity to SIT low.
Moreover, in some instances rAvCystatin was aggravating hallmarks of asthma when




3.4.3 Suppressive capacity of AvCystatin in the
OVA-induced immunotherapy model of asthma
As the additive effect of rAvCystatin to specific immunotherapy - SIT low was
not observed, it was important to explore whether rAvCystatin by its own has any
suppressive capacity in this relatively strong OVA-induced immunotherapy model of
allergic asthma, in comparison with SIT treatments. Thus, rAvCystatin was applied
alone i.p. as a ‘therapy’ before challenges on day 28, 30 and 32 as shown in Fig. 3.25.
Measurement of AR by whole-body plethysmography in response to inhaled in-
creasing doses of MCh showed that rAvCystatin applied i.p. before challenges slight-
ly decreased AHR when compared with asthmatic animals (p=0.12). However,
Penh values from this group remained higher than SIT high or SIT low treatment
(p=0.0005, p=0.003, respectively) (Fig. 3.27A).
Examination of the BAL fluid and cell counts revealed a minor, not significant
improvement of the inflammatory cell infiltration into the lungs after rAvCystatin
i.p. application (Fig. 3.27B).
It was clear that rAvCystatin had a strong suppressive systemic effect in the
OVA-induced model. Levels of OVA-specific Th2-associated cytokines (IL-4, IL-5,
IL-10 and IL-13) were significantly decreased after rAvCystatin i.p. treatment, as
assessed by examination of supernatants from spleen cells cultured in vitro with
OVA (p<0.0001, p=0.0005, p=0.0007 and p=0.01, respectively) (Fig. 3.27C).
Further, examination of antibodies in serum revealed that rAvCystatin had a ca-
pacity to interfere with antibody production. Levels of total IgE and OVA-specific
IgE showed a decreased trend (p=0.08) (Fig. 3.27B). However, no significant alte-
ration in OVA-specific IgG1 or IgG2a production was observed after rAvCystatin
i.p. treatment when compared with asthmatic controls (p=0.9, p=0.6, respectively)
(Fig. 3.27D).
Surprisingly, although SIT high and SIT low reduced all main hallmarks of asthma
presented above, allergen-specific immunotherapy did not improve lung pathologi-
cal changes caused by the allergen. Neither number of eosinophils, lymhocytes nor
goblet cell hyperplasia was diminished in the lungs as assessed on H&E and PAS-
stained lung sections (Fig. 3.28C, D and J, K). Importantly, rAvCystatin had a
downregulatory effect on mucus producing goblet cells. After histological analysis
of PAS-stained lung sections, reduced goblet cell hyperplasia was observed in all
groups, where rAvCystatin was applied (Fig. 3.28L-N). No clear difference in re-
cruitment of inflammatory cells was observed between lungs of animals from any of
the groups treated with rAvCystatin and lungs of asthmatic animals (Fig. 3.28B,
E-G). Data show that rAvCystatin applied i.p. exerted partial immunosuppressive






























































Figure 3.28: Allergen-specific immunotherapy with OVA did not improve the lung
pathology. Application of rAvCystatin suppressed goblet cell hyperplasia in the
lungs. Representative lung sections stained with (A-G) H&E for eosinophils, in blue:
stained nuclei of cells. (H-N) Staining with PAS for analysis of goblet cells, black
arrows indicate goblet cells producing mucus. Naive: naive control, asthmatic: OVA
sensitized and challenged control; SIT high: OVA high dose; SIT low: OVA low dose;
rAvCys + OVA s.c.: rAvCystatin mixed with OVA, applied s.c.; rAvCyst i.p. & OVA
s.c.: rAvCystatin treated i.p. & OVA s.c.; rAvCyst i.p.: treated with rAvCystatin i.p.
before OVA-challenge. aw: airways; bv: blood vessel. Original magnification: H&E
x100 (inset x400); PAS x400; left side scale bars = 100 µm, right side scale bars =
20 µm.
62
3.4 Allergen-specific immunotherapy and AvCystatin
Table 3.3: Cystatin-specific cytokines measured in the supernatants from spleno-
cytes cultured with rAvCystatin in vitro.
Spleen cytokines, mean ±SD (ng/ml)
Group IL-10 IL-13 IFN-γ
Naive 0.13 ±0.04 0.01 ±0.002 0.24 ±0.05
Asthmatic 2.36 ±0.65 4.30 ±0.38 0.10 ±0.04
SIT high 0.29 ±0.20 3.17 ±1.17 1.21 ±0.16
SIT low 1.37 ±0.48 2.61 ±1.56 0.33 ±0.31
rAvCys + OVA s.c. 3.27 ±0.26 1.38 ±1.20 1.37 ±0.26
rAvCys i.p. & OVA s.c. 0.40 ±0.27 2.76 ±1.21 nda
rAvCys i.p. 0.72 ±0.03 nd nd
and - not detected
High levels of IL-10 were detected in rAvCystatin-restimulated supernatants from
asthmatic animals as well as from rAvCystatin + OVA s.c.-group. Cystatin-triggered
IL-13 secretion was observed in animals from all groups except from naive and rAv-
Cystatin i.p. alone-treated mice. Increased production of IFN-γ after rAvCystatin
treatment was detected in supernatants from rAvCystatin + OVA s.c.-treated group.
No IFN-γ was detected in supernatants from spleen cultures of rAvCystatin i.p. &
OVA s.c.-group as well as of rAvCystatin i.p. alone-treated animals. It seems that
rAvCystatin i.p. application did not lead to any other rAvCystatin-specific cytokine
production than the regulatory cytokine IL-10 (Table 3.3).
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3.5 Cells from allergic patients and AvCystatin
3.5.1 Establishment of an in vitro system with human
peripheral blood mononuclear cells
As a first approach an in vitro system outside of the pollen season was established
in order to determine the optimal timing and dosage of allergen and rAvCystatin
restimulation.
Grass pollen-induced proliferation of lymphocytes
In order to optimize the culture conditions a primary kinetic experiment with various
amounts of GPE was performed. PBMCs were obtained from subjects outside of
the pollen season. The most potent proliferation of human PBMCs was observed
at day 7 with 5 µg/ml of GPE as assessed by differences in frequencies of CFSElow
lymphocytes between three grass pollen allergic subjects and two healthy controls
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Figure 3.30: Cystatin applied prior to stimulation with GPE reduced production
of allergen-specific IL-13 and increased levels of IFN-γ. Levels of (A) IL-13, (B) IFN-
γ and (C) IL-10 in supernatants from allergic subjects and healthy controls. The
mean values ±SEM from the group. Compared to GPE stimulation. (D) FACS plots
with frequency of CD4+IFN-γ+ proliferating T cells of allergic patients. The mean
values from the group as % of CD4+ live T cells. Allergic: N=3; healthy controls:
N=2. *, p< 0.05; **, p< 0.01; ***, p<0.001 are considered statistically significant.
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3 Results
To analyze an eventual influence of Lipopolysaccharide (LPS) on lymphocyte pro-
liferation, PBMCs were stimulated with corresponding doses of LPS as detected in
GPE. LPS induced proliferation of less than 2% PBMCs and there were no diffe-
rences in response to LPS between lymphocytes from allergic and healthy subjects
(1.25 ±0.24 and 1.41 ±0.14, p=0.38, respectively) (Fig. 3.29C). This indicates LPS
in GPE had no significant influence on the proliferative responses of human PBMCs.
Time- and dose-dependent effect of AvCystatin
In a preliminary study, culture periods, conditions and doses with rAvCystatin were
verified in order to evaluate the most prominent immunosuppressive effect of the
protein on Th2-type responses of allergic cells. The application of a lower dose 2.5
µg/ml (0.15 µM) of rAvCystatin (rAvCys low) two hours prior to GPE stimula-
tion (rAvCys low+GPE) resulted in a significant suppression of IL-13 levels and
increased IFN-γ production of PBMCs from allergic subjects (p=0.004, p=0.01, re-
spectively) (Fig. 3.30A, B; Table 3.4). Although levels of IL-10 were increased, the
differences were not statistically significant when compared with GPE stimulation
alone (p=0.49) (Fig. 3.30C; Table 3.4). PBMCs from healthy controls did not show
increased IL-13 or IFNγ production after GPE stimulation (Fig. 3.30A, B). Howe-
ver, higher levels of IL-10 from healthy cells stimulated either with GPE alone or
rAvCystatin and GPE were observed (Fig. 3.30C).
Table 3.4: Timing and doses of incubation with rAvCystatin in vitro: cytokine
levels, N=2-3 allergic subjects.
Cytokines, mean ±SEM (ng/ml)
Stimulation IL-13 IL-10 IFN-γ
unstimulated 0.39 ±0.23 nda 0.13 ±0.09
GPE 8.42 ±0.82 0.05 ±0.02 0.69 ±0.32
rAvCys low+GPE 4.26 ±0.45 0.09 ±0.05 2.98 ±1.24
GPE+rAvCys low 6.04 ±0.95 0.04 ±0.01 0.49 ±0.04
rAvCys high+GPE 5.82 ±0.25 0.06 ±0.01 0.87 ±0.14
GPE+rAvCys high 7.05 ±0.38 0.05 ±0.01 0.19 ±0.07
and - not detected
Furthermore, the frequency of allergen-specific CD4+IFN-γ+ T cells was increased
after stimulation with rAvCystatin prior to GPE (Fig. 3.30D). Stimulation with
rAvCystatin alone did not induce proliferation nor cytokine production (data not
shown).
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3.5 Cells from allergic patients and AvCystatin
In contrary to stimulation with low doses of rAvCystatin before GPE, application
at the same time as GPE (GPE+rAvCys low) or incubation with high dose of
rAvCystatin (rAvCys high) neither before (rAvCys high+GPE) nor at the same
time (GPE+rAvCys high) as GPE showed promising suppressive effects on allergic
responses (Table 3.4). Data indicate that rAvCystatin exerted immunomodulatory
effect at the specific timing and dose.
3.5.2 Allergen-induced immune responses in the grass pollen
season
The effect of rAvCystatin in vitro on human T cell immune responses from allergic
subjects was further evaluated during the pollen season. To this end, human PBMCs
isolated from peripheral blood of clinically characterized patients allergic to timothy
grass pollen were examined in the in vitro assay as established before.
Clinical characteristics of allergic study subjects
A group of 21 timothy grass pollen allergic subjects was examined in the grass pollen
season. Clinical characteristics of the study subjects are indicated in Table 3.5.
All recruited patients showed allergic symptoms (asthma and/or allergic rhinitis).
In the serum of all subjects P. pratense-specific IgEs were detected. The majority of
patients had elevated allergen-specific IgE levels (> 3.53 kUA/I), which correspond
to the defined by ImmunoCAP assay (Phadia AB, Uppsala, Sweden) class of three
and higher (reviewed in Cox et al. 2008). Only five subjects had lower allergen-
specific IgE levels (range 0.66-1.76 kUA/I) and were ranked as class one or two. On
entering the study, subjects were free of oral steroids or immunotherapy for at least
3 months. All of the subjects were otherwise in a good health condition. From the
clinical files it was known that most of recruited allergic subjects suffered from other
than timothy grass pollen allergies. The most common was allergy to animal dander,
HDMs and spring flowers. Only three subjects did not show allergy to anything else
than timothy grass.
In order to understand the effect of rAvCystatin on the recall response of allergen-
specific T cells, PBMCs from grass pollen allergic subjects were stimulated with
GPE and allergen-specific responses were assessed. The aim was to monitor allergen-
specific proliferation and to quantify cytokines involved in the Th2 immunity (such as
IL-4, IL-5, IL-13) as well as cytokines encompassed in the regulation of the allergic
responses, such as IL-10 and IFN-γ. Levels of these cytokines were measured in
the culture supernatants after 3 days of GPE-stimulation of PBMCs. Additionally,
proliferative and cytokine responses of CD4+ T cells to GPE were measured at day




























































































































































































































































































































































































































































































































































































































































stimulated PBMCs, however not significantly (p=0.36) (Fig. 3.32C). This can be ex-
plained by the fact that no significant change in IL-13 production was observed after
in vitro application of rAvCystatin prior to GPE-stimulation (Fig. 3.32A), but there
was a considerable increase in IFN-γ in the presence of rAvCystatin (Fig. 3.32B). The
Th2/Th1 ratio was substantially decreased after application of rAvCystatin when
compared with GPE-stimulation alone (Fig. 3.32C). Further analysis of 3-day cul-
ture supernatants showed no significant change in levels of IL-10 of GPE-stimulated
PBMCs in the presence of rAvCystatin when compared with supernatants of GPE-
stimulated PBMCs (data not shown).
Table 3.6: Cytokine response to allergen and rAvCystatin; subgroup mean ±SEM.
Moderate and severe subgroup of allergy, in total examined N=21 allergic subjects.
Allergy subgroups
Cytokines Stimulation Moderate Severe
(pg/ml) (0-17 kUA/I)a, N=9 (>17.5 kUA/I), N=12
IL-13 Unstimulated 56 ±9 120 ±42
GPE 314 ±71 2064 ±988
rAvCys+GPE 378 ±111 2523 ±1379
rAvCys 82 ±34 291 ±138
IFN-γ Unstimulated 192 ±89 19 ±10
GPE 3588 ±1101 6304 ±2314
rAvCys+GPE 5725 ±1480 11110 ±3493
rAvCys 120 ±61 20 ±7
IL-10 Unstimulated 9 ±5 4 ±3
GPE 562 ±112 434 ±73
rAvCys+GPE 592 ±104 349 ±60
rAvCys 14 ±13 2 ±1
akUA/I - kilounits of IgE antibody per liter
Intracellular allergen-specific cytokine secretion
Under conditions of optimal GPE concentration a significant increase of proliferation
(CFSElowCD4+ T cells) was detected at day 7 of cell culture when compared with
unstimulated PBMCs (p=0.02) (Fig. 3.34A). However, stimulation with rAvCystatin
and allergen did not alter the percentages of grass pollen-reactive CD4+ T cells that
proliferated (p=0.8) (Fig. 3.34A).
In order to evaluate the effects of rAvCystatin on the cytokine patterns of indi-
vidual allergen-responding T cells, an intracellular staining for the cytokines IL-4,
IL-10 and IFN-γ on the single cell level at the day 7 of culture was performed. In-





4.1 Mast cells and Th2 response
Both parasites and allergens induce Th2-driven immunopathologies. The key players
in Th2-type immunity are effector CD4+ Th2 cells producing signature Th2 cyto-
kines (IL-4, IL-5, IL-10 and IL-13). Th2-associated cytokines are essential for the
differentiation, survival and activity of MCs, basophils, eosinophils, neutrophils and
mucus producing cells as well as for the tissue homing of Th2 cells and for produc-
tion of the antibody isotypes like IgG4 and IgE (Maizels and Yazdanbakhsh, 2003;
Finkelman et al., 2004; Anthony et al., 2007; Saenz et al., 2008). Additionally, novel
tissue-derived cytokines with proinflammatory functions, such as IL-25, IL-33 and
TSLP were described to initiate and regulate Th2 immune response in helminth
infections as well as in allergy (Bilsborough et al., 2006; Wang et al., 2007; Gos-
wami et al., 2009; Massacand et al., 2009; Liew et al., 2010; Iwakura et al., 2011;
Medzhitov et al., 2011). MCs are involved in type 2 immune responses and typically
have been regarded as effector cells in later stages of helminth infections and allergy,
while their task in Th2 priming has been relatively neglected. The present study
reveals a role of MCs in the early events of Th2 immunity induced by parasites as
well as the function of tissue-derived cytokines.
Two independent mouse models of MC-deficiency showed that mice lacking MCs
were unable to develop proper Th2 immunity, failed to expulse worms and to control
parasitic egg production. This was observed in the present study for the infection
with the duodenal helminth H. polygyrus as well as the ceacal dwelling nematode
T. muris. Bone marrow (BM) ‘repair’ of the MC-compartment led to restoration
of the anti-parasitic responses and Th2 priming. It has been shown that transfer of
whole BM but not bone marrow-derived-cultured MCs (BMMCs) restored mucosal
MCs in the intraepithelial layer of the intestinal tract. In vitro generated MCs tend
to appear as too immature and inactive to properly restore their tissue distributi-
on and function in the small intestine and give a raise to different types of MCs,
depending on the site of development (Abe and Nawa, 1987). Nakano et al. (1985)
showed that i.p. transfer of BMMCs successfully restored MCs populations in the
peritoneal cavity, spleen, skin and stomach of KitW/KitW−v mice. Interestingly, no
restoration of MCs in the small intestine and some other organs after i.p. or i.v.
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BMMCs injections has been reported (Nakano et al., 1985; Tanzola et al., 2003).
Additionally, many studies circumvent problems associated with BMMCs reconstitu-
tion in the small intestine by transfer with whole BM, and such approach has been
accepted when investigating the role of MCs in the small intestine (Ierna et al.,
2008; Sakata-Yanagimoto et al., 2011). However, in general it is difficult to predict
whether engrafted cells can restore all functions of the corresponding populations of
MCs existing in wild type mice. The most convincing and widely accepted argument
about a particular role of MCs is when transferred and engrafted BM, BMMCs or
in vivo-derived MCs convert the phenotype of MC-deficient mice similarly to that
observed in WT animals (Kawakami, 2009).
Although transfer experiments with whole BM might not be MC-specific, in the
present study it is unlikely that BM transfer, even if bringing type 2 producing cell
progenitors (e.g. multipotent progenitor type 2), restored Th2 immunity indepen-
dently of MCs reconstitution. Saenz et al. (2010) showed that the accumulation of
multipotent progenitor (MPP) type 2 cell population in the gut-associated lymphoid
tissue was absolutely dependent on IL-25 expression. With such a signal MMP(type
2) cells were able to promote Th2-cytokine responses. In the present study no IL-25
levels were observed in KitW/KitW−v mice upon helminth infection, thus this cell
progenitors were unlikely to be responsible for the restoration of the phenotype in
MC-deficient mice. Therefore, it is probable that the absence/inactivity of cell pro-
genitors is caused by a lack of IL-25 expression following infection in MC-deficient
mice.
Furthermore, it was evident that MCs were involved in regulating the tissue-
derived cytokines IL-25, IL-33 and TSLP during the first days of helminth infection
with H. polygyrus and T. muris. Fort et al. (2001) proved the relevance of IL-25
in induction of Th2 immune responses. Exogenous administration of IL-25 led to
expression of IL-4, IL-5 and IL-13, eosinophilia and increased IgE levels, thus am-
plifying allergic type inflammatory responses by its actions on accessory cells that
were MHCIIhigh CD11cdull and lineage−. Moreover, Zhao et al. (2010) showed that
mice treated with IL-25 exhibited strong induction of Th2-derived cytokines and
changes in the function of the intestinal tract including enhanced smooth muscle hy-
per contractility and enhanced mucosal permeability. In frame of the present work,
reconstitution of MC-deficient animals with rIL-25 reversed the Th2 impairment and
led to worm expulsion and decreased egg burden, pointing to the importance of MCs
and tissue-derived cytokines in early Th2 immune responses in helminth infections.
It became clear that MCs residing in the intestinal mucosa are required for the in-
duction of IL-25 in the tissues leading to mucosal homeostasis. As it was not possible
to directly prove that MCs are the source of IL-25 during infection with H. polygy-
rus, it cannot be excluded that MCs contribute to the production of tissue-derived
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4.2 AvCystatin in the grass pollen-induced model of allergy
cytokines via other mechanisms. MCs are able to produce various pro-inflammatory
molecules, which are released from pre-stored granules. It is very probable that a
certain pre-formed mediator released from MCs gives an adjuvant boost to epithelial
cells and/or other cells for expression of IL-25/IL-33/TSLP cytokines. It would be
very interesting to investigate the following questions: What exact mediator is re-
sponsible for this effect? Which cells are responding to MC-specific signals by early
production of tissue-derived cytokines? Are there any other cells that together with
MCs orchestrate Th2 immunity during helminth infection but also during allergic
reactions?
The data in this study on MC-deficient mice as well as reconstitution experiments
provide an evidence for a critical involvement of MCs in priming of Th2 responses.
Thus, this work shows that MCs orchestrate protective Th2 immunity upon helminth
infection (Hepworth et al., 2012). Moreover, current understanding of the early role
of MCs in type 2 responses could be applied in the prevention of the development
of other Th2-driven inflammatory conditions such as asthma and allergies.
4.2 Influence of the helminth immunomodulator
AvCystatin in the model of allergic asthma
Allergic asthma induced by the clinically relevant allergen
Animal models of asthma present an excellent experimental tool to investigate all-
ergic disorders and to evaluate possible treatments in vivo.
In frame of this thesis an improved mouse model of airway hyperreactivity and
inflammation induced by the clinically relevant human aeroallergen, timothy grass
(P. pratense) pollen, was established. Three sensitizations with the recombinant
major pollen allergen group V isoform b (rPhl p 5b) followed by challenges with
standardized timothy grass pollen extract (GPE) led to all hallmarks of allergic
airway hyperreactivity, including inflammatory cell influx into the BAL fluid, local
and systemic induction of Th2-associated cytokines and increased levels of allergen-
specific antibodies. Isoform b of Phl p 5 (Phl p 5b) was described to be one of
the most reactive allergens from the group V of grass allergens, partially due to
bearing at least one more IgE antibody binding epitope than an isoform a (Phl p
5a) (Andersson and Lidholm, 2003). The major timothy grass pollen allergen group
V is an RNAse involved in the plant’s defence against infections. Contribution of
plant RNAses in the development of allergies in human is so far unknown in contrast
to other allergens exhibiting proteolytic activity that contribute and enhance allergic
responses, like the major HDM allergen (Der p 1) or papain allergen (Car p 1), acting
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as cysteine proteases (Chapman et al., 2007; Gunawan et al., 2008; Cunningham
et al., 2012).
In order, to establish an improved model induced by the grass pollen allergen,
the BALB/c mouse strain was chosen. In line with other studies, a very successful
induction of allergic asthma was achieved in this mouse strain in our study. Seitzer
et al. (2005) showed that BALB/c but not C57BL/6 or SJL/j mice were efficiently
responding to timothy grass pollen allergens and were qualified as ‘high’ responders
to P. pratense grass pollen. The same group reported earlier that the IgE response
of BALB/c mice to P. pratense extract and allergens resembles the one observed
in allergic human patients. The only difference to humans was that BALB/c mice
did not react to Phl p 1 that most of the human patients respond to (96%) followed
by a response to Phl p 5 (80%) and Phl p 6 (75%) allergens (Niederberger et al.,
1998; Vrtala et al., 1999; Rossi et al., 2000; Seitzer et al., 2003). Additionally, the
sensitization with a single allergen like Phl p 5b gives a possibility to produce a
fusion protein with any other molecule that would serve as a treatment in the future
and would enable such a chimeric construct to target allergen-specific Th2 cells. For
these reasons recombinant Phl p 5b, as a clinically relevant allergen, was chosen for
sensitization of BALB/c mice in frame of this thesis.
Numerous studies report on sensitization with OVA antigen by intraperitoneal
(i.p.) (Hamelmann et al., 2000; Whitehead et al., 2003), subcutaneous (s.c.) (Corry
et al., 1996; Faustino et al., 2012), intranasal (i.n.) (Mori et al., 2011) and intra-
treacheal (i.t.) (Mizutani et al., 2010) delivery. In this regard, i.p. injections were
reported to induce higher production of allergen-specific IgEs than i.n. sensitization
(Zhang et al., 1997). However, there is not so much information available on diffe-
rent ways of sensitization to grass pollen allergens in mice and the best described
route so far is i.p. injection (Darcan et al., 2005; Wallmann et al., 2010). In the pre-
sent study challenge was achieved by i.n. applications of whole pollen grass extract
(GPE). Such delivery mimics the way humans are being challenged in the pollen
season when getting in contact with the aeroallergen. Some studies report on use
of recombinant Phl p 5 for a successful i.n. challenge (Darcan et al., 2005; Gabler
et al., 2006). However, considering the cost of recombinant allergens and the fact
that extracts apart from various allergens bear other components like oxidases or
bioactive lipid mediators (PALMs), which act as ‘natural adjuvants’ and contribute
to Th2-polarization and development of allergic responses (Plötz et al., 2004; Bol-
dogh et al., 2005; Traidl-Hoffmann et al., 2005), the whole pollen extract was chosen
in this study.
Grass pollen extracts from different companies show relatively big heterogenei-
ty regarding the presence of individual allergens (Focke et al., 2008). In frame
of this work, all experiments were performed with a standarized batch of GPE
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with a defined content of Phl p 5 per amount of grass extract (6.09 ng/PNU as
38.5 µg/mg). Numerous studies describe the usage of adjuvants, i.e. suspensions of
aluminum hydroxide (Alum) or magnesium hydroxide that promote and enhance
Th2-inflammatory responses (Kumar et al., 2008). Nakae et al. (2007) showed that
sensitization with OVA/Alum develops IgE- and MC-independent AHR and air-
way inflammation in contrast to MC-driven allergic inflammation when OVA was
administered without Alum. Potentially, dropping usage of non-natural adjuvants
in the future would closer resemble allergic development as it happens in natural
sensitization and challenge in humans.
Besides experimental models using OVA or grass pollens to induce allergy in mi-
ce, there are a few other, alternative models being developed. Vrtala et al. (2000)
reported that four sensitizations with the major pollen allergen group I of Betula
verrucosa (Bet v 1) over 94 days adsorbed to Complete Freund’s Adjuvant, led to
strong induction of IL-4, IL-5 and IL-13, as well as production of allergen-specific
antibodies. Batanero et al. (2002) sensitized BALB/c mice with native olive allergen
Ole e 1 (nOle e 1) and recombinant Ole e 1 (rOle e 1) together with Alum. Olive
allergens induced high levels of specific IgE and IgG1 versus low IgG2a. Splenocytes
from olive-sensitized mice exhibited a proliferative response to nOle e 1. Allergen-
specific IL-4, but no IFN-γ, was detected (Batanero et al., 2002). A novel mouse
model using cockroach (rBla g 2) and HDM (rDer f 1) allergens - ‘inner city’ environ-
ment allergens - was developed by Sarpong et al. (2003). After two i.p. sensitizations
with allergens/Alum followed by a single challenge via a tracheal catheter, A/J mice
exhibited a strong influx of inflammatory cells, especially when the two allergens we-
re applied together. However, the cockroach allergen but not HDM induced airway
hyperreactivity in allergic mice (Sarpong et al., 2003). In a recent study Murdock
et al. (2012) demonstrated that four i.n. challenges with A. fumigatus in C57BL/6
mice caused chronic pulmonary inflammation characterized by eosinophilia, goblet
cell metaplasia and Th2-associated cytokine production.
In this study sensitization and challenge with the clinically relevant grass pollen
allergen and pollen extract induced high numbers of total inflammatory cells and
eosinophils into the lungs when compared with an OVA-induced model. The diffe-
rences in strength of Th2-immunological parameters between the two models may
be caused by a stronger allergenicity of rPhl p 5b as a clinically relevant allergen as
well as due to the fact that animals were sensitized with three i.p. rPhl 5b-injections
versus two i.p. OVA-sensitizations. In line with that, expanded contribution of Th2-
cytokines, especially IL-4 and IL-13 led to increased (more than in the OVA-model)
levels of total and rPhl p 5b-specific antibodies.
Indeed, IL-4 and IL-13 stimulate multiple features of asthma like eosinophilia, IgE
production, goblet cell metaplasia, AHR, smooth muscle remodeling, and overall Th2
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induction and maintenance. IL-4 binds to the type I and II IL-4 receptor (IL-4R).
Whereas IL-13 selectively targets IL-4RII (composed of the IL-4Rα and IL-13Rα1
chains), which all together induce IL-4Rα-mediated activation of the transcription
factor Stat6 and upregulation of the expression of GATA-3, the master regulator
for the Th2-differentiation (Zhu et al., 2001; Paul and Zhu, 2010). Therefore, on the
one hand the roles of IL-4 and IL-13 in the development of allergic airway disease
overlap. But on the other side, IL-4 but not IL-13 stimulates T cells, B cells and
MCs, and directs naive T helper cells into Th2-biased responses (Nelms et al., 1999;
Finkelman et al., 2010). Moreover, IL-4 mediates antibody class switch on B cells to
IgEs, enhances tissue homing of inflammatory effector cells, and induces expression
of endothelial vascular cell adhesion molecule (VCAM)-1, which directs eosinophils
to sites of inflammation (Oliphant et al., 2011; Williams et al., 2012). Interestingly, it
was shown that IL-13Rα1 regulated baseline IgE, which was independent of changes
in IL-4. Additionally, IL-13Rα1 was proposed to be the key regulator of IL-13- and
OVA-induced TGF-β production, that in contrary to regulatory TGF-β (Taylor
et al., 2006), leads to allergen-driven fibrotic reactions (Munitz et al., 2008).
However, a development of airway hyperreactivity and eosinophilia is not exclu-
sively regulated by IL-4 or IL-13. In our study airway reactivity of asthmatic mice,
numbers of eosinophils and levels of IL-5 were highly increased when compared to
naive animals and were comparable to each other between rPhl p 5b- and OVA-
induced models. IL-5 plays a central role in the induction of eosinophilia and AHR.
IL-5-transgenic mice have been reported for high numbers of eosinophils in the pe-
ripheral blood and organ eosinophilia (Dent et al., 1990). Studied by two groups,
anti-IL-5 mAb treatment of allergic mice suppressed AHR (Hamelmann et al., 1997a;
Hogan et al., 1997a). Within the last years, there have been several clinical trials
conducted using anti-IL-5 antibodies (mepolizumab and reslizumab) or anti-IL5R
(benralizumab) to prove their efficacy and safety in patients mostly with severe
asthma (reviewed in Corren, 2012). From the animal data it is known that allergen-
sensitized and challenged IL-5-deficient mice, lacking production of IL-5, showed no
significant eosinophilic airway inflammation, which was associated with no change in
the development of airway responsiveness to methacholine (Hamelmann et al., 2000).
Therefore high levels of Th2-cytokines (namely IL-4, IL-5 and IL-13) in our model
surely contributed to the strong development of all hallmarks of allergic asthma
induced by the clinically relevant aeroallergen.
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AvCystatin’s effect in the murine model with the clinically
relevant allergen
There is an evidence from field studies with helminth-infected individuals on a ne-
gative correlation between allergic Th2-based immunopathologies and incidence of
helminth infections. Additionally, this is supported by reports on experimental ani-
mal models (reviewed in Daniłowicz-Luebert et al., 2011). One of the aims of this
thesis, based on previous work (Schnoeller et al., 2008), was to evaluate the bystan-
der effect of a single parasitic cysteine protease inhibitor from the rodent filariae A.
viteae, AvCystatin (cystatin), in the mouse model of allergic asthma.
Indeed, this work shows that AvCystatin interfered with allergen sensitization and
minimized the effect of challenges with grass pollen extract. Airway hyperreactivity
(AHR) assessed in vivo was significantly reduced after treatment with AvCystatin
when compared with airway reactivity of asthmatic animals and, at the same time,
was on the level of naive mice.
Downstream the ‘allergic cascade’ effector cells such as eosinophils, B cells and
MCs are being recruited into airways mainly through Th2-cytokine sensing. AvCy-
statin was able to interfere not only with inflammatory cell recruitment into the
lungs but also with local and systemic production of Th2-cytokines (such as IL-4
and IL-5) and IgE levels. Suppression of above possibly contributed to decreased
AHR. Other authors showed that depletion of Th2-cytokine-producing CD4+ and
CD8+ T cells hindered eosinophil infiltration into the airways and the development
of AHR (Gavett et al., 1994), additional lack of CD8+ T cells abrogated local produc-
tion of IL-5 by the lymph nodes (Hamelmann et al., 1996). Moreover, reconstitution
with IL-5 increased number of eosinophils and restored AHR of OVA-sensitized and
challenged IL-4-deficient mice (Hamelmann et al., 2000). Thus, possibly reduction
of IL-4 and IL-5 after treatment with AvCystatin contributed to a suppressed AHR.
Additionally in the present study, AvCystatin decreased local and systemic pro-
duction of IL-13. This was in contrast with a previous work on the OVA-induced
model where AvCystatin did not alter IL-13 production (Schnoeller et al., 2008). It
cannot be excluded that decrease of IL-13 mediated by AvCystatin, could be solely
responsible for reduced AHR in the timothy grass pollen-induced model. One ex-
planation for this might be that IL-13 independently of IL-4, IL-5 and eosinophilia
induces AHR as it was shown in several studies. Mice lacking IL-13 did not develop
allergen-induced AHR, although other Th2 cytokines and eosinophilic pulmonary
inflammation were present (Hogan et al., 1997b). Administration of exogenous re-
combinant IL-13 restored AHR in Il13−/− animals. Moreover when SCID mice were
transfered with OVA-specific Th2 cells from OVA TCR-transgenic Il13−/− mice,
they failed to induce AHR, although Il13−/− Th2 cells were capable to produce IL-4
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and IL-5 (Walter et al., 2001). Interestingly, in the present work levels of allergen-
specific IL-13 were around 20 - 50 fold higher over levels of IL-4, detected in superna-
tants of allergen-restimulated PBLNs and spleen cells of AvCystatin-treated animals
but significantly lower than levels detected in asthmatic animals. Rothenberg et al.
(2011) also reports on increased IL-4/IL-13 ratios in HDM-induced model of allergy.
As anti-IL-13 reagents are under clinical trials for asthma, findings on the capacity
of AvCystatin to suppress IL-13 bear promising potential. Whether AvCystatin acts
e.g., via blockade of IL-13Rα, might be approached in further studies.
Effect of AvCystatin on mast cells
Furthermore, AvCystatin suppressed local recruitment of MCs and reduced levels
of MC-protease therefore interfered with MC-activation. One mechanism might be
that AvCystatin may suppress IgE production via decreasing levels of IL-4 and
IL-13. This can lead to restrained IgE binding to high-affinity receptor FcϵRI on
MCs and to further reduced allergen-triggered MC-degranulation and release of pre-
formed mediators like MC-proteases (i.e. mMCP-1) or histamine. Such mediators
are described to contribute to tissue remodeling and influence cellular recruitment
(Marshall and Jawdat, 2004). A histamine receptor-1 has been shown to play an
important role in the development of AHR, airway inflammation and Th2-cell re-
cruitment to sites of allergic inflammation (Bryce et al., 2006). Other authors showed
that treatment with histamine-1-receptor (H1R)-antagonists before or during sen-
sitization with OVA prevented eosinophilic inflammation and development of AHR
(Blumchen et al., 2006).
Another mechanism of AvCystatin acting on MCs might be cross-linking of FcϵRI
with the low-affinity IgG receptor (FcγRIIb), although it has not been proven yet.
However, it is known that AvCystatin is able to form dimers and oligomers when the
additional N-terminal cysteine is present. Therefore such scenario would be feasible
as then AvCystatin could act on these two receptors simultaneously. This would
interfere with signal-transduction cascade of MCs leading to the inhibition of MC-
mediator release. Cross-linking of the FcϵRI-IgE complex on the MC-surface with the
FcγRIIb-IgG complex was shown to lead the suppression of FcϵRI signaling and MC-
activation through FcγRIIb immunoreceptor tyrosine-based inhibition motif (ITIM)
phosphorylation by FcϵRI-associated activation (Kraft and Novak, 2006).
Furthermore, Zhu et al. (2005) and Eggel et al. (2011) reported successful coag-
gregations of FcϵRI and FcγRIIb by produced chimeric fusion proteins of a part of
human IgG1 with either a cat allergen (Fel d 1) or a genetically engineered antibo-
dy mimetic protein (DARPin). Moreover, Melendez et al. (2007) reported a filarial
nematode protein ES-62 to reduce FcϵRI-mediated responses of human and murine
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MCs. However, whether MCs play a critical role in the induction of chronic asth-
ma in the clinically relevant timothy grass pollen model is unclear. Related animal
models that use sensitization with model allergens, such as OVA, mixed with Alum
(Williams and Galli, 2000) do not require MCs whereas development of disease in
mice exposed to repetitive i.n. antigen challenges in the absence of Alum was shown
to be MC-dependent (Nakae et al., 2007). To further study effects of AvCystatin
on the interference with MCs and resulting downmodulation of allergy, it would be
interesting to use an adjuvant-free protocol to achieve MC-dependent sensitization
in the grass pollen-induced model or/and to employ MC-deficient mice strains or to
perform experiments with sensitized/non-sensitized MCs in vitro.
Another plausible activity of AvCystatin interacting with MCs could be in the
beginning of Th2 development during sensitization phase. As revealed in the first
part of this work, MCs orchestrate Th2 immunity in helminth infections by regula-
tion of early cytokines like IL-25, IL-33 or TSLP (Hepworth et al., 2012) and play
a key role in an initiation of allergic responses (reviewed in Williams et al., 2012).
Although not proven here, in such situation AvCystatin may not only act as a later-
stage suppressor of MCs but also may hinder early activation of MCs through such
cytokines or may block adjuvant stimuli of MCs on activation of cells producing
IL-25, IL-33 and TSLP, that are important initiators of Th2 responses and play a
role in the development of allergies (Smithgall et al., 2008; Corrigan et al., 2011).
Additionally, AvCystatin could also interfere with MCs through increased num-
bers of Treg cells and production of IL-10. Treg cells were described to regulate MCs
activity by altering expression and signaling of IgE receptor and by producing IL-10
to silence their function (Kashyap et al., 2008; Kennedy Norton et al., 2008). Moreo-
ver, IL-10 diminishes IgE expression and favors antibody subclass switch to IgG4 in
humans (Meiler et al., 2008). IL-10 was described to inhibit the FcϵRI expression on
MCs and basophils thus limiting both their initiate and effector functions (Gillespie
et al., 2004). Although there is no direct proof on suppression of FcϵRI by AvCystatin
in the grass pollen-induced model, increased production of IL-10 possibly favors not
only decreased maintenance and proliferation but also reduced activation of MCs
as discussed above. Hence, it would be interesting to further investigate whether
AvCystatin acts via suppressed expression of Fc receptor on MCs and basophils.
These modes of action may be approached in further studies and could explain
an interference of AvCystatin with MCs and its contribution to diminished airway
remodeling and inflammation in the grass pollen-induced model.
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AvCystatin induces IL-10 production and CD4+CD25+Foxp3+ T cells
Further, AvCystatin led to significantly increased IL-10 levels and total numbers
of CD4+CD25+Foxp3+ T cells in the spleen. Work from our group on AvCystatin
and Ov17 from the human filarial nematode O. volvulus showed that both mole-
cules have immunomodulatory capacities and induce secretion of IL-10 in mouse
splenocytes or human PBMCs, respectively (Hartmann et al., 1997; Schönemeyer
et al., 2001). The immunomodulatory effect was restricted to parasitic cystatins on-
ly (Schierack et al., 2003). The effect of Ov17 was mediated by monocytes and was
IL-10-dependent. Neutralization of IL-10 restored the expression of costimulatory
molecules, and further depletion of monocytes from the PBMC cultures reversed
the effects of Ov17 in vitro (Schönemeyer et al., 2001). Finally in the previous stu-
dy when AvCystatin was administered i.p. during the sensitization phase as well
as before the challenge with OVA, it effectively ameliorated allergic disease in an
IL-10-dependent manner. Blocking of IL-10 with an anti-IL-10R mAb reversed the
beneficial effect on cell recruitment and production of IgE. Treatment with Av-
Cystatin significantly increased numbers of CD4+CD25+ Treg in the peribronchial
lymph nodes. Apparently, Treg cells were not the main source of IL-10 as anti-CD25
treatment did not lead to reduction of IL-10 levels. However, depletion of macro-
phages with clodronate liposomes before airway allergen challenge diminished the
anti-allergic effect of AvCystatin, thus pointing into macrophages and IL-10 as main
players in this system (Schnoeller et al., 2008). In a recent study, Klotz et al. (2011b)
showed that AvCystatin upon uptake by macrophages induces phosphorylation of
the mitogen-activated protein kinase signaling pathways ERK1/2 and p38 and IL-
10 production. Such data encourages to speculate that IL-10 plays a central role in
the immunomodulatory effect of AvCystatin in the grass pollen-induced model of
asthma.
Although IL-10 was originally described as a unique product of Th2 clones (Fio-
rentino et al., 1989), it is a cytokine with broad immunoregulatory function secre-
ted by Th2 lymphocytes themselves, Th1 cells, macrophages, DCs, B lymphocytes,
MCs, eosinophils and different regulatory CD4+ T subsets (reviewed in Saraiva and
O’Garra, 2010). In the context of asthma, IL-10 inhibits eosinophilia, by suppression
of IL-5 and GM-CSF, effecting in eosinophil apoptosis (reviewed in Ogawa et al.,
2008).
Furthermore, human immune responses to insect venoms show that success-
ful allergen-immunotherapy is associated with induction of allergen-induced IL-10-
secreting T cells, which results in changed balance of IgE and human IgG4 antibodies
as well as decreased allergen-specific Th2 responses (Akdis et al., 1998; Akdis and
Akdis, 2011). However, in this context different CD4 T cell subsets, as a part of their
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regulatory function are capable to secrete IL-10. These are: natural and inducible
Foxp3+ Treg as well as Tr1 cells (Lloyd and Hawrylowicz, 2009).
Fortunately in frame of allergic disorders, numerous animal models help to un-
derstand the complex role of IL-10. In that way, sensitized and OVA-exposed IL-
10-deficient mice were reported for enhanced airway inflammation in comparison
to allergic WT controls (Tournoy et al., 2000). Furthermore, in vivo IL-10 gene
delivery suppressed airway inflammation, AHR and downregulated APC functions
in the lung (Nakagome et al., 2005). Thus, induction of IL-10 synthesis is associa-
ted with amelioration of disease symptoms. Therefore, AvCystatin-induced levels
of IL-10 may drive or directly act on the inhibition of inflammatory cell influx and
downregulation of Th2 cytokines. These observations fit the contexts, especially that
AvCystatin is derived from a parasitic worm.
Other authors showed that infections with helminths such as S. mansoni (Mangan
et al., 2006) and H. polygyrus (Bashir et al., 2002; Kitagaki et al., 2006) decreased
allergen-induced inflammation and the effect was observed in the presence of incre-
ased levels of IL-10 and very often elevated numbers of CD4+CD25+Foxp3+ T cells.
Moreover, B cells can also serve as a source of IL-10 (Mangan et al., 2004; Amu
et al., 2010) In the context of discussed regulatory effect of helminths in asthma,
AvCystatin has more advantages because as a single filarial molecule with therapeu-
tic potential acts as a selective immunomodulator. There are only a few examples
of individual helminth-derived proteins described (reviewed in Table 1.1, Subsection
1.3.2) that have immunomodulatory capacity in allergy. Interestingly, most of them
act via IL-10-, TGF-β-, IFN-γ- and/or CD4+CD25+ T cell-dependent mechanism
(reviewed in Daniłowicz-Luebert et al., 2011). As in the present study, treatment
with AvCystatin in the grass pollen-induced mouse model of asthma induced high
levels of IL-10 and increased numbers of CD4+CD25+Foxp3+ T cells, it would be
appealing to further check whether any other cell population (e.g. macrophages, B
lymphocytes or DCs) serves as a source of AvCystatin-induced IL-10 in this model.
Although AvCystatin induced high levels of IL-10, asthmatic but not AvCystatin-
treated mice were also capable to produce high levels of IL-10 in response to the
grass pollen allergen. Thus, it is not yet clear if IL-10 directly mediates the effects of
AvCystatin and if so how AvCystatin-specific IL-10 mediates its outcome when high
levels of grass pollen-specific IL-10 are also detected in allergic disease controls. This
striking fact points into pleiotropic characteristics of this cytokine. And although
IL-10 has regulatory capacities (discussed in Romagnani, 2004), some studies indi-
cate that IL-10 rather promotes than regulates airway responsiveness in the allergic
asthmatic state. Thus, the role of IL-10 in asthma remains controversial. Robinson
et al. (1996) as well as Colavita et al. (2000) reported significantly higher expression
of IL-10 mRNA in asthmatic compared with healthy control subjects. Moreover,
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IL-10 was shown to augment airway smooth muscle responsiveness and to upregu-
late mRNA expression and release of IL-5 from cultured asthmatic serum-sensitized
airway smooth muscle cells. Thus, there is an association between induced upregu-
lated IL-10 and IL-5 expression. Therefore, the release of IL-5 could be dependent
on the induction of IL-10 in the sensitized cell (Grunstein et al., 2001). On the
one hand, in our model IL-10 with inflammatory capacities may play a role in the
development of asthma by acting directly on the sensitized airway smooth muscle
and by promoting expression of IL-5 in asthmatic animals. And on the other side,
AvCystatin-induced regulatory IL-10 should immediately prevent sensitization with
the grass pollen allergen, which indeed resulted in low levels of IL-5 in this work.
Further, Makela et al. (2000) reported that Th2-type cytokine IL-10 is necessary
for the development of AHR but not for airway inflammation or eosinophilia after
allergen challenge in already sensitized mice. van Scott et al. (2000) confirmed that
IL-10, despite anti-inflammatory activity, augments AHR in ragweed-induced aller-
gy. A recent report shows that IL-10+ Th2 inhibitory (Th2i) cells can originate from
non-suppressive Th2 effector precursors under action of effector cytokines such as
IL-2 and IL-21. This sheds some light on how Th2 responses may prevent further
immunopathologies (Altin et al., 2012). However, it remains unknown how the ba-
lance of immunostimulatory and suppressive actions of IL-10 is coordinated during
Th2 response induced by an allergen. Thus, a possibility exists that either AvCysta-
tin directly drives the conversion of pathogenic Th2 cells into immunosuppressive
IL-10+ Th2 (Th2i) cells in an allergic setup or that upon AvCystatin’s treatment
IL-10 ‘switches’ its cytokine-modulatory effects in a cell type-specific manner. Also
one possibility is that the source of AvCystatin-induced IL-10 is critical. In the pre-
sent study AvCystatin additionally increased the frequency of regulatory T cells in
treated animals, although it is not known whether these cells produced IL-10. Possi-
bly the induction of Tregs or alternative cell sources of IL-10 in AvCystatin-treated
mice may actively suppress the pathogenic Th2 cell pool, however this might be
addressed in further studies.
The route of AvCystatin’s administration
It is important to evaluate treatment regiments that raise effective levels of drug
concentration in vivo and are convenient for administration for physicians as well
as patients themselves. In frame of this work, two parenteral routes of AvCystatin
administration in the mouse model of allergy were compared: intraperitoneal (i.p.)
and subcutaneous (s.c.).
The route of administration in principle should allow drugs to dissolve in body
fluids and preferably enter the circulatory system before they can be distributed to
sites of action. Intraperitoneal administration is the injection of a substance into
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the peritoneal cavity and due to its ease of administration compared with other
parenteral methods in animals, it is rather applied to animals than humans. Moreo-
ver any irritating compound, is less irritating if administered i.p. In humans, some
chemotherapy drugs (i.e., for treatment of ovarian cancer) are administered via i.p.
injections, however there are some controversies about this method (Swart et al.,
2008). Intraperitoneally delivered drugs drain into the thoracic lymphatic and the
vena cava, and are exposed to a larger absorptive surface area than s.c. regimens. On
the other hand, s.c. is delivered as a bolus into the subcutis (directly below the der-
mis and epidermis) and is relatively easy to self-administer. Subcutaneous injections
are highly effective, fast (the drug enters the blood after 3-5 minutes), however this
may depend on drug solubility and are usually applied for administering vaccines
and medications such as insulin, morphine etc., or allergens in subcutaneous im-
munotherapy. Subcutaneously administered drugs quickly drain to the lymph nodes
closest to the injected site where the drug becomes concentrated.
Unfortunately, there are very few studies on animal models examining differences
in the routes of drug administration. An extensive search of published reports sug-
gests that the present work is possibly one of very few investigations done on the
effect of administration routes of a biological molecule in animal models of allergy.
In this study AvCystatin (in PBS as a solvent) applied four times i.p. during sensiti-
zation with the allergen downregulated all hallmarks of asthma as discussed before
in this Section. However, s.c. treatment under the same conditions did not improve
the outcome of allergy, all Th2-associated parameters of allergic asthma remained
unaltered. Moreover, there was no increase in levels of AvCystatin specific-IL-10.
This shows that s.c. injection is an uneffective way of AvCystatin administration in
this mouse model of allergy. As substances injected s.c. enter the blood very fast, it
might be that AvCystatin requires a longer time to be present in the cavity, slower
migration to lymph nodes and adsorption by the vascular system. AvCystatin op-
timally acts in the peritoneum but not in the subcutis, probably due to the fact
that both sites are said to have different pattern of absorption and excretion, and
drug distribution depends also on its molecular weight and solubility. Therefore, one
explanation could be that AvCystatin administered s.c. is directed rapidly into the
blood circulation and thus is not available to the right cell population. Apparently
AvCystatin is capable to exert immunomodulatory capacity efficiently on peritone-
al exudate cells (PECs) i.e., macrophages. The peritoneal surface is described as a
source of monocytes and anti-inflammatory peritoneal exudate cells (macrophages),
thus it has been long time ago proposed as another site to administer tumor or viral
vaccines, as well as immunomodulators (Regelson and Parker, 1986).
In the previous work, the tissue distribution of AvCystatin was studied after a
single i.v. or i.p. injection of 125I-labelled AvCystatin to healthy BALB/c mice.
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125I-labelled AvCystatin within 30 min when injected i.v. showed distribution into
the sera, gut, skin, kidneys, liver and finally urine. Whereas, after 30 min of i.p.
injections it was found particularly in the gut and body. Three hours after i.p./i.v.
administration, AvCystatin was still detected in the gut, skin, body, partially in liver
and to the major extend in urine. AvCystatin could not be detected at any time in
PBMCs, PBLNs, MLNs, spleen or bladder. Moreover, the half-life of AvCystatin in
the animal body was 70 min and it was totally cleared away after 20 hours (Hoffmann
2009, unpublished). This points into various tissue distribution of AvCystatin after
different ways of administration. Moreover, AvCystatin is available for rather short
time in vivo, possibly after s.c. administration as well. Thus, the second justification
would be that due to its short-half life and availability in the body as well as probably
particular solubility when administered s.c., AvCystatin fails to be distributed to the
organs where it could prime the target cells. Papamatheakis et al. (1978) showed
14C-labelled pyran was uptaken by peritoneal macrophages after i.p. injection. Pyran
(MVE) activates macrophages that constitute the primary mechanism of pyran-
induced host resistance to microbial infection. As AvCystatin was shown to be taken
up by macrophages (Klotz et al., 2011b) it would be interesting to assess which organ
or cell-compartment is the primary source of such AvCystatin-targeted macrophages
and which way of AvCystatin administration activates these cells in the most efficient
way.
More work on ways of drugs administration is published for cancer treatment.
Earlier pre-clinical and clinical studies on MVE-2, a macrophage activating, interfe-
ron inducing anti-cancer component, showed that the site of injection is very crucial.
Translation of i.p. data from laboratory animals to i.v. injections in human patients
failed. As i.p. site differs in absorption and clearance, drug formulations for i.v. in-
jections in the clinical trials should have been made in different way than for i.p.
administration (Wiliam, 1986). Therefore, when thinking about translating the i.p.
pre-clinical animal data on AvCystatin to clinical patients, it seems interesting to
propose a usage of any stabilizing agent e.g., beads, liposomes or microparticles as
alternative ways of AvCystatin i.p. administration to patients. Microparticles were
described to retain longer in the peritoneal cavity without the need for frequent
drug administration (Kohane et al., 2006). Anti-cancer drug treatment called DTX
formed with a polymer-lipid depot delivered i.p. was shown to have good efficacy
also on the systemic level suppressing distal metastatic disease sites located outside
of the peritoneal cavity (Zahedi et al., 2012). This supports our own data where
AvCystatin i.p. had immunomodulatory capacity on the local as well as the syste-
mic level in a stark contrast to s.c. administration. In contrast to the present study,
Hough et al. (1996) reported better effects and distribution after s.c. than after i.p.
administration of ibogaine, a substance for an anti-addictive treatment. Authors
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suggested that i.p. delivered drug undergoes hepatic clearance, and after s.c. deli-
very some of ibogaine metabolites still remain and account for its activity. In this
context, what the metabolites of AvCystatin are and whether any toxicity disabling
immunosuppressive effect of the molecule when applied s.c. is exerted, these could
be addressed in further studies.
Interestingly AvCystatin s.c.-administered animals showed a trend of decreased
MCs numbers in the lungs and MCs activity in the serum (reduced levels of MC-
protease). AvCystatin injected s.c. although, lack of suppressive capacity on Th2-
induced allergy, strikingly had partial influence on MCs. MCs are also located in
the skin tissue as well as mucosa. This might suggest s.c. injections target a distinct
mechanism leading to interference with local MC-proliferation and systemic degra-
nulation, independently from Th2-reducing capacity. It was described for omalizu-
mab, that apart from binding free IgEs, it significantly reduced basophil mediator
release and decease FcϵRI expression in skin MCs of allergic subjects (Beck et al.,
2004). Theoretically, AvCystatin administered either way could cross-link, bind to
or suppress activation of Fc receptors on MCs, which was discussed earlier in this
Section.
Of a clinical interest as treatment for asthma, it would be interesting to evaluate
immunomodulatory capacities of nebulized AvCystatin (inhaled application), which
was described to be a very efficient way of therapy in case of treatment of asthma
and other diseases (reviewed in Siekmeier and Scheuch, 2008; Rubin, 2010).
4.3 Influence of AvCystatin’s characteristics on
mediated immunomodulation
When thinking about any specific features of AvCystatin that may play a role in
its immunomodulatory capacity, the literature and our own study bring three main
factors into consideration: (1) protease inhibitory function, (2) structural characte-
ristics of the molecule, (3) potential posttranslational modifications.
Cysteine protease inhibitory function
First of all, recombinant AvCystatin, expressed in E. coli, was described to exhi-
bit biological activity as a cysteine protease inhibitor (Hartmann et al., 1997) and
showed high homology to other nematode, arthropod as well as vertebrate cystatins
(reviewed in Klotz et al., 2011a). In the present study, amino acid mutations of three
conserved domains that constitute cysteine protease-cystatin interaction site and di-
rect the cystatin molecule into the active cleft of the protease, led to a complete loss
of biological activity as a protease inhibitor. Mutated AvCystatin (AvCystatinmut)
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was not able to inhibit protease in the standard papain-inhibition test.
The inhibitory activity is essential for parasitic organisms to regulate their nor-
mal biological and physiological processes. A cystatin from human filarial nematode
O. volvulus was suggested to regulate parasite proteases and lead to cuticle loss
during molting and in the development of microfilariae due to its activity as an inhi-
bitor (Lustigman et al., 1992). Analyses of Caenorhabditis elegans cystatin CPI-2a
pointed into its role during oogenesis and fertilization (Hashmi et al., 2006). Other
parasitic cystatins were described to support alimentary needs of S. mansoni (Wasi-
lewski et al., 1996) or some ticks by either allowing successful blood meal protecting
from host’s proteases (Karim et al., 2005) or preventing endogenous peptidases to
digest stored blood (Grunclová et al., 2006). On the other hand protease inhibitory
activity of cystatins was described to contribute to interference with host’s immune
responses e.g., the antigen processing and presentation pathway. Schönemeyer et al.
(2001) reported that O. volvulus cystatin inhibited immunologically relevant host
cysteine proteases cathepsin L and S (involved in the endosomal antigen processing)
and in consequence interfered with antigen presentation of human APCs. Two tick
saliva cystatins sialostatin L and L2 inhibited various mammalian cathepsins and
contributed to the blood-feeding success of the ticks (Kotsyfakis et al., 2007). Thanks
to their inhibitory activity sialostatins were able to downmodulate MHC-II and co-
stimulatory molecule CD86 on DCs and to suppress antigen-specific proliferation in
vitro and in vivo (Kotsyfakis et al., 2006).
Additionally, cysteine protease inhibitors are described to reduce unrelated in-
flammatory immune responses. Treatment with nippocystatin from N. brasiliensis
of OVA-sensitized mice decreased allergen-specific spleen cell proliferation, reduced
OVA-specific IgE levels and cytokine production. Authors postulated the effect was
due to the inhibition of cathepsin B- and L-dependent antigen processing (Daini-
chi et al., 2001b). Furthermore, active sialostatin L was reported to reduce AHR,
OVA-induced lung pathology and inhibit IL-9 production of Th9 cells (Horka et al.,
2012). Also in a study from our group AvCystatin as an active inhibitor suppressed
OVA-induced allergic responses (Schnoeller et al., 2008). Therefore, it was striking
to see in the present work that AvCystatin was equally efficient in inhibiting eosi-
nophil migration into the lungs, in decreasing allergen-specific antibody levels and
Th2-associated cytokines in the grass pollen-induced model independently of its
protease inhibitor function. Moreover, mutated AvCytatin (no inhibitory activity)
was able to induce production of IL-10 in spleen cells, which speaks for rather a
IL-10-driven immunomodulation independent of the protease inhibitory activity. In
contrary to our work, Layton et al. (2001) reported that the therapeutic effect of the
broad-spectrum cysteine proteinase inhibitor E64 on allergic lung inflammation was
mediated by membrane-associated cysteine proteases, possibly cathepsin B. And
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although, imbalance between cysteine proteases and cystatins has been suggested to
contribute to connective tissue remodelling associated with lung inflammatory pro-
cesses (Serveau-Avesque et al., 2006), in our study, the effect of AvCystatin surely
was not mediated via inhibition of host’s proteases. Nevertheless, some endogenous
human cystatins were described to interfere with the function of many clinically
relevant allergens that as proteases cause allergic reactions. Major allergens of HDM
that are active cysteine proteases, Der p 1 and Der f 1, enhance IgE production, in-
duce Th2 responses and contribute to allergy and atopic dermatitis (AD) in human
(Comoy et al., 1998; Gough et al., 1999; Thomas et al., 2002). Kato et al. (2005)
reported that cystatin A produced by keratinocytes constituted the major biochemi-
cal skin barrier, which eliminated HDM cysteine proteases activity in AD scenario.
However, not all endogenous cystatins seem to be involved in downregulation of
allergies. Asthmatic patients were reported for significantly elevated concentrations
of cystatin C in serum when compared to controls (Cimerman et al., 2000). This
shows that excess of this protease inhibitor could be rather correlated with asthma,
thus probably its inhibitor activity function does not play a role at least not in
diminishing of the allergy, although to which allergens subjects were sensitized to,
authors did not report (Cimerman et al., 2000).
Imbalance between cystatin C and cysteine proteinases, as well as improper func-
tion as an inhibitor has been associated with different diseases such as inflammati-
on, cancer, multiple sclerosis, HIV infection, cardiovascular and kidney disfunction,
amyloid angiopathy (reviewed in Turk et al., 2008). Bäcklund et al. (2011) reported
that deficiency of cystatin C enhanced collagen-induced arthritis and delayed-type
hypersensitivity reaction, which was possibly due to affected priming in vivo of the
immune system and more activated APCs. However, our study provides an evidence
that function as an inhibitor is not necessary for AvCystatin’s immunomodulation
of Th2-driven pathology via interference with host’s proteases.
Hypothetically, inhibitory activity of AvCystatin could play a role in case when
allergy is induced by allergens with proteolytic functions such as mite (Der p 1, Der
f 1, Eur m 1), coackroach (Per a 10), mold (Cur l 1) or fruit (pineapple - Ana c 2,
cantaloupe - Cuc m 1, papaya - Car p 1) allergens. Others reported that inhibition
of enzymatic activity of such allergens led to milder inflammation and Th2 cytokine
responses (Sudha et al., 2009; Tripathi et al., 2009; Cunningham et al., 2012). Re-
cent reports showed that serine-protease from cockroach and cysteine-proteases of
HDM and papaya modulate the innate immune response via activation of protease-
activated receptor-2 (PAR-2) (Asokananthan et al., 2002; Day et al., 2010; Liang
et al., 2012). Clearly, activity of proteases at mucosal surfaces regulates Th2 immu-
ne responses. In case that AvCystatin immunomodulated protease-induced allergy,
this inhibitor (AvCystatin) would block allergenic proteases or could interact with
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receptors expressed on APCs or airway epithelial cells targeted by such proteoly-
tic allergens. However, in the present study animals were sensitized with Phl p 5b,
which functions as an RNAse in plants, so the only proteases driving allergy in this
case might come from endogenous proteases (i.e. MCs tryptase) that are released
after inflammatory events.
Strikingly some active cysteine protease inhibitors may function as allergens as
well. When AvCystatin amino acid sequence was blasted with ALLERGOME data-
base (data not shown), two proteins of A. simplex (cystatin - Ani s 4 and paramyosin
- Ani s 2) as well as domestic cat cystatin - Fel d 3 showed up as top three allergens
with high sequence similarity to AvCystatin. Indeed, Ani s 4 and Fel d 3 have be-
en reported as IgE-reactive cystatins with all main conserved motifs that form the
complex with a cystein proteinase (Ichikawa et al., 2001; Rodriguez-Mahillo et al.,
2008). However, AvCystatin applied i.p. or i.n. did not induce airway hyperreacti-
vity, did not increase IgE production nor significant numbers of inflammatory cells
in the lungs. Moreover, AvCystatin in active and also in non-active form, increa-
sed secretion of IL-10 in PEC-derived macrophages (Schnoeller 2008, PhD thesis).
Therefore although quite surprising, it becomes clear that inhibitory activity does
not lead to AvCystatin’s allergenictiy nor constitute the main immunosuppressive
feature of this molecule.
Structural aspects
Our own unpublished observations showed that recombinant AvCystatin in the so-
lution forms monomers, dimers and oligomers. Further investigation of AvCystatin’s
primary amino acid sequence revealed an additional N-terminal cysteine, which can
form an intermolecular disulfide bridge with another AvCystatin molecule. Indeed,
truncation of this additional cysteine residue predisposed AvCystatin to stay mainly
as a mixture of monomers. Two independent techniques, Western blot analysis and a
biochemical method - gel filtration and RALS confirmed the results. However, a trace
of dimers could be observed in N-terminal truncated AvCystatin (rAvCystatintr).
Under physiological conditions cystatins form monomers (Turk et al., 1985; Ekiel
et al., 1997; Kotsyfakis et al., 2010). However, a notable feature of cystatins is
appearance as dimers or oligomers. Cystatins’ dimers can assemble into tetramers
and other higher order structures (Sanders et al., 2004; Jenko Kokalj et al., 2007).
Determined dimeric structures of human cystatin C (HCC) as well as human cystatin
F (HCF) indicate diverse mechanisms of dimer formation. Protein aggregation of
HCC, through conformational changes of the β-hairpin loop L1 as three-dimensional
(3D) domain swapping leads to dimerization and then to oligomerization and in
return to a severe phenotype of pathological amyloidosis in humans (Janowski et al.,
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2001). Additionally, it was found that either naturally occurring point mutation in
HCC (L68Q) or first-ten-amino acid residue N-terminally truncated HCC amplify
formation of a new crystal structure composed of dimers (Janowski et al., 2004).
Moreover HCC oligomers fibrilize faster than monomers (Wahlbom et al., 2007),
and as suggested, interact via 3D domain swapping, which was also observed under
in vitro conditions in chicken cystatin C (Staniforth et al., 2001) and human stefin
B (Zerovnik et al., 2007).
Kotsyfakis et al. (2010) also reported dimerization of a cystatin from tick I. scapu-
laris, sialostain L, via domain swapping. Analysis by gel filtration chromatography
revealed that a small fraction of sialostatin L was dimerizing at high concentrati-
ons of around 10 mg/ml (Kotsyfakis et al., 2010). Therefore it is very likely that
the visible dimer band on Western blot or a clear dimer peak species in RALS of
AvCytstaintr with no free cysteine available, comes from domain swapped dimers.
In contrast to Western blot analysis, high concentrations of AvCystatin were used
when preparing samples for RALS, thus it is very likely that increased concentration
contributes to AvCystatin’s domain swapping. However, the most precise answer for
domain swapping of AvCystatin would give crystallographic resolution of the struc-
ture, not a method in solution, as only crystals can efficiently stabilize the structure,
as shown for HCC or sialostatin L (Ekiel et al., 1997; Kotsyfakis et al., 2010).
In HCF dimers are formed by two monomers interacting via an intermolecular
disulphide bond (Schüttelkopf et al., 2006). Aggregations can cause complete loss of
inhibitory activity (Ekiel and Abrahamson, 1996). Dimers of HCC, HCF and sia-
lostatin L were described to reduce the inhibitory function of cystatin because the
protease-binding surfaces of the cystatin were disturbed (Abrahamson and Grubb,
1994; Wei et al., 1998; Langerholc et al., 2005; Kotsyfakis et al., 2010). In con-
trast to that, although clear oligomerization is present, AvCystatin remains active
as cysteine protease inhibitor. This suggests that despite conformational alterations
resulting from oligomerization, the protease binding sites are still accessible to pro-
teases. However, this does not exclude the possibility that aggregation may affect
conformation of other domains, which possibly account for the overall immunomo-
dulatory character of AvCystatin.
Additionally, in this study treatment of grass pollen allergic mice with either re-
combinant AvCystatin’s derivate that is not active as protease inhibitor or with
its monomeric version showed comparable immunosuppressive effect as unmodified
recombinant AvCystatin, which was used in previous studies in the OVA-induced
model of asthma (Schnoeller et al., 2008). Concerning oligomerization, interestin-
gly Yang et al. (1993) proposed that high ‘density’ of antigen can modify immune
responses possibly due to minimal antigen presentation of the oligomeric form. An
oligomeric form of antigen induced a different profile of T cell cytokines, than that
caused by a natural monomeric version (Yang et al., 1993). However, in the present
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study the effect of AvCystatin immunomodulatory capacity in an asthma model was
independent of oligomerization via N-terminal disulfide bond. Concerning an even-
tual involvement of PTMs in the immunomodulatory effect of AvCystatin, apart
from performed here an in vitro proliferation assay, more studies on the confirmati-
on of an obtained modification by e.g., mass-spectrometry analysis, and validation
of demethylated recombinant AvCystatin (rAvCystatindm) in an in vivo model of
allergic asthma could be addressed in future studies.
4.4 AvCystatin and allergen-specific
immunotherapy
Allergen-specific immunotherapy is the most promising so far existing treatment for
allergy. Data discussed above and published work demonstrated that AvCystatin
might be a promising candidate potentiating regulatory mechanisms in the allergen-
specific immunotherapy. Thus, in frame of this thesis based on the OVA-induced
mouse model for allergic asthma, a pre-clinical model of OVA-induced imunotherapy
(SIT) in mice was established in order to test an adjuvant effect of AvCystatin.
OVA-sensitized and challenged animals showed all clinical symptoms of allergy,
including airway eosinophilia, increased Th2-cytokine production in the BAL fluid
and serum levels of total IgE, OVA-specific IgE and IgG1 antibodies. Subcutaneous-
ly treated mice with three, either low or high, doses of OVA (SIT therapy) showed an
abrogation in nearly all allergic parameters, such as reduced inflammatory cell mi-
gration into the lungs, decreased production of IL-5 and IL-13 and allergen-specific
IgEs. Thus, the protocol applied in the present work mimics beneficial results from
immunotherapy in humans. Similarly, van Oosterhout et al. (1998) reported that
increasing doses of OVA led to reduced eosinophil influx into the BAL fluid, lower
levels of IL-4 and decreased production of OVA-specific IgE in their newly establis-
hed mouse model. However, unlike in our study, van Oosterhout et al. observed also
an increase in OVA-specific IgG2a antibodies. van Oosterhout et al. used a protocol
of 8-week treatment with increasing doses of OVA (van Oosterhout et al., 1998).
In our study, animals received SIT high or low dose for four days before allergen-
challenge. Moreover, in the present work application of SIT high dose increased IL-10
production in the BAL and levels of allergen-specific IgG1 (as IgG4 in human) that
constitute immunemodifying mechanisms of specific immunotherapy. Interestingly,
only immunotherapy with entire OVA, but not with the immunodominant OVA epi-
tope, was shown to have beneficial effects on downmodulation of disease symptoms
in a mouse model of allergic asthma (Janssen et al., 1999). Currently Treg cells
that produce the immunosuppressive cytokines IL-10 and TGF-β are thought to be
mostly responsible for clinically successful SIT (reviewed in Akdis and Akdis, 2009).
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Thus, considering above, investigation of refined strategies for immunotherapy that
facilitate the induction of regulatory mechanisms e.g., using improved and/or alter-
native adjuvants in combination with SIT would raise safety and increase efficacy
of SIT (Kopp, 2011).
Adjuvant capacity
In the present study, the combination of AvCystatin with SIT resulted in the oppo-
site effects than hypothesized. Cystatin either did not have any boosting effect or
it deteriorated the beneficial outcome of SIT. AvCystatin mixed and delivered s.c.
with SIT, or administered s.c./i.p. separately from SIT did not ameliorate OVA-
induced allergy. All applications of AvCystatin together with allergen s.c. led to
recall Th2 cytokine production in response to AvCystatin in vitro. No substantial
IL-10 induction was observed, except when AvCystatin was mixed and injected s.c.
together with OVA. Strikingly, when AvCystatin was delivered i.p. and subsequently
with SIT, it rather enhanced total cell and eosinophil infiltration into the lungs, as
well as increased levels of OVA-specific IgG1, although IL-4 levels were decreased.
This suggests divergent and independent mechanisms of action of the allergen and
AvCystatin when it is applied after a sensitization phase along with the allergen.
In the context of AvCystatin as an adjuvant, the timing and route of adminis-
tration plays an important role. It becomes clear that in general AvCystatin s.c.
injections during allergen sensitization do not elicit desired immunoregulatory me-
chanisms as it was observed in the model with the clinically relevant grass pollen
allergen (discussed in Section 4.2). In another study, the beneficial effect was ob-
served for glucocorticoid and vitamin D3 as adjuvants to SIT when the drugs were
given at the same time and route as the allergen (Taher et al., 2008). In immunothe-
rapy the antigen composition and route of administration of the allergen determine
the effectiveness of SIT treatment. Subcutaneous immunotherapy with OVA but not
i.n. had beneficial effects. Interestingly, s.c. application of OVA peptide deteriorated
allergy symptoms (Janssen et al., 2000). It remains of interest to determine which
mode of delivery can elicit a boosting mechanism of AvCystatin as an adjuvant that
is required for suppression of Th2-cell activity.
There is more evidence that alternative delivery of allergens coupled to carbo-
hydrate or virus-like particles or administered as fusion proteins gives promising
results. Carbohydrate based particles (CBP)-bound rPhl p 5b administered s.c. as
immunotherapy was shown to decrease allergen-specific IgE levels, to induce mixed
allergen-specific Th1 immune responses detected as elevated production of IFN-
γ and allergen-specific IgG2a antibodies, and in contrast to a standard adjuvant -
Alum, did not cause granuloma formation at the injection sites. Moreover, CBPs mi-
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xed with rPhl p 5b (but not coupled to the allergen) promoted strong Th2 responses
(Grönlund et al., 2002). Antigens joined with CBPs are more effectively processed
and presented by the APCs than uncoupled antigens (Kovacsovics-Bankowski et al.,
1993). In this context, macrophages were described to phagocyte various types of
larger particles (Geiser, 2002). Moreover, Andersson et al. (2004) showed that re-
combinant cat allergen (rFel d 1) coupled with CPBs efficiently activated human
DCs in vitro. Coupled particles rFel d 1-CBP were uptaken by DCs and unlike free
rFel d 1, the complexes upregulated expression of the costimulatory molecule CD86
on DCs surface. In a more recent study, improved therapeutic efficacy and reduced
reactogenicity of rFel d 1 was shown by coupling to a repetitive structure of virus-like
particles (VLPs). Application of rFel d 1-VLP s.c. protected mice from systemic ana-
phylaxis, inhibited local MCs degranulation and prevented IgE memory responses
after challenge with an allergen. The effect of allergen-particle complexes was media-
ted by rFel d 1-specific serum IgGs (Schmitz et al., 2009). Although not described in
this model so far, it is appealing to speculate that CPB/particle-AvCystatin coupled
with an allergen would display a boosting effect without alteration of its immuno-
logical properties. Because of the particulate nature of the CBPs such complexes
would possibly be presented to proper APCs inducing desired T cell responses.
Another possibility to achieve determined immunomodulatory boosting effects
would be creating a fusion protein - rAvCystatin:allergen. Recently, Schülke et al.
(2011) provided a strong evidence that the fusion of a recombinant flagellinA, the
Toll-like receptor (TLR) 5 agonist, with OVA (rflaA:OVA) enhanced suppression of
IL-4 and IL-5 from naive and Th2-biased CD4+ T cells and reduced OVA-induced
intestinal allergy in vivo. The effect was mediated by IL-10. The fusion protein
rflaA:OVA but not equimolar amounts of rflaA or OVA administered alone or as
a mixture induced OVA-specific IgG2a while reducing levels of OVA-specific IgE.
Similarly to the present study, administration of a mixture OVA plus flagellinA
deteriorated OVA-specific IgE levels. It was proposed that the fusion protein facili-
tates targeting of effector cells. In an earlier study another group reported that the
major birch allergen Bet v 1 fused with the bacterial cell surface (S-layer) protein
(rSbsC-Bet v 1) induced production of IFN-γ together with IL-10, but no Th2-like
responses in cells of birch allergic patients. It was noted that Bet v 1 allergen was
correctly folded with all relevant Bet v 1-specific B and T cell epitopes, however
with reduced capacity to induce histamine release (Bohle et al., 2004).
Above discussed components have intrinsic Th1-enhancing properties and target
TLRs. Despite the unknown receptor-triggered mechanism by AvCystatin, it would
be interesting to study recombinantly fused AvCystatin with the allergen. Although
not addressed in the present work, such fusion could allow the molecule to directly
target antigen-specific cells and possibly instead of worsening the effect of SIT, AvCy-
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statin could enhance its suppressive capacity targeting the effector cells. Moreover,
one of the advantages of a rAvCystatin:allergen fusion protein would be the constant
ratio between allergen and adjuvant (AvCystatin). This would allow standardization
and prevent variability of immunological responses in vivo. Additionally, the allergen
and the parasitic immunomodulator could be delivered to the same APCs. Howe-
ver, in such approaches, considering all results from the present study, schedule of
an application route, dosage and frequency of CPB-AvCystatin-allergen particles or
a rAvCystatin:allergen fusion protein should be carefully evaluated. Furthermore,
an approach of direct expression of a fusion S-layer protein with AvCystatin and the
clinically relevant allergen (i.e., rPhl p 5) could be applied, as recently showed by
a production of a pyrogen-free fusion S-layer protein with Bet v 1 allergen in the
non-pathogenic transformed Bacillus subtilis cells. The fusion protein was secreted
directly to the culture medium giving self-assembly functional products (Ilk et al.,
2011). Another method employing engineered bacterial cells was used by Li et al.
(2003). Rectal but not s.c. administration of heat-inactivated producing peanut all-
ergen E. coli decreased Th2 cytokine production while increasing IFN-γ and TGF-β
in a murine model of peanut allergy (Li et al., 2003). Thus, it would be interesting to
evaluate engineered systems to produce AvCystatin with a function as an adjuvant
for SIT.
In the course of this work on SIT, the question emerged whether AvCystatin ap-
plied alone can interfere with this rather strong OVA-induced model. Hence, when
AvCystatin was applied i.p. after the sensitization phase but before challenge, re-
duced AHR, significantly decreased eosiophilia and levels of allergen-specific Th2
cytokines, suppressed total and OVA-specific IgE in the serum were observed. This
proves that AvCystatin was in general capable to suppress the model and elicit
its immunomodualtory effect. An increase in AvCystatin-specific IL-10 was obser-
ved. AvCystatin applied i.p. induced only production of IL-10 when cells where
restimulated with the molecule in vitro. That was in contrast to other ‘AvCystatin
and/plus SIT’ approaches that induced also production of Th2-associated cytoki-
nes after AvCystatin-restimulation. AvCystatin delivered i.p. but also s.c. reduced
goblet cell hyperplasia.
Data obtained in this work suggest that AvCystatin itself has immunomodulatory
capacity in the strong OVA-induced allergy model. However, when it is applied
along with the allergen (mixed and/or injected at the same side), it is not able
to elicit beneficial effects. The possibility exists that when applied along with the
allergen as two separate molecules, AvCystatin is presented by different APCs than
the allergen, thus causes a different activation state in the APCs, which may greatly
affect the outcome of the target cell response. Alternatively, the distribution of the
protein may differ after s.c. administration, which can result in various T-cell or other
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cell (preferably macrophage) activation at different locations. Therefore, approaches
discussed above or application of AvCystatin as adjuvant along with the allergen via
different routes (e.g., intralymphatic injections, reviewed in Kündig, 2011) could be
taken into consideration to advance an adjuvant effect of this parasitic molecule in
the SIT treatment.
4.5 AvCystatin and human allergics
In frame of this thesis, the last step towards evaluation of AvCystatin’s effect on
allergy was a ‘translational’ model with cells from grass pollen allergic patients.
In the pilot experiment outside of the grass pollen season with three allergic
and two healthy controls, induction of significant Th2 allergen-specific responses
were detected for allergic subjects. Stimulation with timothy grass pollen extract
of allergic PBMCs resulted in increased allergen-specific cell proliferation, the effect
was LPS-independent. Moreover, allergen stimulation induced strong production of
IL-13.
Furthermore, in line with many studies, levels of allergen-induced IL-4 and IL-5
were difficult to detect in supernatants at day 3 of the cell culture. Possibly, IL-4
and IL-5 cytokines could be secreted at low levels earlier, with peak production
as early as 24 - 48h of culture as described by Hough et al. (1996). Interestingly,
results from allergic PBMCs stimulated with a HDM allergen showed peak of IL-4
production before that of IL-5 and IFN-γ, with a rapid decline in the time. However,
increase of IL-5, IL-13 and IFN-γ was present in a time-dependent manner until
day 7 (Wakugawa et al., 2001). Other studies also report on difficulties with IL-4
detection after antigen stimulation, due to low levels of this cytokine in the cell
culture supernatants (Looney et al., 1994; Wurtzen et al., 1998). However in some
studies it was possible to measure early allergen-induced IL-4 production in minute
amounts of the femtogram per milliliter range (Kimura et al., 1998).
The pilot experiment revealed that pre-incubation with AvCystatin before allergen
stimulation led to a significant decrease of grass pollen-specific IL-13 by PBMCs from
allergic patients and resulted in increased levels of IL-10 and a significant producti-
on of IFN-γ by allergen-specific CD4+ T cells. Furthermore, increased production of
IFN-γ by responding allergic CD4+ T cells was confirmed via flow cytometry. In the
same line to our observations, Park et al. (2012) recently reported that stimulation
with the recombinant MIF homologue of A. simplex (rAs-MIF) increased levels of
IFN-γ and IL-10, while decreasing Th2-cytokines in PBMCs from atopic asthmatics
but not from patients with non-atopic asthma (Park et al., 2012). However, in this
study patients’ PBMCs were only stimulated polyclonally with mitogen and not in
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an allergen-specific manner as in the present study. Our and their work show that a
parasitic molecule may induce IFN-γ, which can be involved in the immunomodu-
lation of human PBMCs from allergic patients.
Having the system established, the capacity of AvCystatin was evaluated in the
pollen season on PBMCs from 21 allergic subjects. In the studied group of allergic
patients it was possible to induce Th2 immune responses that were characterized by
significant increase of allergen-specific IL-13, IL-10 and proliferating CD4+IL-4+ T
cells. A statistical analysis with Spearman’s test revealed a significant correlation
between frequencies of proliferating allergen-specific CD4+IL-4+ T cells and allergen-
specific IgE levels. This means that the stronger the allergy, the higher precursor
frequency or the better CD4+ T cell were responding to the allergen. Nurse et al.
(2000) also observed positive correlation between allergen-stimulated proliferation
of PBMCs and allergen-specific IgE levels it their study. Moreover, a positive as-
sociation between Th2 cytokine production and proliferation was reported pointing
into the fact that the allergen provoked Th2-type responses in cells that specifical-
ly recognize the allergen (Nurse et al., 2000). Additionally, Machura et al. (2010)
showed that the severity of asthma was associated with increased IgE levels.
In an allergic state certain proportions of Th1 and Th2-type cytokines are produ-
ced by allergen-specific T cell clones. It has been proposed that the overall imbalance
in Th2 to Th1 cytokine ratios rather than absolute amounts of individual cytokines
is responsible for the development of allergy (Tournoy et al., 2002; Romagnani, 2004;
Ngoc et al., 2005). Some studies analyzed amount of Th2-type allergen-stimulated
cytokine produced in relation to levels of IFN-γ, the major Th1 cytokine. Presence
of AvCystatin, in relation to Th2 cytokine production, resulted in a significant con-
version from a Th2- to a Th1-biased response. The Th2/Th1 cytokine ratio was
calculated based on IL-13 to IFN-γ ratio in stimulated PBMCs and was decrea-
sed after treatment with AvCystatin. This can be explained by the fact that no
significant change in IL-13 production was observed after in vitro application of
AvCystatin prior to GPE-stimulation, but there was a notable increase in IFN-γ.
Thus, Th2/Th1 ratio was substantially decreased.
Furthermore, a reduction of proliferating CD4+IL-4+ T cells and increased fre-
quencies of proliferating CD4+IFN-γ+ T cells were detected after stimulation with
AvCystatin. This suggests that AvCystatin is able to downregulate IL-4 cytokine
responses of allergen-specific CD4+ T cells, which goes in line with induced levels
of IFN-γ that possibly generate the inhibitory effect on allergen-reactive CD4+IL-4
producing T cells.
With regard to allergy treatment many studies have reported that IFN-γ seems
to be beneficial and is detected in patients after successful allergen-specific immu-
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notherapy (Larche et al., 2006). Immunotherapy in atopic patients induces allergen-
specific Th1 cells that suppress the effector function of allergen-specific Th2 cells
and alter antibody production (Ebner et al., 1997; Akdis and Akdis, 2011). IFN-γ
is known to be present in healthy subjects but not in atopic patients when assessing
levels of this cytokine produced in vivo (Hough et al., 1996; Holgate and Polosa,
2008). Leonard et al. (1997) proposed that the difference between atopy and asthma
is not related to high production of Th2 cytokines (i.e., IL-4), but may be inversely
correlated with levels of IFN-γ in response to HDM stimulation of allergic PBMCs
(Leonard et al., 1997) . Similarly another study demonstrated a selective redirection
of ragweed-specific Th2 responses towards Th1 responses with a significant increase
of IFN-γ production (Simons et al., 2004). However, the exact role of IFN-γ in regu-
lating allergic disease remains controversial. Nevertheless, there are also numerous
studies reporting a significant negative correlation between levels of Th2-associated
cytokines and IFN-γ as promising allergy treatment in the human system (Pochard
et al., 2002). A defective production of IFN-γ after in vitro restimulation of PBMCs
constitutes a general feature of atopic disease (Machura et al., 2010). IFN-γ can
directly inhibit the production of Th2 cytokines in a bystander manner and thus, in
this fashion may mediate decreases in Th2 associated changes that lead to allergic
disease including the production of allergen-specific IgE (Pène et al., 1988; Roma-
gnani, 1990; Parronchi et al., 1992). Of interest, in the frame of this thesis neither in
the animal model of grass pollen-induced allergy nor in the SIT model any substan-
tial induction of IFN-γ in AvCystatin-treated animals was observed. Additionally,
upon in vitro restimulation of spleen cells from asthmatic animals with AvCystatin
prior to the allergen, no IFN-γ production was detected (own unpublished data).
This points into a unique effect of AvCystatin elicited in vitro on human cells from
allergic patients.
Future studies may address following issues: whether upon stimulation with Av-
Cystatin the IFN-γ-producing cells are only restricted to CD4+ T cells, whether
AvCystatin-induced IFN-γ+ cells show suppressive capacity or which mechanism
can be observed by blocking AvCystatin-specific IFN-γ.
AvCystatin in a mouse system in vivo acts on macrophages (Schnoeller et al.,
2008; Klotz et al., 2011b), which results in the production of IL-10. In PBMCs, the
source of IL-10 is thought to be the monocyte, dendritic cell, B or T cell (reviewed
in Braga et al., 2011; Moldaver and Larche, 2011; Platts-Mills and Woodfolk, 2011).
In an early study on monocytes from allergic subjects, exogenous IL-10 significantly
increased the proportion of suppressive cells and led to decrease of allogenic mixed
lymphocyte proliferation (Tormey et al., 1998). Moreover, a decreased spontaneous
and LPS-induced IL-10 production was observed by monocytes from allergic pati-
ents (Borish et al., 1996). In the present study in the pollen season, there was no
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substantial change in frequencies of allergen-proliferating CD4+IL-10+ T cells after
incubation with AvCystatin and subsequently with GPE. One plausible explana-
tion for that could be that in the mixed T cell population, which is the PBMCs
culture, AvCystatin cannot efficiently target APCs or T cells to induce IL-10 pro-
duction. Our observations led to the conclusions that AvCystatin may act on the
APCs/T cells via induction of regulatory macrophages that possibly are able to in-
terfere with antigen presentation or interact with T cells (N.L. O‘Regan, personal
communication). Of note, there are no macrophages present in the PBMCs. Nor-
mally, circulating monocytes that originate from progenitors in the bone marrow
leave the bloodstream and migrate into tissues where, following conditioning by lo-
cal growth factors, they differentiate into macrophage or dendritic cell populations.
In vitro differentiation from human PBMCs-derived monocytes to macrophages can
be achieved in the laboratory (reviewed in Shi and Pamer, 2011). Furthermore, work
of our group in mice shows that AvCystatin targets murine macrophages and chan-
ges their phenotype to regulatory ones. Such regulatory type of macrophages are
able to downregulate unrelated inflammation in vivo in a mouse system (Ziegler, in
preparation). In the present study, the suppressive capacity of AvCystatin in human
allergic PBMCs obtained in the pollen season could not be observed. One possibility
could be that AvCystatin was not able to act on its target cell, the macrophage to
initiate its immunomodulatory actions. Another explanation for that can be that
AvCystatin was exposed to already established allergic Th2-biased cells that were
present in the PBMCs culture. Thus, AvCystatin was not effective in the presence
of effector cells and only a minority of naive T cells. This likely led to inability
to alter Th2-established responses. Possibly AvCystatin failed the competition with
GPE to modulate APCs or influence T cell responses. PBMCs were derived from
patients with already well built allergy. In the grass pollen-induced mouse model,
AvCystatin possibly targets naive cells at the very first time of treatment (day 1),
whereas in the culture with allergic PBMCs the abundance of naive cells is very
low for AvCystatin to dysregulate the Th2 established responses. Thus, it becomes
evident that results from treatment with AvCystatin in the murine model of allergy
induced by the clinically relevant allergen should be carefully interpreted and trans-
lated with caution into the human system in vitro although restimulation was done
by the same allergen. Apparently the molecule may target distinct mechanisms in
both systems.
One explanation of differences between results from the pilot study and the trial
with 21 allergic patients may be caused by the timing of both experiments. The first
was performed outside of the pollen season, the latter during the season. Differences
based on the pollination season in the profile of cytokine production and allergen-
specific proliferation by PBMCs from allergic patients were reported by Gagnon
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et al. (1993). Natural exposure to pollens in allergic subjects causes the imbalance
between Th1 and Th2 cells in peripheral blood of atopic subjects by stimulation and
release of Th2 cells into the systemic circulation leading to increased Th2-cytokines
production. In addition, allergen-specific memory T cells decrease after the pollen
season, but 60% survive up to 8 months after the season (Horiguchi et al., 2008).
Outside the pollen season there are relatively low numbers of allergen-reactive Th2
cells in PBMC of allergic patients, which is as low as 1 per 20 000 cells (Gabrielsson
et al., 1997). Difference in results may be caused also by the fact that both study
groups were exposed to different pollination seasons. It is important to keep in mind
that each pollen season differs in the amount of pollen count and other environmental
variables that influence immunological responses of individual patients throughout
years (Sakaguchi et al., 2001; Andersson and Lidholm, 2003; Horiguchi et al., 2008;
Anderson et al., 2009; Puc, 2011). Hence, a possibility exists that AvCystatin’s effect
depends on the season and that it modulates T cell responses only out of the pollen
season, where a lower percentage of memory Th2 cells circulate. As promising data
was obtained only from the pilot study out of the season, it would be interesting to
perform further detailed timing and dose establishing experiments that take place
in different pollination seasons.
More experiments in different times of the year, revealing the target cell and
mechanism of AvCystatin’s action would give deeper understanding on its immuno-




in the MC-deficient mouse strains (proposed model in Fig. 5.1). Moreover, an in
vitro system with activated MCs (pre)incubated with AvCystatin can be analyzed
to further investigate mechanism of AvCystatin’s MC-inhibitory effect.
Furthermore, the present study demonstrates an immunomodulatory capacity of
AvCystatin to interfere with a more clinically relevant setting of allergy induced
by grass pollen. The effect has been shown to be administration route-specific. Mo-
reover AvCystatin’s immunomodulation was independent of its intrinsic features
(summarized in Fig. 5.1).
Future work may address other clinical routes of AvCystatin’s delivery, such as
inhalation aerosol or oral application. Additionaly, applying AvCystatin in the the-
rapeutic setup with a stabilized allergy (so after sensitization and challenge phase)
and before a second round of challenges, would closer resemble the situation allergic
subjects experience in the pollen season. Moreover, studies on the protein’s structure
might investigate whether posttranslational modifications, such as methylations play
a role in the AvCystatin’s modulatory behavior in vivo. Furthermore, by crystalli-
zation experiments, the possibility of dimerization through domain swapping could
be examined. This may shed a light on AvCystatin’s crystal-stabilized structure and
would be beneficial in case of formulation as a drug in the future.
Another aspect to be tested is the target cell and mechanism of AvCystatin’s action
in vitro on human cells from allergic as well as healthy subjects. This may be done
in the cell culture with defined proportions of antigen presenting cells (such as
monocytes, DCs but also B cells) and naive/memory T cells incubated with the
clinically defined antigen such as grass pollen allergen. In such setup cytokine (i.e.,
IFN-γ and/or IL-10) depletion experiments could be implemented.
Regarding AvCystatin’s capability as an adjuvant in allergen-specific immunothera-
py (SIT), future studies may focus on investigation of boosting effects of AvCystatin-
coupled-carbohydrate based particles (CBP) or on AvCystatin fused to e.g., clinically
relevant grass pollen allergen (rAvCystatin:rPhl p 5b) in the SIT treatment. Such
approach may enable to combine the AvCystatin’s potent cytokine-modulating acti-




6.1 Molecular biology and biochemical methods
6.1.1 Expression and purification of recombinant
Acanthocheilonema viteae cystatin and derivates
The cDNA of A. viteae cystatin (AvCystatin) was cloned in pET28b(+) and expres-
sed in Escherichia coli as previously described (Hartmann et al., 1997).
Unmodified recombinant filarial cystatin (rAvCystatin) was purified by affinity chro-
matography using a Ni-NTA column and dialyzed overnight (O/N), 4◦C against
PBS/0.05% Triton X-100 or PBS. Next day proteins were dialyzed for additional
2 hours in fresh PBS/0.05% Triton X-100 or PBS. The procedure of expression
of recombinant mouse dihydrofolat reductase (rDHFR) was similar to rAvCystatin
(Hartmann et al., 1997) but bacterial cultures contained 50 µg/ml kanamycin and
100 µg/ml ampicillin. Further rDHFR was purified by an Imidazol gradient using
FPLC (fast performance liquid chromatography) and HiTrap FF columns (similar
to Ni-NTA). Dialysis was performed as described above.
6.1.2 Production of mutated and truncated AvCystatin’s
derivates
Point mutations in the conserved motifs involved in cysteine protease inhibitor ac-
tivity were introduced (J. Russ and T. Buhrke, unpublished).
Briefly, rAvCystatinmut was obtained by site-directed mutagenesis of three
domains to, first of all disrupt the protease inhibition function and at the same
time to preserve the overall conformational structure of the molecule. Thus, two
leucines and two glycines (LLGG) from N-terminal active domain were exchan-
ged to serine and three alanines (SAAA), from the second conserved motif one
glutamine and two valines (QVV) were mutated to serine, alanine and serine
(SAS), mutation of tryptophan (W) effected in alanine (A) in C-terminal domain.
To this end, rpET28b(+)/AvCystatin was used as a template for the two-step
PCR with the high-fidelity Phusion DNA Polymerase (New England Biolabs,






3’; Fw2 5’GTGGCAGGCCTGAGATACAAGATG 3’ and Rv2 5’AGC-
TAAGCTTTCACACTGATGAGAGTACTTCTTTTTTTTCCAGAATTTT-
GACTTGCAAAAAATTTTCAGCTGATTTCTCCCATGCCTCC 3’.
Obtained products were cloned first into the high-copy number plasmid pSL1180
and DH5α E. coli cells were transformed. Then, the entire sequence of mutated
rAvCystatin was recloned to pET28b(+), with which BL21(DE3) E. coli were trans-
formed. Expression and purification of mutated rAvCystatin (rAvCystatinmut) was
performed as previously described (Hartmann et al., 1997).
In order to force rAvCystatin to form monomers, the first 15 N-terminal nucleotides
(at positions 1-15) were truncated (T. Buhrke, unpublished). A truncated form
(rAvCystatintr) was cloned in the same way as unmodified rAvCystatin (Hartmann
et al., 1997).
6.1.3 Demethylation, expression and purification of
AvCystatin
In order to remove the methylation detected at lysine (K) p.137, a site-directed mu-
tagenesis on rpET28b(+)/AvCystatin using Phusion Kit (Finnzymes, Espoo, Finn-
land) was performed.
The mutagenesis protocol comprised three steps (Fig. 6.1):
1. PCR amplification of rpET28b(+)/AvCystatin with two phosphoryla-
ted primers that were designed in the way to introduce the desi-
red mutation so that they first anneal back to back to the plas-
mid. Primers: forward containing mutation (underlined) dmAv17F1
5’PH-GGCATGGGAGCTGTCATGGG 3’ and reversed dmAv17R3 5’PH-
TCCAACGTGATAATCTGATCCGGATGTCC 3’ (TIB, Berlin, Germany).
Conditions of the reaction: 2 min at 98◦C; 35 cycles: 30 sek at 98◦C, 45 sek
at Tm=56◦C, 1 min 30 sek at 72◦C; 10 min at 72◦C. To improve yield and
specificity 3% DMSO was used in the reaction. In the PCR reaction, Phusi-
on Hot Start DNA Polymerase (New England Biolabs, Frankfurt, Germany)
extended the primers and amplified the plasmid with the mutation.
2. Circularization of 6 ng/µl mutated PCR product was done by ligation with
Quick T4 DNA Ligase (New England Biolabs, Frankfurt, Germany) for 5 min




6.1.4 Endotrap system to remove endotoxin contaminations
EndoTrap blue columns were used according to the manufacturer’s instructions (Pro-
fos, Regensburg, Germany) to remove endotoxin contaminations in the purified four
derivates of rAvCystatin.
6.1.5 Limulus amoebocyte test (endotoxin measurement)
Final endotoxin concentrations were detected by a Limulus amoebocyte lysa-
te test from horseshoe crab, Limulus polyphemus (Cambrex, BioSciences, Wal-
kersville, USA). Average endotoxin concentration of rAvCystatin, rAvCystatinmut,
rAvCystatintr and rAvCystatindm was approx. 1.5 LPS pg/µg protein, 0.03 endoto-
xin units (EU) per protein application.
6.1.6 Quantification of protein (BCA assay)
Protein concentrations were measured with the bicinchoninic acid test using BCA
protein assay kit (Pierce, ThermoFisher Scientific, IL, USA) according to the ma-
nufacturer’s instructions.
6.1.7 SDS-PAGE and Coomassie staining
Recombinant proteins were resolved on polyacrylamide gel by SDS-PAGE using
the discontinuous buffer system (Laemmli, 1970) with and without reducing agent
(β-mercaptoethanol, BME). For the production of polyacrylamide gels Bio-Rad ap-
paratus was used (Bio-Rad Laboratories, Munich, Germany). The concentration of
the acrylamide for the running gel was according to the molecular weight of the
fractioned proteins (12-14%). For the stacking gel 6% acrylamide solution was used.
The protein fractions (100 ng/well) were mixed with 2x sample buffer, heated for
3 min at 95◦C. After loading the polyacrylamide gel, the samples were separated
at 120-160V at RT for 1 h. To characterize the molecular weight of the fractiona-
ted proteins a standard with prestained proteins was used (New England Biolabs,
Frankfurt, Germany). After the electrophoresis, separated protein fractions on the
polyacrylamide gel were either stained for 30 min at 50-60◦C with the Coomas-
sie solution, destained and dried. Further immunological characterization, separated
fractions were electrophoretically transferred into a nitrocellulose membrane (NC)
(Towbin et al., 1979).
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6.1.8 Inhibitor protease activity test
Cystatin was tested for cysteine proteinase inhibitor function in activity test to
papain cleavage as described earlier (Hartmann et al., 1997). Briefly, rAvCystatin
was incubated with papain and the substrate BAPNA for 30 min in 37◦C. Test was
read at 450 nm on ELISA plate reader (BioTek, Bad Friedrichshall, Germany) and
inhibition of substrate cleavage by papain was calculated.
6.1.9 Analytical gel filtration and right angle static light
scattering: oligomerization assay
Right angle static light scattering (RALS) system and refractive index detector
(Malvern) were connected in line to an analytical gel filtration column Superdex
75 10/300 (GE Healthcare) to determine absolute molecular masses of the applied
proteins. Molecular weight distributions were determined, thus the aggregations in
each protein solution was assessed. To this end, 100 µl of 3-5 mg/ml unmodified
rAvCystatin and rAvCystatintr was applied and eluted through Superdex 75 10/300
column. The running buffer was PBS, pH 7.3 with a flow rate of 1 ml/min. Data
were analyzed with the provided OmniSec software.
6.1.10 RNA and cDNA preparation
To prepare RNA from the intestinal tissue frozen segments were blended using a tis-
sue homogenizer (MP Biomedicals, Eschwege, Germany) in RNA lysis buffer (Ana-
lytik Jena, Jena, Germany). Tissue supernatants were subsequently processed using
the innuPREP RNA kit following the manufacturer’s instructions (Analytik Jena,
Jena, Germany).
6.1.11 Real time PCR
Real time PCR was used to analyse the expression levels of several cytokines at the
residing site of helminths. 2 µg of RNA was reverse transcribed to cDNA using a High
Capacity RNA to cDNA kit (Applied Biosystems, NJ, USA). The relative expression
of β-actin, IL-25, IL-33 and TSLP was then determined via real time PCR using
5 ng of cDNA and FastStart Universal SYBR Green Master Mix (Roche, Zürich,
Switzerland) and 300 nM primer pairs: β-actin F1 5’ TCTTGGGTATGGAAT-
CCTGTGGCA 3’ and β-actin R1 5’ TCTCCTTCTGCATCCTGTCAGCAA 3’;
IL-25 (IL-17E) F1 5’ ACAGGGACTTGAATCGGGTC 3’ and IL-25 (IL-17E)
R1 5’ TGGTAAAGTGGGACGGAGTTG 3’; IL-33 F1 5’ AGGAAGAGATCCTT-
GCTTGGCAGT 3’ and IL-33 R1 5’ ACCATCAGCTTCTTCCCATCCACA 3’;
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TSLP F1 5’ AGCAAGCCAGCTTGTCTCCTG 3’ and TSLP R1 5’ TGTGC-
CATTTCCTGAGTACCGTCA 3’ (TIB, Berlin, Germany) on AB7000 (Applied
Biosystems, Darmstadt, Germany). Buffer conditions were used according to the
manufacturer’s instructions. PCR conditions: denaturation 10 min at 95◦C; 40 cy-
cles: 15 s at 95◦C and 60 s at 60◦C; 15 s at 95◦C. Relative gene expression was
determined via normalisation to the endogenous reference - the housekeeping ge-
ne (β-actin) and to strain specific naive controls using the 2-∆∆Ct method (Livak




Western blot analysis was used for the detection of proteins by polyclonal antibodies
from rabbit serum raised against unmodified rAvCystatin. SDS-PAGE separated
proteins were transfered into a NC at overnight at 80 mA. The NC membrane was
then incubated in 5% non-fat dry milk/TBS for 1 h at RT to block the binding
sites of the NC membrane. Afterwards the NC membrane was washed three times in
0.2% Tween20/TBS (TBST) while shaking. Primary antibody was applied for 2.5 h
at RT. After the incubation, unbound antibodies were removed by washing the NC
membrane 3 times with TBST. The secondary antibody (peroxidase-conjugated) was
incubated with the NC membrane for 1.5 h at RT. Then, after washing 3 times with
TBS, the color reaction was induced by addition of the corresponding substrate. To
stop the reaction the NC membrane was washed with TBS. The NC membrane was
then incubated with Amersham ECL Plus Western Blotting Detection System (GE
Healthcare, Freiburg, Germany) and the protein bands were detected by enhanced
chemiluminescence (1 min in the dark) (GE Healthcare).
Antibodies (Ab):
• 1st Ab: anti-rAvCystatin-rabbit serum, dilution 1:80 000 in 5% non-fat dry
milk/TBS
• 2nd Ab: Peroxidase-conjugated goat anti-rabbit IgG, dilution 1:2000 in 5%
non-fat dry milk/TBS
6.2.2 Antibody detection
Total IgE and allergen-specific (OVA- and rPhl p 5b-) IgE, IgG1 and IgG2a levels
in serum were determined by sandwich ELISA, as described before (Beier et al.,
2004). For establishment of the grass pollen-induced model and comparison with an
OVA-induced morel, kinetics of OVA- and Phl p 5b-specific antibodies was assessed
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before sensitization on day 0, during the sensitization on day 12, before challenge on
day 26 and after challenge on the day of the dissection (day 32). Standard sera using
OVA were previously prepared as described earlier (Beier et al., 2004). For standard
sera using grass pollen allergen BALB/c mice were injected i.p. with 5 µg rPhl p
5b and 2 mg Alum on days 1, 14, 21 and 39, followed by i.n. GPE (containing 9
µg/mg of rPhl p 5b, 6.09 ng/PNU as 38.5 µg/mg) challenge on days 53, 54, 55 and
62. Sera were obtained three days later. IgE standard (BD Pharmingen, Heidelberg,
Germany) was used in accordance to samples to calculate total IgE amounts as
µg/ml (dilution 1:2). Standard sera (for OVA-model #67, rPhl p 5b-model #1)
were used to calculate amounts of allergen-specific IgE, IgG1 and IgG2a. For other
experiments than kinetics evaluation, commercial IgG1 standard (BD Pharmingen,
Heidelberg, Germany) was employed (dilution 1:1.5) to calculate specific IgG1 levels.
Thus, in these experiments allergen-specific IgG1 were calculated as µg/ml and
allergen-specific IgE and IgG2a were presented as lab units (LU). Table 6.1 shows
dilutions of according Abs and sera used for immunoglobulin ELISAs performed in
this study.
For biotynylation of allergens a 1 mg/ml solution of OVA grade VI (Sigma-Aldrich,
Munich, Germany) or rPhl p 5b Batch#PP5br04001 (Allergopharma, Reinbek, Ger-
many) (pH 8.3 with 100 mM NaHCO3) were used. Allergens were incubated 1 h with
13.4 M sulfo-NHS-LC-Biotin at RT, in the dark shaking. Afterwards the solution










































































































































































































































































































































Cell culture supernatants were harvested and tested for IL-2, IL-4, IL-5, IL-6, IL-9,
IL-10, IL-12p40, IL-13 and IFN-γ by cytokine ELISA kits (BD Biosciences, Heidel-
berg, Germany or eBioscience, CA, USA).
To assess the production of IL-25, IL-33 and TSLP in the intestinal tissue, frozen
sections of small intestine were homogenized with tissue homogenizer (MP Biomedi-
cals, Eschwege, Germany) in a buffer containing protease inhibitor cocktail (Roche,
Mannheim, Germany). Samples were centrifuged at 20 000g for 10 minutes and the
total protein concentration in supernatants was determined via BCA test (Pierce,
ThermoFisher Scientific, IL, USA). Samples were then assessed in duplicates via
sandwich ELISA by DuoSet ELISA kit (R&D Systems, MN, USA) and the concen-
tration (pg/ml) was normalized to total protein content (pg/mg total protein).
Human PBMCs
Cell-free PBMCs culture supernatants were collected and assayed for IL-4, IL-5,
IL-10, IL-13 and IFN-γ by specific ELISA. Capture and detection Abs of IL-5 and
IL-13 were purchased from BD Pharmingen (Heidelberg, Germany) and standards
from Immunotools (Friesoythe, Germany). Detection Abs: 1 µg/ml for IL-5 and 3
µg/ml for IL-13. Capture Abs: 1 µg/ml for IL-5 and 0.5 µg/ml for IL-13. ELISA kits
for IL-4, IL-10 and IFN-γ were ordered from eBioscience (CA, USA) and performed
according to the manufacturers’ instructions. The detection limit of the assay was
1.6 pg/ml for IL-4, 46.8 pg/ml for IL-5, 2.3 pg/ml for IL-10, 39 pg/ml for IL-13 and
3.9 pg/ml for IFN-γ. Optical density values of the samples were read at 450/570 nm
on an ELISA plate reader (BioTek, Bad Friedrichshall, Germany).
6.2.4 Mast cell protease detection
At the day of dissection blood samples were collected and processed for sera. Sera
from: naive, infected, allergic and allergic-AvCystatin-treated animals were assayed
for mouse mast cell protease-1 (mMCP-1) by specific ELISA Ready-Set-Go kit





Following MLN culture in 96-well plates with or without antigen stimuli, cellular
proliferation was analysed via a further 20-hour culture in fresh media containing
1µCi methyl-[3H]-thymidine (Amersham Pharmacia Biotech, Gent, Belgium) and
subsequent detection using a β-counter (Perkin-Elmer, NY, USA). The uptake of
labeled thymidine was measured by scintigraphy and showed proliferation rate in
cpm (counts per minute).
Human PBMCs
In order to detect antigen-specific proliferation of PBMCs from allergic patients,
cells were stained with CFSE (Carboxyfluorescein succinimidyl ester). CFSE passi-
vely diffuses into cells. It is colorless and non-fluorescent until the acetate groups are
cleaved by intracellular esterases to yield highly fluorescent carboxyfluorescein succi-
nimidyl ester. The succinimidyl ester group reacts with intracellular amines, forming
fluorescent conjugates that are well retained and can be fixed with aldehyde fixatives
e.g., formaldehyde. Excess unconjugated reagent and by-products passively diffuse
to the extracellular medium, where they can be washed away.
Freshly isolated human PBMCs (Subsection 6.6.2) were resuspended in PBS at
10x106 cells/ml. CFSE was diluted 1:1250 from a stock solution of 5 mM (stored at
-20◦C) just before use. Cells were mixed and incubated at 37◦C for 5 minutes pro-
tected from the light. Reaction was stopped by washing the cells twice at 390g, 4◦C,
15 minutes with RPMI-1640 medium containing 10% of autologous patient’s serum.
CFSE-labeled cells were washed, counted and resuspended in complete medium and
cultured as described in Subsection 6.6.2.
6.2.6 Flow cytometric analysis
Animal models
After isolation of organs, single cell suspensions (minimum 1x106 cells) were stained
with fluorescent conjugated antibodies against surface CD4, CD25 and intracellular
stains for Foxp3, GATA-3, IL-13 or respective isotype controls. For intracellular cy-
tokine staining 5x106 cells/well were stimulated with 50 ng/ml PMA and 1 µg/ml
Ionomycin for 30 minutes, followed by further 3h incubation with Brefeldin A (10
µg/ml) (Sigma-Aldrich, Germany), which inhibits transport of proteins from endo-
plasmic reticulum (ER) to Golgi apparatus and induces retrograde protein transport
to the ER. This leads to proteins accumulating inside the ER. After 3.5h-incubation,
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cells were harvested, washed followed by a Fixation/Permeabilization Kit protocol
(eBiosciences, CA, USA). Stained samples were acquired using FACSCanto, LSR II
or Fortessa flow cytometers (BD Biosciences) and analyzed using FlowJo software
(Tree Star, OR, USA).
Human PBMCs
Flow cytometric analysis was performed at day 7 of cultured CFSE-stained PBMCs.
At day 7, 1x106 cells/well were incubated with 50 ng/ml PMA and 1 µg/ml Iono-
mycin (Sigma-Aldrich, Germany) for 1 hour, 37◦C, 5% CO2 and for last 4h in the
presence of Brefeldin A (5 µg/ml) (Sigma-Aldrich, Germany). After 5h-incubation,
cells were washed and resuspended in PBS. Cells were prepared for intracellular
cytokine analysis according to the BD Cytofix/Cytoperm Kit protocol (BD Bios-
ciences, Heidelberg, Germany) with modifications. For extracellular analysis on live
cells, Fixable Viability Dye eFluor660 (eBioscience, CA, USA) was added for exclu-
sion of dead cells. Briefly, cells were fixed in Fix/Perm solution (BD Biosciences)
for 30 min, 4◦C, washed and centrifuged in Perm Buffer (BD Biosciences), 390g,
10 min, 4◦C. To avoid Fc receptor binding of fluorochrome-conjugated antibodies
FcγR-blocking antibody (BD Biosciences) was used. Cells were washed again and
subjected to FACS analysis. A total of 1x106 cells/treatment were intracellular stai-
ned with the following antibodies: Alexa Fluor 405-conjugated anti-human CD4 (to
circumvent PMA-induced loss in surface CD4 on human T cells (Acres et al., 1986;
Bigby et al., 1990), PeCy7- conjugated anti-human IL-4, Alexa Fluor 430-conjugated
anti-human IFN-γ (all as a gift from DRFZ, Berlin, Germany), PE-conjugated anti-
human IL-10 (BD Biosciences). Stained cells were acquired on a FACSCanto flow
cytometer (BD Biosciences) with FACS-DIVA software and further analyzed using
FlowJo software (Tree Star, OR, USA).
6.3 Parasitological methods
6.3.1 Heligmosomoides polygyrus and Trichuris muris life
cycle and infection
In frame of this work two helminth infections with H. polygyrus and T. muris in
mouse were used. To further understand the aspects of immune response, life cycles
of both parasites are briefly introduced here.
H. polygyrus (Hp) infection is an example of efficient parasitism. Once the infection
is established, becomes chronic and lasts weeks to months in genetically competent
strains of laboratory mice. The free-lining larvae (L1) hatches from the egg in the
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environment and undergoes two molts. L3 stage is infectious by oral ingestion. It
moves into the gastric mucosa of the stomach as early as 4 hours after inoculation,
emerges 36 hours later, enters the duodenum and lies next to the longitudinal muscle
layer of the gut. The third molt is 2 days post infection, the fourth molt 4 to 6 days
later, and adults appear at day 8 p.i. into the lumen, where they mate and produce
eggs. From day 9 p.i. eggs are passed in the feaces and continue to appear for several
days (reviewed in Donskow-Schmelter et al., 2009).
T. muris (Tm) is transmitted via the ingestion of embryonated eggs that pass
through the digestive tract. After reaching ceacum, eggs are hatching and the first
stage larvae (L1) appears. L1 penetrates the mucosal layer and epithelium of ceacum,
where it grows and undergoes molting at day 9, 17 and 22 p.i. At day 32 p.i. it reaches
maturity, migrates into the lumen where the adult worms mate and release eggs into
the host feaces (reviewed in Cliffe and Grencis, 2004).
In frame of this work mice were in infected with H. polygyrus via oral gavage with
200 infective L3 in 200 µl distilled H2O. Infection with T. muris was performed
with 200 embryonated eggs via oral gavage. Adult parasite burdens were assessed
via longitudinal dissection of either small intestine (Hp) or the caecum and proximal
colon (Tm) and counted using a binocular microscope.
6.3.2 Fecal egg count
The shedding of H.polygyrus eggs was assessed via collection and weighing of murine
faecal pellets at days 14, 16 and 18 p.i. from each mouse. Faeces were suspended in
1 ml distilled H2O. Saturated NaCl solution (5 ml) was added, mixed and 650 µl of
the solution was placed into MacMaster chambers. Eggs were counted in duplicated
via light microscopy.
Total eggs per gram (g) faeces were calculated by the following formula:
Number of eggs in sample × sample volume × 6.67
faeces weight in g
Counts were expressed as the median counts of eggs enumerated on three indepen-
dent days per mouse.
6.3.3 H. polygyrus adult worm antigen
Worm antigen was prepared from H. polygyrus adult worms incubated for 24h in
RPMI-1640 medium containing 100 U/ml penicillin and 100 µg/ml streptomycin.
Worms were homogenized and sonicated (1 min, 60W) on ice in PBS, followed by
centrifugation for 20 min, 20 000g at 4◦C). For sterilization, the antigen extract was
filtered through a 0.4 µm filter and stored at -80◦C until usage.
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6.4 Protocols for animal models
Female BALB/c and C57BL/6 were purchased from Charles River (Sulzfeld, Ger-
many) and either housed at the animal facilities of the Charité-University Medicine
Berlin Campus Virchow-Klinikum or Humboldt University Berlin. MC-deficient mi-
ce KitW/KitW−v; KitW−sh/KitW−sh and WBB6 background control (wild type, WT)
strain mice were bred and housed at the animal facilities of the Charité-University
Medicine Berlin Campus Mitte. All mice were handled following national guidelines
and experiments were approved by the animal ethics committee.
6.4.1 MC-deficiency and worm infection
Infection of MC-deficient (KitW/KitW−v; KitW−sh/KitW−sh) and WBB6 background
control (WT) strain mice with H. polygyrus and T. muris was performed as descri-
bed in Subsection 6.3.1.
At the day of the dissection following analyses were performed:
1. removal of spleen, MLNs to perform cell culture, proliferation and FACS ana-
lyses
2. removal of parts of intestine for adult worm counts
3. cryoconservation of parts of intestine to perform tissue homogenates for real
time PCR analyses
4. preparation of intestinal sections for histological analyses
5. collection of blood to monitor antibody production and levels mMCP-1 in
serum
6.4.2 rPhl p 5b- vs. OVA-induced model of allergy and
treatment with AvCystatin
Female BALB/c mice, 8-week-old mice were sensitized three times (day 1, 14 and
21) i.p. with 5 µg rPhl p 5b (Genbank acc. no. Q40963, gift from Allergopharma,
Reinbek, Germany) emulsified in 2 mg of aluminum hydroxide, Alum (Imject Alum,
Pierce, ThermoFisher Scientific, IL, USA) for the rPhl p 5b-induced model. For the
OVA-induced model, animals were injected two times (day 1 and 14) i.p. with 20 µg
OVA (Grade VI, Sigma-Aldrich, Germany) emulsified in 2 mg Alum. Subsequently,
on days 28 and 29, mice were anesthetized by an i.p. injection of ketamine/rompun
(Bayer and Bela-Pharm, Berlin, Germany) and challenged twice i.n. with grass pollen
extract (GPE) (Allergopharma, Reinbek, Germany) containing 9 µg Phl p 5b (6.09
ng/PNU as 38.5 µg/mg) (rPhl p 5b-induced model) or with 50 µg OVA (OVA-
induced model). Scheme of both models is presented in Fig. 3.9.
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Sensitized with rPhl p 5b mice were treated i.p with 20 µg unmodified rAvCystatin,
rAvCystatinmut, rAvCystatintr or the control protein rDHFR on four occasions, on
days 1, 7, 14 and 21 (during the sensitization phase) and challenged i.n. with GPE
on days 28 and 29 (Fig. 3.11).
Naive controls were injected with Alum in PBS and challenged under anaesthesia
with PBS.
Airway reactivity (AR) was measured in vivo on day 31 (described in Subsection
6.4.4).
Analyses were performed one day after AR measurement and included:
1. lavage of lungs to collect BAL fluids to assess levels of cytokines, cell numbers
and types
2. removal of PBLNs and spleen to cell cultures and/or FACS analyses
3. preparation of lungs for histological analysis (formalin)
4. collection of blood to obtain sera for assessment of antibody production and
levels of mMCP-1
6.4.3 Model of allergen-specific immunotherapy (SIT) and
AvCystatin
Female BALB/c mice, 8-12-week-old (Charles River, Sulzfeld, Germany) on day 1
and 14 received i.p. sensitizations with 20 µg OVA emulsified in 2 mg of Alum.
Aerosol challenges with 1% OVA in PBS (1 g in 100 µl) were applied on days 42,
44 and 46. The allergen-specific immunotherapy (SIT) treatment was performed s.c.
with 1 mg (SIT high) or 100 µg (SIT low) OVA between sensitization and challenge
phase days 28, 30 and 32 (Fig. 3.23).
Cystatin was applied after sensitization and before challenge: on days 28, 30 and 32
rAvCystatin was mixed beforehand with OVA and applied together s.c. (rAvCystatin
+ OVA s.c.) as a therapy in the first approach. In the second and third setup, it
was administered on days 28, 30 and 32 in two separate injections either s.c. or i.p.
at the same time with OVA s.c. (SIT) (rAvCystatin s.c. & OVA s.c. or rAvCystatin
i.p. & OVA s.c.) (Fig. 3.25). In the last approach rAvCystatin was applied i.p. alone
after allergen sensitization and before challenge on days 28, 30 and 32 (Fig. 3.25).
One day before analysis, AR was measured in vivo (day 49, Subection 6.4.4).
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Analyses on day 50 included:
1. lavage of lungs to collect BAL fluid to assess levels of cytokines, cell numbers
and types
2. removal of PBLNs, spleen to cell cultures and/or FACS analyses or prolifera-
tion
3. preparation of lungs for histological analysis (formalin)
4. collection of blood to obtain sera for assessment of antibody production
6.4.4 Measurement of airway reactivity (AR)
Airway responsiveness was determined one day before dissections by whole body
plethysmography in unrestrained animals to inhaled increasing doses of metacho-
line (MCh) (Sigma-Aldrich, Germany) as described elsewhere (Hamelmann et al.,
1997b). Baseline was established in response to PBS inhalation. The mean values
of the Penh (enhanced pause) for every MCh concentration were calculated. Index
Penh values of individual animals (Penh value of MCh minus baseline) were analysed
as mean values of each group.
6.4.5 Bronchoalveolar lavage (BAL) fluid
One day after AR measurements, mice were sacrificed, blood samples were collected
and BAL fluids harvested by flushing the lung airways via the trachea two times
with ice cold 0.8 ml suspension of protease inhibitor cocktail (Roche, Mannheim,
Germany) in PBS. The tubes were weighted and BAL fluid from the first lavage was
centrifuged (10 min at 2 000 rpm, 4◦C), supernatants were collected and stored at
-80◦C for subsequent analysis of cytokines.
BAL cells were recovered and combined from both lavages, resuspended in PBS and
counted (total cell number). 20 µl aliquot was stained with Kimura stain and MCs
were counted via light microscopy. 100 µl of remaining cells was spun down using
a cytospin centrifuge for staining and differentiation (ThermoShandon Cytospin 4,
Frankfurt, Germany). Dried grass slides with cytospined cells were stained with
DiffQuick (Fisher Scientific, Germany) according to the manufacturer’s instructions.
The numbers of eosinophils, lymphocytes and macrophages were differentiated by
morphological criteria (count of 200 cells/slide under light microscopy in a blinded




Lungs were fixed in 3.7% phospate-buffered formalin, embedded in paraffin wax, 2
µm sections were cut and stained using standard histological protocols with Hema-
toxylin and Eosin (H&E) for histomorphological evaluation, with periodic acid-Schiff
reagent (PAS) for carbohydrates detecting goblet cells and Toluidine blue for MCs.
Sections were evaluated via light microscopy.
6.4.7 Reconstitution with rIL-25
In some experiments with MC-deficient mice, KitW/KitW−v and WBB6 mice strains,
on days 1-4 p.i. with Hp, animals received i.p. 0.4 µg rIL-25 in PBS (R&D Systems,
MN, USA).
6.4.8 Reconstitution with bone marrow
In some experiments with MC-deficient mice, KitW/KitW−v mice were reconstituted
with Kit+/+ (WT) bone marrow via intravenous transfer of 1x107 purified mono-
nuclear bone marrow cells. Reconstituted animals rested for 6 weeks prior to parasite
infection.
6.5 Recruitment criteria for allergic subjects
Allergic patients were recruited via an announcement at the Charité Campus Mitte,
Berlin, e-mail or telephone contact directly by the study nurse. The blood samples
(up to 40 ml) from 3 allergic subjects and 2 healthy controls were taken by the study
nurse once out of the pollen season and from 21 allergic patients once in the season.
Patients signed in the written consent. The whole study was monitored by the study
doctor and approved by the local Ethics Committee (Charité-University Medicine
Berlin).
Inclusion/exclusion criteria were set up for the recruitment of allergic patients recrui-
ted in the pollen season. Some patients did not strictly meet the criteria concerning
fixed class of allergen-specific IgE. However, all of them were allergic to timothy
grass pollen and because of the low sample size, all of them were considered in the
study. The subgroup analysis of the results was further performed.
Inclusion criteria were following:
1. Positive test: ImmunoCAPTM class 3 or higher to sweet vernal grass (Anthox-
anthum odoratum), timothy grass (P. pratense) and rye (Secale cereale), high
titer of allergen-specific IgEs
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2. Clinical symptoms and documented history of grass pollen allergy
3. No oral steroid therapy or immunotherapy received at least 3 months before
the study
Exclusion criteria:
1. Negative test: ImmunoCAPTM class 0 to sweet vernal grass (A. odoratum),
timothy grass (P. pratense) and rye (S. cereale), no allergen-spec. IgE detected
2. No clinical symptoms or history of grass pollen allergy
3. Oral steroid therapy or immunotherapy received not later than 3 months before
the study
4. Illnesses within the past two weeks or any chronic or acute medical problems
apart from allergy that would influence immune parameters
5. Receiving any kind of suppressive medications
Twenty-one allergic patients (age 21-49; eight males and thirteen females) with cli-
nical symptoms and history of grass pollen allergy were examined during the pollen
season. Patients were verified for allergen-specific IgE to three common grass pollen
allergens: sweet vernal grass (A. odoratum), timothy grass (P. pratense) and rye (S.
cereale). All asthmatic patients had allergen-specific IgE to grasses detected in the
serum (>0.35 kU/l, class >1) (ImmunoCAPTM System, Phadia AB, Uppsala, Swe-
den). For the establishment experiment three allergic subjects with serum IgE class
three and two healthy controls with no history of allergic symptoms and negative
(<0.35 kU/l, class 0) to common grass allergens, were examined out of the pollen
season. On entering the study, subjects were free of oral steroids or immunotherapy
for at least 3 months. All patients were in a good health conditions. However, in the
written questionnaire five of them reported atopic dermatitis, one communicated
urticaria and one high blood pressure. Clinical characteristics of allergic subjects
are presented in Table 3.5, Section 3.5
6.6 Cell culture techniques
6.6.1 Preparation of organs for cell culture
Mouse models of asthma, MC-deficiency and helminth infection
Spleens, PBLNs and MLNs of mice were passaged under sterile conditions via
through a 70 µm nylon mesh. If necessary, erythrocytes were removed by resuspen-
sion of washed cells in erythrocyte lysis buffer for 5 min on ice. Cells were washed
twice and resuspended in RPMI-1640 supplemented with 100 U/ml penicillin, 100
µg/ml streptomycin, 20 mM L-glutamin, and 5-10% fetal calf serum (FCS) (HyClo-
ne, Perbio Science, ThermoFisher, Germany) and cultured (MC-deficiency model:
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1x106 cells/well and asthma model: 3.5x105 cells/well) for 48 or 96 h (MC-deficiency
and asthma model, respectively) in 5% CO2 at 37◦C. Cells for FACS analysis after
isolation were directly resuspended at least 1x106 cells/staining and analysis was
processed. For intracellular cytokine staining were resuspended 5x106 cells/well and
handled as described in Subsection 6.2.6.
Otherwise, cell culture supernatants were stimulated as indicated below, cultured
for a given time and harvested. Supernatants were tested for cytokines as described
in Subsection 6.2.3.
Stimulations of cells were following:
Asthma model
• RPMI-1640 alone
• 2.5 µg/ml ConA
• 20 µg/ml OVA (OVA-model)
• 5 µg/ml rPhl p 5b (rPhl p 5b-model)
• 10 µg/ml cystatins (unmodified rAvCystatin, rAvCystatinmut, rAvCystatintr)
MC-deficiency and helminth infection model
• RPMI-1640 alone
• 20 µg/ml H. polygyrus antigen (Hp-Ag)
• 50 µg/ml T. muris E/S (Tm E/S-Ag)
• 1 µg/ml anti-CD3 and anti-CD28 mAb
SIT model
Spleen and PBLNs were isolated aseptically and organs were passed through through
a 70µm nylon mesh under sterile conditions. If necessary, erythrocytes were remo-
ved by resuspension of washed cells in erythrocyte lysis buffer for 5 min on ice.
Cells were washed twice. Spleen mononuclear cells were isolated by density gradient
centrifugation (Lympholyte-M, Cedarlane Laboratories, Ontario, Canada). Spleen
mononclear cells and PBLNs were resuspended in RPMI-1640 supplemented with
100 U/ml penicillin, 100 µg/ml streptomycin, 20 mM L-glutamin, and 10% fetal
calf serum (FCS) (HyClone, ThermoFisher, Bonn, Germany) and cultured for 96
h (MC-deficiency and asthma model, respectively) in the presence of RPMI-1640
media alone, 2.5 µg/ml ConA, 50 µg/ml OVA or 10 µg/ml rAvCystatin in 5% CO2
at 37◦C. Cells for FACS analysis after isolation were immediately resuspended at
least 1x106 cells/staining and analysis was performed as described in Subsection
6.2.6. Otherwise, cell culture supernatants were harvested and stored at -20◦C until
performance of cytokine ELISA as described in Subsection 6.2.3.
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6.6.2 Isolation and culture of human PBMCs
Blood was collected by a certified study nurse into tubes containing anticoagulant
(Lithium Heparin) (BD, Heidelberg, Germany) and centrifuged at 700g, RT for 5
minutes to isolate patients’ plasma. Plasma was collected and further centrifuged
at 1400g in order to remove remaining blood cells. The upper fraction without cells
was collected and used as autologous patient’s sera. Remaining red blood fraction
was diluted with an equal volume of RPMI-1640 medium, carefully layered and cen-
trifuged (800g, RT, 20 minutes) over LymphoprepTM density gradient (Axis-Shield
PoC AS, Oslo, Norway). After centrifugation the mononuclear cells that formed
a distinct band at the sample/medium interface were removed from the interface
using a Pasteur pipette without removing the upper layer. The harvested fracti-
on was diluted with RPMI-1640 medium to reduce the density of the solution and
the cells were washed at 600g, 4◦C, 15 minutes. Supernatant was aspirated and in
order to remove the platelets, the cells were pelleted one more time by centrifuga-
tion for 15 minutes at 250g, 4◦C. Isolated and washed PBMCs were resuspended
at 2x106 cells/ml in RPMI-1640 culture medium, 5% patient autologus serum, 1%
L-glutamine (2 mM), 1% penicillin (100 U/ml)/ streptomycin (100 mg/ml), 0.1%
β-mercaptoethanol (BME) and incubated for 3 days (for supernatants) or for 7 days
(for surface marker and intracellular cytokine staining) in 24-well plate at the density
of 1x106 cells/well. In all experiments viability of isolated PBMCs was over 95%.
Dose and time response experiments with GPE
The titration experiment with three timothy grass pollen allergic patients and two
healthy controls was performed in order to define the dose and timing of GPE used
for an in vitro restimulation of PBMCs. Cells were incubated with different concen-
trations range: 2, 5, 10 and 20 µg/ml of GPE (Allergopharma, Reinbek, Germany) for
7, 9 and 11 days in conditions described in Subsection 6.6.2. The GPE-concentration
and time inducing the best proliferative response before an in vitro treatment with
rAvCystatin was determined and used for evaluating the course of the T cell reacti-
vity to GPE during the study period.
Dose and timing of incubation with AvCystatin
The titration experiment with three timothy grass pollen allergic patients and two
healthy control was performed out of the pollen season in order to define the dose
and timing of incubation with rAvCystatin in an in vitro restimulation of PBMCs.
Cells were incubated with different concentrations (2.5 and 20 µg/ml) of rAvCystatin
that was either added 2 hours prior to or at the same time of stimulation with 5
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µg/ml GPE. Cells were incubated for 3, 5, 7 and 9 days in conditions described in
Subsection 6.6.2. The concentration and incubation time with rAvCystain showing
the strongest suppressive capacity was determined and used in experiments in the
pollen season.
6.7 Statistical analysis
Each animal experiment was performed with 4-6 animals per group, and the experi-
ments shown are representative of three independent experiments unless otherwise
stated. Experiments with human PBMCs were performed once out and once in the
grass pollen season. Patient number was indicated in each experiment. Statistical
analysis was performed with the unpaired Student’s t test, Kruskal Wallis analysis
or 1-way ANOVA where applicable. Data are presented as means ±SEM. Values of
*, p< 0.05; **, p< 0.01; ***, p< 0.001 were considered statistically significant.
The Spearman’s correlation coefficient test was used to determine the correlation
among different variables. The line fitting results was determined using linear re-




E. coli DH5α Invitrogen, Darmstadt, Germany
E. coli BL21 (DE3) Novagen, Merck KGaA, Darmstadt, Germany
pET28b(+) Novagen, Merck KGaA, Darmstadt, Germany
BALBc and C57BL/6 mice Charles River, Sulzfeld, Germany
KitW/KitW−v; KitW−sh/KitW−sh mice Charité , Berlin, Germany
WBB6 control (WT) mice Charité, Berlin, Germany
7.2 Laboratory equipment
Bio-Rad apparatus Bio-Rad, Munich, Germany
Centrifuges Eppendorf, Hamburg, Germany
Cytocentrifuge (cytospin) ThermoShandon 4, Frankfurt, Germany
ELISA-reader BioTek, Bad Friedrichshall, Germany
FastPrep-24 Homogenizer MP Biomedicals, Eschwege, Germany
Flow cytometer: LSRII, FACSCanto BD Biosystems, CA, USA
Real-time PCR system 7300 Applied Biosystems, CA, USA
Scintillation-spectroscope Trilux 1450 Wallac, Turku, Finland
Square wave electroporator BTX ECM830, BTX, Holliston, USA
Ultrasound-disintegrator Heinemann, Schw. Gmünd, Germany
Whole-body plethysmograph (AHR) emka technologies, Paris, France
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7.3 Buffers and media
Coomassie 20% EtOH 10% acetic acid
2 tabl. PhastGel BlueR (Amersham)
up to 1 l dest. H2O
Destaining buffer 20% EtOH
10% acetic acid









10x TBS 1 M NaCl
50 mM Tris, pH 7.5
TBST 0.2% Tween20
1x TBS
LB-Medium 10 g NaCl
10 g Trypton
5 g Yeast extract





SOB-Medium 20 g Trypton
5g Yeast extract
0.5 g NaCl
10 ml KCl (250 mM)
add 995 ml H2O
pH 7.0
5 ml sterile 2 mM MgCl2
autoclaved
SOC-Medium SOB-Medium
10 mM filtered glucose




Cell culture medium RPMI-1640





7.4 Protein purification buffers
Cell culture medium RPMI-1640





all from Biochrom, Berlin, Germany
BAL-wash-solution 10 ml PBS (Dulbecco’s w/o)
1 tabl. complete protease inhibitor (Roche)
Lympholyte-M Cedarlane Laboratories, Ontario, Canada
LymphoprepTM Axis-Shield PoC AS, Oslo, Norway
FACS staining buffer 0.2% BSA in PBS
FACS fixation buffer 0.2% BSA, 0.5% paraformaldehyde (PFA) in PBS
7.4 Protein purification buffers



















Lysis buffer PBS/0.1% (v/v) Triton, pH 8
Wash buffer PBS/10% (v/v) Glycerin, pH 5.8
Elution buffer PBS/10% (v/v) Glycerin, pH 3
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Neutralization buffer PBS, pH 10
Dialysis 1 PBS, pH 7.4 or PBS/0.05% (v/v) Triton, pH 7.4
Dialysis 2 PBS, pH 7.4 or PBS/0.05% (v/v) Triton, pH 7.4
7.5 Chemicals and biologicals
1µCi methyl-[3H]-thymidine Amersham Pharmacia Biotech, Gent, Belgium
Alum (Imject Alum) Pierce, ThermoFisher Scientific, IL, USA
BAPNA (92 µM) Bachem, Weil a. Rhein, Germany
BSA, fraction V AppliChem, Darmstadt, Germany
mCD3 eBioscience, CA, USA
mCD28 eBioscience, CA, USA
CFSE eBioscience, CA, USA
ConA Sigma-Aldrich, Germany
Cytokine standards Immunotools, Friesoythe, Germany
Fetal Calf Serum (FCS) HyClone, ThermoFisher, Bonn, Germany
GPE Batch#177CHB W8000480 Allergopharma, Reinbek, Germany
Ketamine/rompun Bayer and Bela-Pharm, Berlin, Germany
rIL-25 R&D Systems, MN, USA
Metacholine (MCh) Sigma-Aldrich, Germany
OVA grade VI Sigma-Aldrich, Munich, Germany
Papain (100 µM) Sigma, Munich, Germany
Paraformaldehyde Sigma, Munich, Germany
PhastGel BlueR AmershamPharmacia, Uppsala, Sweden
rPhl p 5b Batch#PP5br04001 Allergopharma, Reinbek, Germany
Phusion Hot Start DNA Polym. New England Biolabs, Frankfurt, Germany
PMA, Ionomycin, Brefeldin A Sigma, Munich, Germany
Proteinase inhibitor cocktail Roche, Mannheim, Germany




Amersham ECL Plus WB Detection GE Healthcare, Freiburg, Germany
BCA kit Pierce, ThermoFisher Scientific, IL, USA
BD Cytofix/Cytoperm Kit BD Biosciences, Heidelberg, Germany
Cytokine bead array flex sets BD Biosciences, Heidelberg, Germany
DiffQuick Fisher Scientific, Germany
DuoSet ELISA kit R&D Systems, MN, USA
ELISA kit eBioscience, CA, USA
ELISA Ready-Set-Go kit eBioscience, CA, USA
EndoTrap system blue Profos, Regensburg, Germany
Fixation/Permeabilization kit eBiosciences, CA, USA
High Capacity RNA to cDNA kit Applied Biosystems, NJ, USA
ImmunoCAPTM System Phadia AB, Uppsala, Sweden
innuPREP RNA kit Analytik Jena, Jena, Germany
LAL QCL-1000 Cambrex, BioSciences, Walkersville, USA
OptEIA ELISA kit BD Biosciences, Heidelberg, Germany
Phusion kit Finnzymes, Espoo, Finnland
Plasmid-Mini-Kit Qiagen, Hilden, Germany
Primers TIB, Berlin, Germany
SYBR Green Master Mix Roche, Zürich, Switzerland
QIAshredder spin columns Qiagen, Hilden, Germany
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7.7 Antibodies and secondary reagents
anti-mIgE BD Pharmigen, Heidleberg, Germany
anti-mIgG1-biotinylated BD Pharmigen, Heidleberg, Germany
anti-mIgG2a-biotinylated BD Pharmigen, Heidleberg, Germany
FcγR-blocking Ab BD Biosciences, Heidelberg, Germany
Fixable Viability Dye eFluor660 eBioscience, CA, USA
anti-mCD4 e450 eBioscience, CA, USA
anti-mCD25 Alexa700 eBioscience, CA, USA
anti-mCD103 Bio-SA-Cy7 eBioscience, CA, USA
anti-mF4/80 Cy5 eBioscience, CA, USA
anti-m/hFoxp3 PE eBioscience, CA, USA
anti-mGATA-3 APC eBioscience, CA, USA
anti-mIL-13 PE eBioscience, CA, USA
anti-hCD4 Alexa Fluor 405 a gift from DRFZ, Berlin, Germany
anti-hIL-4 PeCy7 a gift from DRFZ, Berlin, Germany
anti-hIL-5, anti-hIL-13 ELISA Abs BD Pharmingen, Heidelberg, Germany
anti-hIL-10 PE BD Biosciences, Heidleberg, Germany
anti-hIFN-γ Alexa Fluor 430 a gift from DRFZ, Berlin, Germany
7.8 Software
BD FACSDiva BD Biosciences, Heidelberg, Germany
FCAP Array Software Applied Biosystems, Darmstadt, Germany
FlowJo Tree Star, OR, USA
PrimerExpress Applied Biosystems, Darmstadt, Germany
Prism GraphPad Software, CA, USA
SPSS Statistics IBM Corporation, NY, USA
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